<SEC-DOCUMENT>0001641172-25-009854.txt : 20250513
<SEC-HEADER>0001641172-25-009854.hdr.sgml : 20250513
<ACCEPTANCE-DATETIME>20250513090114
ACCESSION NUMBER:		0001641172-25-009854
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20250512
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Material Modifications to Rights of Security Holders
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250513
DATE AS OF CHANGE:		20250513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GT Biopharma, Inc.
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40023
		FILM NUMBER:		25937444

	BUSINESS ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111
		BUSINESS PHONE:		(800) 304-9888

	MAIL ADDRESS:	
		STREET 1:		505 MONTGOMERY STREET
		STREET 2:		10TH FLOOR
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OXIS INTERNATIONAL INC
		DATE OF NAME CHANGE:	19940916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:GTBP="http://gtbiopharma.com/20250512">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_GTBP_gtbiopharma.com_20250512 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20250512_20250512 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0000109657 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000004" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000005" name="dei:EntityCentralIndexKey">0000109657</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="gtbp-20250512.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-05-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000109657</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-05-12</xbrli:startDate>
        <xbrli:endDate>2025-05-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt">Washington,
D.C. 20549</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_900_edei--DocumentType_c20250512__20250512_zoqxcAaPbTJd"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000010" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">CURRENT REPORT</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 20pt; text-align: center">Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">Date of Report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Date of earliest event reported)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="text-decoration: none"><span id="xdx_900_edei--DocumentPeriodEndDate_c20250512__20250512_zkan8vZ7HB9k"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:datemonthdayyearen" id="Fact000011" name="dei:DocumentPeriodEndDate">May 12, 2025</ix:nonNumeric></span></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="text-decoration: none">&#160;</span></p>



<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: bold 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_905_edei--EntityRegistrantName_c20250512__20250512_zHGBaiQ43DWh"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000012" name="dei:EntityRegistrantName">GT
Biopharma, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Exact name of registrant as specified in its charter)</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="text-decoration: none"><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20250512__20250512_zTRJs4gDXYue"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(State or other Jurisdiction of Incorporation)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span id="xdx_90E_edei--EntityFileNumber_c20250512__20250512_zbp8SWZpjeMb"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000014" name="dei:EntityFileNumber">1-40023</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Commission</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">File Number)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20250512__20250512_zjIb3tov49Ca"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000015" name="dei:EntityTaxIdentificationNumber">94-1620407</ix:nonNumeric></span></b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b></b>(IRS Employer</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Identification No.)</p></td></tr>
</table>

<p style="margin-top: 0; margin-bottom: 0"></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">N/A<sup>1</sup></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Address of Principal Executive Offices and
zip code)&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b><span id="xdx_902_edei--CityAreaCode_c20250512__20250512_zq70PPKsnmQ5"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000016" name="dei:CityAreaCode">(415)</ix:nonNumeric></span>-<span id="xdx_904_edei--LocalPhoneNumber_c20250512__20250512_zmQcu3gI6WZ2"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000017" name="dei:LocalPhoneNumber">919-4040</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">(Registrant&#8217;s telephone number, including area
code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following
provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--WrittenCommunications_c20250512__20250512_z7LUNHnkOuOk"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleanfalse" id="Fact000018" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the
  Securities Act (17 CFR 230.425)</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--SolicitingMaterial_c20250512__20250512_zLwgAC42O9Xj"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleanfalse" id="Fact000019" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12(b) under
  the Exchange Act (17 CFR 240.14a-12(b))</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250512__20250512_zoOkbGsVOyO8"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleanfalse" id="Fact000020" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--PreCommencementIssuerTenderOffer_c20250512__20250512_ziuO7lBa8Zzj"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleanfalse" id="Fact000021" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
  <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">Securities registered
pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 38%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Title
    of each Series</span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 18%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 40%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif">Name
    of each Exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--Security12bTitle_c20250512__20250512_zYcIMvY6wI3d"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000022" name="dei:Security12bTitle">Common stock, $0.001 par value</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--TradingSymbol_c20250512__20250512_zcEWNnqKv5U9"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000023" name="dei:TradingSymbol">GTBP</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: normal 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--SecurityExchangeName_c20250512__20250512_zbDnO9SobNHh"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt-sec:exchnameen" id="Fact000024" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><span style="font-weight: normal">Emerging
growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20250512__20250512_zNcHjVYoKi6d"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt:booleanfalse" id="Fact000025" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-weight: normal"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-size: 10pt"><sup>1</sup></span>Effective
as of July 1, 2024, the Company became a fully remote company. We do not maintain a principal executive office. For purposes of compliance
with applicable requirements of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, any stockholder
communication required to be sent to the Company&#8217;s principal executive offices may be directed to <span id="xdx_901_edei--EntityAddressAddressLine1_c20250512__20250512_zSMEOK7QFgIk"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000026" name="dei:EntityAddressAddressLine1">505 Montgomery Street</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20250512__20250512_zVlDnC0blW53"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000027" name="dei:EntityAddressAddressLine2">10th Floor</ix:nonNumeric></span>,
<span id="xdx_907_edei--EntityAddressCityOrTown_c20250512__20250512_zG0qVYZx2fsk"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000028" name="dei:EntityAddressCityOrTown">San Francisco</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressStateOrProvince_c20250512__20250512_zXZ9sx5PB34a"><ix:nonNumeric contextRef="AsOf2025-05-12" format="ixt-sec:stateprovnameen" id="Fact000029" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20250512__20250512_zyRz7ozOy9Bc"><ix:nonNumeric contextRef="AsOf2025-05-12" id="Fact000030" name="dei:EntityAddressPostalZipCode">94111</ix:nonNumeric></span>, or by email to auditcommittee@gtbiopharma.com.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">&#160;</p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">&#160;</p>



<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;Item 1.01 Entry into a Material Definitive
Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Private Placement of Preferred
Stock and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 12, 2025, GT Biopharma, Inc. (the &#8220;Company&#8221;)
entered into a Securities Purchase Agreement (the &#8220;Securities Purchase Agreement&#8221;) with the purchasers identified therein
(collectively, the &#8220;Purchasers&#8221;) providing for the issuance and sale to the Purchasers of (i) up to 6,056 shares of the Company&#8217;s
Series L 10% Convertible Preferred Stock (the &#8220;Preferred Stock&#8221;), (ii) warrants to purchase up to a number of shares of common
stock of the Company (the &#8220;Common Stock&#8221;) equal to 100% of the shares of the Company&#8217;s Common Stock issuable upon conversion
of the shares of Preferred Stock (the &#8220;Common Warrants&#8221;), and (iii) warrants to purchase up to a number of shares of Company&#8217;s
Common Stock equal to the number of Greenshoe Conversion Shares (as defined in the Securities Purchase Agreement) issuable upon exercise
of the Greenshoe Right (as defined below) (the &#8220;Vesting Warrants&#8221; and together with the Common Warrants, the &#8220;Warrants&#8221;),
with an aggregate stated value of $6,055,555.56, for an aggregate purchase price of $5,450,000.00 (the &#8220;Offering&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Securities Purchase Agreement, each
Purchaser may elect to purchase shares of Preferred Stock with an aggregate stated value of up to $22,000,000 (the &#8220;Greenshoe Rights&#8221;)
for an aggregate purchase price of $19,800,000, subject to adjustments, as further described in the Securities Purchase Agreement. Each
Purchaser is entitled to exercise its respective Greenshoe Rights for an amount of Preferred Stock equal to the ratio of such Purchaser&#8217;s
original subscription amount to the original aggregate subscription amount of all Purchasers.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Certificate of Designation designating
the Preferred Stock (the &#8220;Certificate of Designation&#8221;) and subject to certain ownership limitations, the Preferred Stock may
be converted at any time at the option of the Purchasers into shares of the Company&#8217;s Common Stock at an initial conversion price
of $2.043, subject to certain conditions, as further described in the Certificate of Designation. In addition, the holders of the Preferred
Stock are entitled to receive cumulative dividends at the rate per share (as a percentage of the stated value per share) of 10% per annum
until May 11, 2026, increasing to 12% per annum thereafter, payable quarterly on January 1, April 1, July 1 and October 1, beginning on
the first date after the date of issuance of the Preferred Stock and on each Conversion Date (as defined in the Certificate of Designation),
in cash, shares of the Company&#8217;s Common Stock (subject to the Company&#8217;s satisfaction of the conditions set forth in the Certificate
of Designation), or a combination thereof. Upon the occurrence of certain triggering events, each holder has the right to require the
Company to redeem the Preferred Shares at a premium, in accordance with and subject to certain conditions as further described in the
Certificate of Designation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Securities Purchase Agreement, each
Purchaser will be issued (i) a Common Warrant, each to purchase up to a number of shares of the Company&#8217;s Common Stock equal to
100% of the Conversion Shares underlying the Preferred Shares issued to such Purchaser and (ii) a Vesting Warrant (the exercisability
of which shall vest ratably from time to time in proportion to the Purchaser&#8217;s (or its permitted assigns&#8217;) exercise of such
Purchaser&#8217;s Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement), each to purchase up to a number of shares of the
Company&#8217;s Common Stock equal to the number of Greenshoe Conversion Shares (as defined in the Securities Purchase Agreement) applicable
to such Purchaser, in accordance with the Securities Purchase Agreement. The Common Warrants have an initial exercise price of $2.043
per share, are exercisable, subject to certain ownership limitations, immediately upon issuance and have a term of exercise equal to five
years. The Vesting Warrants have an initial exercise price of $2.043 per share, are exercisable subject to certain vesting and ownership
limitations, and have a term of exercise equal to five years from the date that the applicable warrant shares vest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Preferred Shares and Warrants both have full ratchet
price protection and are subject to other adjustments, as further described in the Certificate of Designation or the Warrants, as applicable,
subject, solely with respect to adjustments in connection with the exercise of Greenshoe Rights, a floor price of $0.454 per share (subject
to adjustment for reverse and forward splits, recapitalizations and similar transactions).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The securities in the Offering were offered privately
pursuant to Rule 506(b) of Regulation D under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Registration Rights Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company and the Purchasers entered into a registration
rights agreement pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission covering
the public resale of the Common Stock issuable upon conversion of the Preferred Stock and upon exercise of the Warrants. The Company has
agreed to file a registration statement within 30 days after the initial closing and after each closing of the exercise of a Greenshoe
Right in accordance with the Securities Purchase Agreement, to become effective no later than 90 days after filing. If these deadlines
are not met, the Company will be liable for liquidated damages of 1.5% of the subscription amount paid by each Purchaser pursuant to the
Securities Purchase Agreement. Further, if the Company fails to pay such liquidated damages within 7 days from the date payable, the Company
will pay interest thereon at the prime rate plus 12% to each holder of the registerable securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Voting Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Securities Purchase Agreement, the
Company agreed to hold a meeting of its stockholders at the earliest practical date after the execution of the Securities Purchase Agreement
for the purpose of obtaining stockholder approval for the issuance, in the aggregate, of more than 19.99% of the number of shares of the
Company&#8217;s Common Stock outstanding on the date of the initial closing (&#8220;Shareholder Approval&#8221;). In connection with the
required Shareholder Approval, all of the Company&#8217;s officers and directors (each a &#8220;Voting Agreement Party&#8221;) entered
into a Voting Agreement pursuant to which each Voting Agreement Party agreed to vote all shares of voting stock over which the Voting
Agreement Party has voting control in favor of any resolution presented to the stockholders of the Company seeking Shareholder Approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>Lock-Up Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Pursuant to the Securities Purchase Agreement, the
Company and its directors and officers entered into Lockup Agreements (the &#8220;Lockup Agreements&#8221;), pursuant to which each officer
and director agreed not to sell or transfer any securities of the Company held by them for a period commencing on the date of the Lockup
Agreement until 30 days after the later of (i) the Effective Date (as defined in the Securities Purchase Agreement) and (ii) the date
that Shareholder Approval is obtained and deemed effective, subject to limited exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The foregoing descriptions of the terms of the Certificate
of Designation, form of Common Warrant, form of Vesting Warrant, Securities Purchase Agreement, Registration Rights Agreement, Voting
Agreement and Lockup Agreement are not intended to be complete and are qualified in their entirety by reference to such exhibits, which
are filed herewith as Exhibits 3.1 4.1, 4.2, 10.1, 10.2, 10.3 and 10.4, respectively, to this Current Report on Form 8-K and are incorporated
by reference herein. Neither this current report on Form 8-K, nor the exhibits attached hereto, is an offer to sell or the solicitation
of an offer to buy the securities described herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity
Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The information set forth in Item 1.01 is incorporated
by reference into this Item 3.02 in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Item 3.03 Material Modification to Rights of Security Holders.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The information set forth in Item 1.01 is incorporated
by reference into this Item 3.03 in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On May 12, 2025, the Company filed a Certificate of
Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock with the Secretary of State of the State
of Delaware, in the form attached as Exhibit 3.1 to this Current Report on Form 8-K. The Certificate of Designation creates and specifies
the rights of Series L 10% Convertible Preferred Stock, including the terms and conditions on which shares of such preferred stock would
convert into shares of our Common Stock, as well as its liquidation preference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
5.03 &#160;Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b></b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The information set forth in Items 1.01 and 3.03 regarding
the Certificate of Designation are incorporated by reference into this Item 5.03 in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><b>Exhibit No.</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt; width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>Description</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">3.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="border-top: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series L 10% Convertible Preferred Stock.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">4.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex4-1.htm">Form of Common Warrant.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">4.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex4-2.htm">Form of Vesting Warrant.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">10.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex10-1.htm">Securities Purchase Agreement, dated as of May 12, 2025, between the Company and the purchasers identified therein.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">10.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex10-2.htm">Registration Rights Agreement, dated as of May 12, 2025, between the Company and the purchasers identified therein.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">10.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex10-3.htm">Form of Voting Agreement.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">10.4</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="ex10-4.htm">Form of Lock-up Agreement.</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 28.35pt">&#160;</p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GT
    BIOPHARMA, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><span style="font-size: 10pt">Date: May 13, 2025</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><span style="font-size: 10pt">By</span>:</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%; text-align: justify"><span style="font-size: 10pt"><i>/s/
    Alan Urban</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Alan Urban</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>



<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->








<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LNpNprA3HSriFBkivhYXpbg1I61z+yT/0rohhkBI7j25QozEhta6RIbLMs/ghFVdKoeQ4w0ZzRW9I93uEvAzx7u2jpVx/foDU/IMemY2lld/752NtlgkIONJOJ1EMch5Imew2Ivgq6dkbrpA47QqQZkCjkw1a3SKu+HDSbVkqOr6pDOy1WQSCMdykN8QyTCCAzXqRfywkGWpCEZ9BWLD9Ky9a9U6NF8SViVWPs4O9L+DD8P5Sk8= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ex3-1.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 3.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>gt biopharma,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION OF PREFERENCES, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>RIGHTS AND LIMITATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Series L
10%</B></FONT><B> CONVERTIBLE PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">PURSUANT TO
SECTION 151 OF THE </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Delaware GENERAL
CORPORATION LAW</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">The undersigned, Michael Breen
and Alan Urban, do hereby certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in">1. They are the Chief Executive
Officer and Secretary, respectively, of GT Biopharma, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in">2. The Corporation is authorized
to issue 15 million shares of preferred stock, 96,230 of which have been issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.75in">3. The following resolutions
were duly adopted by the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the certificate of incorporation
of the Corporation provides for a class of its authorized stock known as preferred stock, consisting of 15 million shares, $0.001 par
value per share, issuable from time to time in one or more series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, the Board of Directors
is authorized to fix the dividend rights, dividend rate, voting rights, conversion rights, rights and terms of redemption and liquidation
preferences of any wholly unissued series of preferred stock and the number of shares constituting any series and the designation thereof,
of any of them; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">WHEREAS, it is the desire of
the Board of Directors, pursuant to its authority as aforesaid, to fix the rights, preferences, restrictions and other matters relating
to a series of the preferred stock, which shall consist of, except as otherwise set forth in the Purchase Agreement, up to 28,056 shares
of the preferred stock which the Corporation has the authority to issue, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">NOW, THEREFORE, BE IT RESOLVED,
that the Board of Directors does hereby provide for the issuance of a series of preferred stock for cash or exchange of other securities,
rights or property and does hereby fix and determine the rights, preferences, restrictions and other matters relating to such series of
preferred stock as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>TERMS OF PREFERRED STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><U>Section 1</U>. <U>Definitions</U>.
For the purposes hereof, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Alternate
Consideration</U>&rdquo; shall have the meaning set forth in Section 7(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bankruptcy
Event</U>&rdquo; means any of the following events: (a) the Corporation or any Significant Subsidiary (as such term is defined in Rule
1-02(w) of Regulation S-X) thereof commences a case or other proceeding under any bankruptcy, reorganization, arrangement, adjustment
of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Corporation or any
Significant Subsidiary thereof, (b) there is commenced against the Corporation or any Significant Subsidiary thereof any such case or
proceeding that is not dismissed within 60 days after commencement, (c) the Corporation or any Significant Subsidiary thereof is adjudicated
insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered, (d) the Corporation or any
Significant Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial part of its property that
is not discharged or stayed within 60 calendar days after such appointment, (e) the Corporation or any Significant Subsidiary thereof
makes a general assignment for the benefit of creditors, (f) the Corporation or any Significant Subsidiary thereof calls a meeting of
its creditors with a view to arranging a composition, adjustment or restructuring of its debts, or (g) the Corporation or any Significant
Subsidiary thereof, by any act or failure to act, expressly indicates its consent to, approval of or acquiescence in any of the foregoing
or takes any corporate or other action for the purpose of effecting any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Base Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall have the meaning set forth in Section 6(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Buy-In</U>&rdquo;
shall have the meaning set forth in Section 6(c)(iv).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing Date</U>&rdquo;
means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto and
all conditions precedent to (i) each Holder&rsquo;s obligations to pay the Subscription Amount and (ii) the Corporation&rsquo;s obligations
to deliver the Securities have been satisfied or waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Price</U>&rdquo; means on any particular date (a) the last reported closing bid price per share of Common Stock on such date on the Trading
Market (as reported by Bloomberg L.P. at 4:15 p.m. (New York City time)), (b) if there is no such price on such date, then the closing
bid price on the Trading Market on the date nearest preceding such date (as reported by Bloomberg L.P. at 4:15 p.m. (New York City time)),
(c) if the Common Stock is not then listed or quoted on another Trading Market and if prices for the Common Stock are then reported on
the Pink Market, the most recent bid price per share of the Common Stock so reported, or (d) if the shares of Common Stock are not then
publicly traded the fair market value as of such date of a share of Common Stock as determined by an independent appraiser selected in
good faith by the Corporation and reasonably acceptable to the Holders of a majority in interest of the shares then outstanding, the fees
and expenses of which shall be paid by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the Corporation&rsquo;s common stock, par value $0.001 per share, and stock of any other class of securities into which such securities
may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock
Equivalents</U>&rdquo; means any securities of the Corporation or the Subsidiaries which would entitle the holder thereof to acquire at
any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Amount</U>&rdquo; means the sum of the Stated Value at issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Date</U>&rdquo; shall have the meaning set forth in Section 6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning set forth in Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Shares</U>&rdquo; means, collectively, the shares of Common Stock issuable upon conversion of the shares of Preferred Stock in accordance
with the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Shares Registration Statement</U>&rdquo; means a registration statement that registers the resale of all or any portion of the Conversion
Shares by the Holders, which shall be named as &ldquo;selling stockholders&rdquo; therein, and meets the requirements of the Registration
Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dilutive Issuance</U>&rdquo;
shall have the meaning set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dilutive Issuance
Notice</U>&rdquo; shall have the meaning set forth in Section 7(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dividend Conversion
Rate</U>&rdquo; means the lesser of (a) the Conversion Price or (b) 90% of the lesser of (i) the average of the VWAPs for the 5 consecutive
Trading Days ending on the Trading Day that is immediately prior to the applicable Dividend Payment Date or (ii) the average of the VWAPs
for the 5 consecutive Trading Days ending on the Trading Day that is immediately prior to the date the applicable Dividend Conversion
Shares are issued and delivered if such delivery is after the Dividend Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dividend Conversion
Shares</U>&rdquo; shall have the meaning set forth in Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dividend Notice
Period</U>&rdquo; shall have the meaning set forth in Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dividend Payment
Date</U>&rdquo; shall have the meaning set forth in Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Dividend Share
Amount</U>&rdquo; shall have the meaning set forth in Section 3(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective
Date</U>&rdquo; means the date that the initial Conversion Shares Registration Statement filed by the Corporation pursuant to the Registration
Rights Agreement is first declared effective by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Equity Conditions</U>&rdquo;
means, during the period in question, (a) the Corporation shall have duly honored all conversions scheduled to occur or occurring by virtue
of one or more Notices of Conversion of the applicable Holder on or prior to the dates so requested or required, if any, (b) the Corporation
shall have paid all liquidated damages and other amounts owing to the applicable Holder in respect of the Preferred Stock, (c)(i) there
is an effective Conversion Shares Registration Statement pursuant to which the Holders are permitted to utilize the prospectus thereunder
to resell the shares of Common Stock in question registered for resale thereunder (and the Corporation believes, in good faith, that such
effectiveness will continue uninterrupted for the foreseeable future) or (ii) all of the Conversion Shares issuable pursuant to the Transaction
Documents (and shares issuable in lieu of cash payments of dividends) may be resold pursuant to Rule 144 without volume or manner-of-sale
restrictions or current public information requirements as determined by the counsel to the Corporation as set forth in a written opinion
letter to such effect, addressed and acceptable to the Transfer Agent and the affected Holders, (d) the Common Stock is trading on a Trading
Market and all of the shares issuable pursuant to the Transaction Documents are listed or quoted for trading on such Trading Market (and
the Corporation believes, in good faith, that trading of the Common Stock on a Trading Market will continue uninterrupted for the foreseeable
future), (e) there is a sufficient number of authorized, but unissued and otherwise unreserved, shares of Common Stock for the issuance
of all of the shares then issuable pursuant to the Transaction Documents, (f) there is no existing Triggering Event and no existing event
which, with the passage of time or the giving of notice, would constitute a Triggering Event, (g) the issuance of the shares in question
to the applicable Holder would not violate the limitations set forth in Section 6(d), (h) the Corporation shall have obtained Shareholder
Approval and the restrictions set forth in Section 6(e) shall no longer apply, (i) there has been no public announcement of a pending
or proposed Fundamental Transaction that has not been consummated, (j) the applicable Holder is not in possession of any information provided
by the Corporation, any of its Subsidiaries, or any of their officers, directors, employees, agents or Affiliates, that constitutes, or
may constitute, material non-public information and (k) for each Trading Day in a period of 20 consecutive Trading Days prior to the applicable
date in question, the daily trading volume for the Common Stock on the principal Trading Market exceeds $100,000 per Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt
Issuance</U>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Corporation
pursuant to any stock or option plan duly adopted by a majority of the non-employee members of the Board of Directors of the Corporation
or a majority of the members of a committee of non-employee directors established for such purpose, (b) securities upon the exercise or
exchange of or conversion of any securities issued pursuant to the Purchase Agreement (including the Vesting Warrants (as defined in Section
1.1 of the Purchase Agreement)) and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued
and outstanding on the date of the Purchase Agreement, provided that such securities have not been amended since the date of the Purchase
Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of any such
securities (other than in connection with stock splits or combinations and other than pursuant to Section 3(b) of the Vesting Warrants)
or to extend the term of such securities or (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority
of the disinterested directors of the Corporation, provided that such securities are issued as &ldquo;restricted securities&rdquo; (as
defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith
during the prohibition period in Section 4.13(a) of the Purchase Agreement, and provided that any such issuance shall only be to a Person
(or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a
business synergistic with the business of the Corporation and shall provide to the Corporation additional benefits in addition to the
investment of funds, but shall not include a transaction in which the Corporation is issuing securities primarily for the purpose of raising
capital or to an entity whose primary business is investing in securities. Notwithstanding anything herein to the contrary, in no event
shall the exercise of the Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement be deemed an Exempt Issuance hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental
Transaction</U>&rdquo; shall have the meaning set forth in Section 7(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
means United States generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Holder</U>&rdquo;
shall have the meaning given such term in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means (a) any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary
course of business), (b) all guaranties, endorsements and other contingent obligations in respect of indebtedness of others, whether or
not the same are or should be reflected in the Corporation&rsquo;s balance sheet (or the notes thereto), except guaranties by endorsement
of negotiable instruments for deposit or collection or similar transactions in the ordinary course of business, and (c) the present value
of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Issuable Maximum</U>&rdquo;
shall have the meaning set forth in Section 6(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Junior Securities</U>&rdquo;
means the Common Stock and all other Common Stock Equivalents of the Corporation other than those securities which are explicitly senior
or <U>pari passu</U> to the Preferred Stock in dividend rights or liquidation preference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liquidation</U>&rdquo;
shall have the meaning set forth in Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>New York Courts</U>&rdquo;
shall have the meaning set forth in Section 11(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Notice of
Conversion</U>&rdquo; shall have the meaning set forth in Section 6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Original Issue
Date</U>&rdquo; means the date of the first issuance of any shares of the Preferred Stock regardless of the number of transfers of any
particular shares of Preferred Stock and regardless of the number of certificates which may be issued to evidence such Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Indebtedness</U>&rdquo; means (a) the Indebtedness existing on the Original Issue Date and (b) lease obligations and purchase money indebtedness
incurred in connection with the acquisition of capital assets and lease obligations with respect to newly acquired or leased assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Lien</U>&rdquo; means the individual and collective reference to the following: (a) Liens for taxes, assessments and other governmental
charges or levies not yet due or Liens for taxes, assessments and other governmental charges or levies being contested in good faith and
by appropriate proceedings for which adequate reserves (in the good faith judgment of the management of the Corporation) have been established
in accordance with GAAP, (b) Liens imposed by law which were incurred in the ordinary course of the Corporation&rsquo;s business, such
as carriers&rsquo;, warehousemen&rsquo;s and mechanics&rsquo; Liens, statutory landlords&rsquo; Liens, and other similar Liens arising
in the ordinary course of the Corporation&rsquo;s business, and which (x) do not individually or in the aggregate materially detract from
the value of such property or assets or materially impair the use thereof in the operation of the business of the Corporation and its
consolidated Subsidiaries or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing
for the foreseeable future the forfeiture or sale of the property or asset subject to such Lien, (c) Liens incurred in connection with
Permitted Indebtedness under clause (a) thereunder, and (d) Liens incurred in connection with Permitted Indebtedness under clause (b)
thereunder, provided that such Liens are not secured by assets of the Corporation or its Subsidiaries other than the assets so acquired
or leased.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Preferred
Stock</U>&rdquo; shall have the meaning set forth in Section 2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchase Agreement</U>&rdquo;
means the Securities Purchase Agreement, dated as of the Original Issue Date, among the Corporation and the original Holders, as amended,
modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the Registration Rights Agreement, dated as of the date of the Purchase Agreement, among the Corporation
and the original Holders, in the form of <U>Exhibit B</U> attached to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale of the Underlying Shares by each Holder as provided for in the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar
rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Preferred Stock, the Warrants, the Warrant Shares and the Underlying Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Share Delivery
Date</U>&rdquo; shall have the meaning set forth in Section 6(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stated Value</U>&rdquo;
shall have the meaning set forth in Section 2, as the same may be increased pursuant to Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shareholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any
successor entity) from the shareholders of the Corporation with respect to the transactions contemplated by the Transaction Documents,
including the issuance of all of the Underlying Shares in excess of 19.99% of the issued and outstanding Common Stock on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; shall mean, as to each Holder, the aggregate amount to be paid for the Preferred Stock purchased pursuant to the Purchase
Agreement as specified below such Holder&rsquo;s name on the signature page of the Purchase Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Corporation as set forth on <U>Schedule 3.1(a)</U> of the Purchase Agreement and shall, where applicable,
also include any direct or indirect subsidiary of the Corporation formed or acquired after the date of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Successor
Entity</U>&rdquo; shall have the meaning set forth in Section 7(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
Pink Open Market operated by OTC Markets Group, Inc. (&ldquo;<U>Pink Market</U>&rdquo;), the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;)
or the OTCQX Best Market (&ldquo;<U>OTCQX</U>&rdquo;), or any successors to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Price</U>&rdquo; means on any particular date (a) the lowest reported trading price per share of Common Stock on such date on the Trading
Market (as reported by Bloomberg L.P. at 4:15 p.m. (New York City time)), (b) if there is no such price on such date, then the lowest
trading price on the Trading Market on the date nearest preceding such date (as reported by Bloomberg L.P. at 4:15 p.m. (New York City
time)), (c) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported
on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the lowest trading price
per share of the Common Stock so reported, or (d) if the shares of Common Stock are not then publicly traded the fair market value as
of such date of a share of Common Stock as determined by an independent appraiser selected in good faith by the Corporation and reasonably
acceptable to the Holders of a majority in interest of the shares then outstanding, the fees and expenses of which shall be paid by the
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Certificate of Designation, the Purchase Agreement, the Warrants, the Registration Rights Agreement, the
Lock-Up Agreements, the Voting Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed
in connection with the transactions contemplated pursuant to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Triggering
Event</U>&rdquo; shall have the meaning set forth in Section 10(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Triggering
Redemption Amount</U>&rdquo; means, for each share of Preferred Stock, the sum of (a) the greater of (i) 130% of the Stated Value and
(ii) the product of (y) the VWAP on the Trading Day immediately preceding the date of the Triggering Event and (z) the Stated Value divided
by the then Conversion Price, (b) all accrued but unpaid dividends thereon and (c) all liquidated damages and other costs, expenses or
amounts due in respect of the Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Triggering
Redemption Payment Date</U>&rdquo; shall have the meaning set forth in Section 10(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underlying
Shares</U>&rdquo; means the shares of Common Stock issued and issuable upon conversion of the Preferred Stock, upon exercise of the Warrants
and issued and issuable in lieu of the cash payment of dividends on the Preferred Stock in accordance with the terms of this Certificate
of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.13(b) of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market other than the Pink Market, the OTCQB or the OTCQX, the daily volume weighted average price of the Common Stock
for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by
Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock
is then listed or quoted on the OTCQB or the OTCQX, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the OTCQB or the OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on the OTCQB
or the OTCQX and if prices for the Common Stock are then reported in the Pink Market, the most recent bid price per share of the Common
Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the
Corporation, the fees and expenses of which shall be paid by the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
shall have the meaning ascribed to such term in Section 1.1 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Designation,
Amount and Par Value; Ranking</U>. The series of preferred stock shall be designated as its Series L 10% Convertible Preferred Stock (the
&ldquo;<U>Preferred Stock</U>&rdquo;) and the number of shares so designated shall be 28,056 (which shall not be subject to increase without
the written consent of the holders of a majority of the then outstanding shares of the Preferred Stock (each, a &ldquo;<U>Holder</U>&rdquo;
and collectively, the &ldquo;<U>Holders</U>&rdquo;)). Each share of Preferred Stock shall have a par value of $0.001 per share and a stated
value equal to $1,000, subject to increase set forth in Section 3 below (the &ldquo;<U>Stated Value</U>&rdquo;). Except to the extent
that holders of at least 75% of the aggregate Stated Value of the then outstanding shares of Preferred Stock (the &ldquo;<U>Required Holders</U>&rdquo;)
expressly consent to the creation of Parity Stock or Senior Preferred Stock, all shares of capital stock of the Corporation shall be junior
in rank to all Preferred Shares with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution
and winding up of the Corporation (such junior stock is referred to herein collectively as &ldquo;Junior Stock&rdquo;). The rights of
all such shares of capital stock of the Corporation shall be subject to the rights, powers, preferences and privileges of the Preferred
Shares. Without limiting any other provision of this Certificate of Designations, without the prior express consent of the Required Holders,
voting separately as a single class, the Corporation shall not hereafter authorize or issue any additional or other shares of capital
stock that are (i) of senior rank to the Preferred Shares in respect of the preferences as to dividends, distributions and payments upon
the liquidation, dissolution and winding up of the Corporation (collectively, the &ldquo;<U>Senior Preferred Stock</U>&rdquo;), (ii) of
pari passu rank to the Preferred Shares in respect of the preferences as to dividends, distributions and payments upon the liquidation,
dissolution and winding up of the Corporation (collectively, the &ldquo;<U>Parity Stock</U>&rdquo;) or (iii) any Junior Stock having a
maturity date or any other date requiring redemption or repayment of such shares of Junior Stock that is prior to the Maturity Date. In
the event of the merger or consolidation of the Corporation with or into another corporation, the Preferred Shares shall maintain their
relative rights, powers, designations, privileges and preferences provided for herein and no such merger or consolidation shall be consummated
if it would result in the Preferred Shares being treated in any manner inconsistently with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Dividends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)  <U>Dividends
in Cash or in Kind</U>. From and after the first date of issuance of any Preferred Stock, Holders shall be entitled to receive, and the
Corporation shall pay, cumulative dividends at the rate per share (as a percentage of the Stated Value per share) of 10% per annum until
May 11, 2026 and 12% per annum thereafter (subject to increase pursuant to Section 10(b)), payable quarterly on January 1, April 1, July
1 and October 1, beginning on the first such date after the Original Issue Date and on each Conversion Date (with respect only to Preferred
Stock being converted) (each such date, a &ldquo;<U>Dividend Payment Date</U>&rdquo;) (if any Dividend Payment Date is not a Trading Day,
the applicable payment shall be due on the next succeeding Trading Day) in cash, or as set forth in this Section 3(a), in duly authorized,
validly issued, fully paid and non-assessable shares of Common Stock, or a combination thereof (the dollar amount to be paid in shares
of Common Stock, the &ldquo;<U>Dividend Share Amount</U>&rdquo;). The form of dividend payments to each Holder shall be determined in
the following order of priority: (i) if funds are legally available for the payment of dividends and the Equity Conditions have not been
met during the 10 consecutive Trading Days immediately prior to the applicable Dividend Payment Date (the &ldquo;<U>Dividend Notice Period</U>&rdquo;),
in cash only, (ii) if funds are legally available for the payment of dividends and the Equity Conditions have been met during the Dividend
Notice Period, at the sole election of the Corporation, in cash or shares of Common Stock which shall be valued at the Dividend Conversion
Rate, (iii) if funds are not legally available for the payment of dividends and the Equity Conditions have been met during the Dividend
Notice Period, in shares of Common Stock which shall be valued at the Dividend Conversion Rate, (iv) if funds are not legally available
for the payment of dividends and the Equity Condition relating to an effective Conversion Shares Registration Statement has been waived
by such Holder (provided that the other Equity Conditions have been met during the Dividend Notice Period), as to such Holder only, in
unregistered shares of Common Stock which shall be valued at the Dividend Conversion Rate, and (v) if funds are not legally available
for the payment of dividends and the Equity Conditions have not been met during the Dividend Notice Period, then, at the election of such
Holder, such dividends shall accrue to the next Dividend Payment Date or shall be accreted to, and increase, the outstanding Stated Value.
In addition, as a condition to paying dividends in shares of Common Stock, as to such Dividend Payment Date, prior to such Dividend Notice
Period (but not more than five (5) Trading Days prior to the commencement of such Dividend Notice Period), the Corporation shall have
delivered to each Holder&rsquo;s account with The Depository Trust Company a number of shares of Common Stock to be applied against such
Dividend Share Amount equal to the quotient of (x) the applicable Dividend Share Amount divided by (y) the Dividend Conversion Rate, assuming
for such purposes that the Dividend Payment Date is the Trading Day immediately prior to the commencement of the Dividend Notice Period
(the &ldquo;<U>Dividend Conversion Shares</U>&rdquo;); provided that on the Dividend Payment Date the Corporation shall issue to the Holder
any additional Dividend Conversion Shares owing to the Holder as a result of a lower Dividend Conversion Price during the applicable Dividend
Notice Period. The Holders shall have the same rights and remedies with respect to the delivery of any such shares as if such shares were
being issued pursuant to Section 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Corporation&rsquo;s
Ability to Pay Dividends in Cash or Kind</U>. On the Closing Date, the Corporation shall have notified the Holders whether or not it
may legally pay cash dividends as of the Closing Date. The Corporation shall promptly notify the Holders at any time the Corporation
shall become able or unable, as the case may be, to legally pay cash dividends. If at any time the Corporation has the right to pay dividends
in cash or shares of Common Stock, the Corporation must provide the Holders with at least 10 Trading Days&rsquo; notice of its election
to pay a regularly scheduled dividend in shares of Common Stock (the Corporation may indicate in such notice that the election contained
in such notice shall continue for later periods until revised by a subsequent notice). If at any time the Corporation delivers a notice
to the Holders of its election to pay the dividends in shares of Common Stock, the Corporation shall timely file a prospectus supplement
pursuant to Rule 424 disclosing such election. The aggregate number of shares of Common Stock otherwise issuable to a Holder on a Dividend
Payment Date shall be reduced by the number of shares of Common Stock previously issued to such Holder in connection with such Dividend
Payment Date. If any Dividend Conversion Shares are issued to a Holder in connection with a Dividend Payment Date and are not applied
against a Dividend Share Amount, then such Holder shall promptly return such excess shares to the <FONT STYLE="font-size: 10pt">Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">c</FONT>)
<U>Dividend Calculations</U>. Dividends on the Preferred Stock shall be calculated on the basis of a 360-day year, consisting of twelve
30 calendar day periods, and shall accrue daily commencing on the Original Issue Date, and shall be deemed to accrue from such date whether
or not earned or declared and whether or not there are profits, surplus or other funds of the Corporation legally available for the payment
of dividends. Payment of dividends in shares of Common Stock shall otherwise occur pursuant to Section 6(c)(i) herein and, solely for
purposes of the payment of dividends in shares, the Dividend Payment Date shall be deemed the Conversion Date. Dividends shall cease
to accrue with respect to any Preferred Stock converted, provided that, the Corporation actually delivers the Conversion Shares within
the time period required by Section 6(c)(i) herein. Except as otherwise provided herein, if at any time the Corporation pays dividends
partially in cash and partially in shares, then such payment shall be distributed ratably among the Holders based upon the number of
shares of Preferred Stock held by each Holder on such Dividend Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)  <U>Late
Fees</U>. Any dividends, whether paid in cash or shares of Common Stock, that are not paid within three Trading Days following a Dividend
Payment Date shall continue to accrue and shall entail a late fee, which must be paid in cash, at the rate of 18% per annum or the lesser
rate permitted by applicable law which shall accrue daily from the Dividend Payment Date through and including the date of actual payment
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)  <U>Other
Securities</U>. So long as any Preferred Stock shall remain outstanding, neither the Corporation nor any Subsidiary thereof shall redeem,
purchase or otherwise acquire directly or indirectly any Junior Securities except as expressly permitted by Section 10(a)(ix). So long
as any Preferred Stock shall remain outstanding, neither the Corporation nor any Subsidiary thereof shall directly or indirectly pay or
declare any dividend or make any distribution upon (other than a dividend or distribution described in Section 6 or dividends due and
paid in the ordinary course on preferred stock of the Corporation at such times when the Corporation is in compliance with its payment
and other obligations hereunder), nor shall any distribution be made in respect of, any Junior Securities as long as any dividends due
on the Preferred Stock remain unpaid, nor shall any monies be set aside for or applied to the purchase or redemption (through a sinking
fund or otherwise) of any Junior Securities or shares <U>pari passu</U> with the Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><U>Section 4</U>. <U>Voting
Rights</U>. Except as otherwise provided herein or as otherwise required by law, the Preferred Stock shall have no voting rights. However,
as long as any shares of Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a
majority of the then outstanding shares of the Preferred Stock, (a) alter or change adversely the powers, preferences or rights given
to the Preferred Stock or alter or amend this Certificate of Designation, (b) authorize or create any class of stock ranking as to dividends,
redemption or distribution of assets upon a Liquidation (as defined in Section 5) senior to, or otherwise <U>pari passu</U> with, the
Preferred Stock, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights
of the Holders, (d) increase the number of authorized shares of Preferred Stock, or (e) enter into any agreement with respect to any of
the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><U>Section 5</U>.   <U>Liquidation</U>.
Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a &ldquo;<U>Liquidation</U>&rdquo;),
the Holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation an amount equal to the Stated
Value, plus any accrued and unpaid dividends thereon and any other fees or liquidated damages then due and owing thereon under this Certificate
of Designation, for each share of Preferred Stock before any distribution or payment shall be made to the holders of any Junior Securities,
and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the
Holders shall be ratably distributed among the Holders in accordance with the respective amounts that would be payable on such shares
if all amounts payable thereon were paid in full. A Fundamental Transaction shall not be deemed a Liquidation. The Corporation shall mail
written notice of any such Liquidation, not less than 45 days prior to the payment date stated therein, to each Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><U>Section 6</U>. <U>Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)  <U>Conversions
at Option of Holder</U>. Each share of Preferred Stock shall be convertible, at any time and from time to time from and after the Original
Issue Date at the option of the Holder thereof, into that number of shares of Common Stock (subject to the limitations set forth in Section
6(d) and Section 6(e)) determined by dividing the Stated Value of such share of Preferred Stock by the Conversion Price. Holders shall
effect conversions by providing the Corporation with the form of conversion notice attached hereto as <U>Annex A</U> (a &ldquo;<U>Notice
of Conversion</U>&rdquo;). Each Notice of Conversion shall specify the number of shares of Preferred Stock to be converted, the number
of shares of Preferred Stock owned prior to the conversion at issue, the number of shares of Preferred Stock owned subsequent to the conversion
at issue and the date on which such conversion is to be effected, which date may not be prior to the date the applicable Holder delivers
by .pdf via email such Notice of Conversion to the Corporation (such date, the &ldquo;<U>Conversion Date</U>&rdquo;). If no Conversion
Date is specified in a Notice of Conversion, the Conversion Date shall be the date that such Notice of Conversion to the Corporation is
deemed delivered hereunder. No ink-original Notice of Conversion shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Conversion form be required. The calculations and entries set forth in the Notice of Conversion
shall control in the absence of manifest or mathematical error. To effect conversions of shares of Preferred Stock, a Holder shall not
be required to surrender the certificate(s) representing the shares of Preferred Stock to the Corporation unless all of the shares of
Preferred Stock represented thereby are so converted, in which case such Holder shall deliver the certificate representing such shares
of Preferred Stock promptly following the Conversion Date at issue. Shares of Preferred Stock converted into Common Stock or redeemed
in accordance with the terms hereof shall be canceled and shall not be reissued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)  <U>Conversion
Price</U>. The conversion price for the Preferred Stock shall equal $2.043, subject to adjustment herein (the &ldquo;<U>Conversion Price</U>&rdquo;);
provided that upon each exercise of a Greenshoe Right pursuant to Section 2.4 of the Purchase Agreement in the event that 90% of the arithmetic
average of the five (5) lowest Trading Prices during the 10 Trading Days immediately prior to such exercise of a Greenshoe Right is less
than the then Conversion Price (each such price, the &ldquo;<U>Adjusted Price</U>&rdquo;), the Conversion Price shall thereafter be reduced
to equal the Adjusted Price, subject to further adjustment hereunder, provided further that the reduced Adjusted Price shall in all events
be subject to a floor of $0.454 (the &ldquo;<U>Floor Price</U>&rdquo;) (subject to adjustment for reverse and forward stock splits, recapitalizations
and similar transactions following the Original Issue Date and provided that if the Adjusted Price is less than the Floor Price, the Adjusted
Price shall equal the Floor Price). The Corporation shall give written notice of all Holders within one Trading Day of the receipt of
each such exercise of a Greenshoe Right along with the Adjusted Price, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"> c) <U>Mechanics of Conversion</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">i.  <U>Delivery
of Conversion Shares Upon Conversion</U>. Not later than the earlier of (i) on (1) Trading Day and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined below) after each Conversion Date (the &ldquo;<U>Share Delivery Date</U>&rdquo;), the Corporation
shall deliver, or cause to be delivered, to the converting Holder (A) the number of Conversion Shares being acquired upon the conversion
of the Preferred Stock (including, if the Corporation has given continuous notice pursuant to Section 3(b) for payment of dividends in
shares of Common Stock at least 10 Trading Days prior to the date on which the Notice of Conversion is delivered to the Corporation, shares
of Common Stock representing the payment of accrued dividends otherwise determined pursuant to Section 3(a) but assuming that the Dividend
Notice Period is the 10 Trading Days-period immediately prior to the date on which the Notice of Conversion is delivered to the Corporation
and excluding for such issuance the condition that the Corporation deliver the Dividend Share Amount as to such dividend payment prior
to the commencement of the Dividend Notice Period) which, on or after the earlier of (i) the six month anniversary of the Original Issue
Date or (ii) the Effective Date (with respect to the shares of Common Stock registered for resale pursuant to a Conversion Shares Registration
Statement), shall be free of restrictive legends and trading restrictions (other than those which may then be required by the Purchase
Agreement), and (B) a bank check in the amount of accrued and unpaid dividends (if the Corporation has elected or is required to pay accrued
dividends in cash). On or after the earlier of (i) the six month anniversary of the Original Issue Date or (ii) the Effective Date (with
respect to the shares of Common Stock registered for resale pursuant to a Conversion Shares Registration Statement), the Corporation shall
deliver the Conversion Shares required to be delivered by the Corporation under this Section 6 electronically through the Depository Trust
Company or another established clearing corporation performing similar functions. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Corporation&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">ii.  <U>Failure
to Deliver Conversion Shares</U>. If, in the case of any Notice of Conversion, such Conversion Shares are not delivered to or as directed
by the applicable Holder by the Share Delivery Date, the Holder shall be entitled to elect by written notice to the Corporation at any
time on or before its receipt of such Conversion Shares, to rescind such Conversion, in which event the Corporation shall promptly return
to the Holder any original Preferred Stock certificate delivered to the Corporation and the Holder shall promptly return to the Corporation
the Conversion Shares issued to such Holder pursuant to the rescinded Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">iii.  <U>Obligation
Absolute; Partial Liquidated Damages</U>. The Corporation&rsquo;s obligation to issue and deliver the Conversion Shares upon conversion
of Preferred Stock in accordance with the terms hereof are absolute and unconditional, irrespective of any action or inaction by a Holder
to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any
action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by such
Holder or any other Person of any obligation to the Corporation or any violation or alleged violation of law by such Holder or any other
person, and irrespective of any other circumstance which might otherwise limit such obligation of the Corporation to such Holder in connection
with the issuance of such Conversion Shares; <U>provided</U>, <U>however</U>, that such delivery shall not operate as a waiver by the
Corporation of any such action that the Corporation may have against such Holder. In the event a Holder shall elect to convert any or
all of the Stated Value of its Preferred Stock, the Corporation may not refuse conversion based on any claim that such Holder or any one
associated or affiliated with such Holder has been engaged in any violation of law, agreement or for any other reason, unless an injunction
from a court, on notice to Holder, restraining and/or enjoining conversion of all or part of the Preferred Stock of such Holder shall
have been sought and obtained, and the Corporation posts a surety bond for the benefit of such Holder in the amount of 150% of the Stated
Value of Preferred Stock which is subject to the injunction, which bond shall remain in effect until the completion of arbitration/litigation
of the underlying dispute and the proceeds of which shall be payable to such Holder to the extent it obtains judgment. In the absence
of such injunction, the Corporation shall issue Conversion Shares and, if applicable, cash, upon a properly noticed conversion. If the
Corporation fails to deliver to a Holder such Conversion Shares pursuant to Section 6(c)(i) by the Share Delivery Date applicable to such
conversion, the Corporation shall pay to such Holder, in cash, as liquidated damages and not as a penalty, for each $5,000 of Stated Value
of Preferred Stock being converted, $50 per Trading Day (increasing to $100 per Trading Day on the third Trading Day and increasing to
$200 per Trading Day on the sixth Trading Day after the Share Delivery Date) for each Trading Day after the Share Delivery Date until
such Conversion Shares are delivered or Holder rescinds such conversion. Nothing herein shall limit a Holder&rsquo;s right to pursue actual
damages or declare a Triggering Event pursuant to Section 10 hereof for the Corporation&rsquo;s failure to deliver Conversion Shares within
the period specified herein and such Holder shall have the right to pursue all remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief. The exercise of any such rights shall not prohibit
a Holder from seeking to enforce damages pursuant to any other Section hereof or under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">iv.  <U>Compensation
for Buy-In on Failure to Timely Deliver Conversion Shares Upon Conversion</U>. In addition to any other rights available to the Holder,
if the Corporation fails for any reason to deliver to a Holder the applicable Conversion Shares by the Share Delivery Date pursuant to
Section 6(c)(i), and if after such Share Delivery Date such Holder is required by its brokerage firm to purchase (in an open market transaction
or otherwise), or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by
such Holder of the Conversion Shares which such Holder was entitled to receive upon the conversion relating to such Share Delivery Date
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Corporation shall (A) pay in cash to such Holder (in addition to any other remedies available
to or elected by such Holder) the amount, if any, by which (x) such Holder&rsquo;s total purchase price (including any brokerage commissions)
for the Common Stock so purchased exceeds (y) the product of (1) the aggregate number of shares of Common Stock that such Holder was entitled
to receive from the conversion at issue multiplied by (2) the actual sale price at which the sell order giving rise to such purchase obligation
was executed (including any brokerage commissions) and (B) at the option of such Holder, either reissue (if surrendered) the shares of
Preferred Stock equal to the number of shares of Preferred Stock submitted for conversion (in which case, such conversion shall be deemed
rescinded) or deliver to such Holder the number of shares of Common Stock that would have been issued if the Corporation had timely complied
with its delivery requirements under Section 6(c)(i). For example, if a Holder purchases shares of Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted conversion of shares of Preferred Stock with respect to which the actual
sale price of the Conversion Shares (including any brokerage commissions) giving rise to such purchase obligation was a total of $10,000
under clause (A) of the immediately preceding sentence, the Corporation shall be required to pay such Holder $1,000. The Holder shall
provide the Corporation written notice indicating the amounts payable to such Holder in respect of the Buy-In and, upon request of the
Corporation, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available
to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect
to the Corporation&rsquo;s failure to timely deliver the Conversion Shares upon conversion of the shares of Preferred Stock as required
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">v.  <U>Reservation
of Shares Issuable Upon Conversion</U>. The Corporation covenants that it will at all times reserve and keep available out of its authorized
and unissued shares of Common Stock for the sole purpose of issuance upon conversion of the Preferred Stock and payment of dividends on
the Preferred Stock, each as herein provided, free from preemptive rights or any other actual contingent purchase rights of Persons other
than the Holder (and the other holders of the Preferred Stock), not less than the Required Minimum (as defined in the Purchase Agreement).
The Corporation covenants that all shares of Common Stock that shall be so issuable shall, upon issue, be duly authorized, validly issued,
fully paid and nonassessable and, if a Conversion Shares Registration Statement is then effective under the Securities Act, shall be registered
for public resale to the extent covered by and in accordance with such Conversion Shares Registration Statement (subject to such Holder&rsquo;s
compliance with its obligations under the Registration Rights Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">vi.  <U>Fractional
Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of the Preferred Stock. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such conversion, the Corporation shall at its
election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion
Price or round up to the next whole share. Notwithstanding anything to the contrary contained herein, but consistent with the provisions
of this subsection with respect to fractional Conversion Shares, nothing shall prevent any Holder from converting fractional shares of
Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">vii.  <U>Transfer
Taxes and Expenses</U>. The issuance of Conversion Shares on conversion of this Preferred Stock shall be made without charge to any Holder
for any documentary stamp or similar taxes that may be payable in respect of the issue or delivery of such Conversion Shares, provided
that the Corporation shall not be required to pay any tax that may be payable in respect of any transfer involved in the issuance and
delivery of any such Conversion Shares upon conversion in a name other than that of the Holders of such shares of Preferred Stock and
the Corporation shall not be required to issue or deliver such Conversion Shares unless or until the Person or Persons requesting the
issuance thereof shall have paid to the Corporation the amount of such tax or shall have established to the satisfaction of the Corporation
that such tax has been paid. The Corporation shall pay all Transfer Agent fees required for same-day processing of any Notice of Conversion
and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day
electronic delivery of the Conversion Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)  <U>Beneficial
Ownership Limitation</U>. The Corporation shall not effect any conversion of the Preferred Stock, and a Holder shall not have the right
to convert any portion of the Preferred Stock, to the extent that, after giving effect to the conversion set forth on the applicable Notice
of Conversion, such Holder (together with such Holder&rsquo;s Affiliates, and any Persons acting as a group together with such Holder
or any of such Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)) would beneficially own in excess of
the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially
owned by such Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon conversion
of the Preferred Stock with respect to which such determination is being made, but shall exclude the number of shares of Common Stock
which are issuable upon (i) conversion of the remaining, unconverted Stated Value of Preferred Stock beneficially owned by such Holder
or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other
securities of the Corporation subject to a limitation on conversion or exercise analogous to the limitation contained herein (including,
without limitation, the Preferred Stock or the Warrants) beneficially owned by such Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 6(d), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. To the extent that the limitation contained
in this Section 6(d) applies, the determination of whether the Preferred Stock is convertible (in relation to other securities owned by
such Holder together with any Affiliates and Attribution Parties) and of how many shares of Preferred Stock are convertible shall be in
the sole discretion of such Holder, and the submission of a Notice of Conversion shall be deemed to be such Holder&rsquo;s determination
of whether the shares of Preferred Stock may be converted (in relation to other securities owned by such Holder together with any Affiliates
and Attribution Parties) and how many shares of the Preferred Stock are convertible, in each case subject to the Beneficial Ownership
Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Corporation each time it delivers
a Notice of Conversion that such Notice of Conversion has not violated the restrictions set forth in this paragraph and the Corporation
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 6(d), in determining the number of outstanding shares of Common Stock, a Holder may rely on the
number of outstanding shares of Common Stock as stated in the most recent of the following: (i) the Corporation&rsquo;s most recent periodic
or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement by the Corporation or (iii) a more
recent written notice by the Corporation or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the
written or oral request of a Holder, the Corporation shall within one Trading Day confirm orally and in writing to such Holder the number
of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving
effect to the conversion or exercise of securities of the Corporation, including the Preferred Stock, by such Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon conversion of Preferred Stock held by the applicable Holder. A Holder, upon notice
to the Corporation, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 6(d) applicable to its Preferred
Stock provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Preferred Stock held by the Holder and
the provisions of this Section 6(d) shall continue to apply. Any such increase in the Beneficial Ownership Limitation will not be effective
until the 61<SUP>st</SUP> day after such notice is delivered to the Corporation and shall only apply to such Holder and no other Holder.
The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 6(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial
Ownership Limitation contained herein or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)  <U>Issuance
Limitations</U>. Notwithstanding anything herein to the contrary, if the Corporation has not obtained Shareholder Approval, then the Corporation
may not issue, upon conversion of the Preferred Stock, a number of shares of Common Stock which, when aggregated with any shares of Common
Stock issued on or after the Original Issue Date and prior to such Conversion Date (i) in connection with any conversion of Preferred
Stock issued pursuant to the Purchase Agreement, (ii) in connection with the exercise of any Warrants issued pursuant to the Purchase
Agreement and (iii) in connection with the exercise of any warrants issued to any registered broker-dealer as a fee in connection with
the issuance of the Securities pursuant to the Purchase Agreement, would exceed 507,025 shares of Common Stock (subject to adjustment
for forward and reverse stock splits, recapitalizations and the like) (such number of shares, the &ldquo;<U>Issuable Maximum</U>&rdquo;).
Each Holder shall be entitled to a portion of the Issuable Maximum equal to the quotient obtained by dividing (x) the original Stated
Value of such Holder&rsquo;s Preferred Stock by (y) the aggregate Stated Value of all Preferred Stock issued on the Original Issue Date
to all Holders. In addition, each Holder may allocate its pro-rata portion of the Issuable Maximum among Preferred Stock and Warrants
held by it in its sole discretion. Such portion shall be adjusted upward ratably in the event a Holder no longer holds any Preferred Stock
or Warrants and the amount of shares issued to such Holder pursuant to such Holder&rsquo;s Preferred Stock and Warrants was less than
such Holder&rsquo;s pro-rata share of the Issuable Maximum. For avoidance of doubt, unless and until any required Shareholder Approval
is obtained and effective, warrants issued to any registered broker-dealer as a fee in connection with the Securities issued pursuant
to the Purchase Agreement as described in clause (iii) above shall provide that such warrants shall not be allocated any portion of the
Issuable Maximum and shall be unexercisable unless and until such Shareholder Approval is obtained and effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><U>Section 7</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)  <U>Stock
Dividends and Stock Splits</U>. If the Corporation, at any time while this Preferred Stock is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions payable in shares of Common Stock on shares of Common Stock or any other Common Stock
Equivalents (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation upon conversion of,
or payment of a dividend on, this Preferred Stock), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of a reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues, in the event of a reclassification of shares of the Common Stock, any shares of capital stock of the Corporation, then the Conversion
Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding any treasury shares
of the Corporation) outstanding immediately before such event, and of which the denominator shall be the number of shares of Common Stock
outstanding immediately after such event. Any adjustment made pursuant to this Section 7(a) shall become effective immediately after the
record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately
after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)  <U>Subsequent
Equity Sales</U>. If, at any time while this Preferred Stock is outstanding, the Corporation or any Subsidiary, as applicable, sells or
grants any option to purchase or sells or grants any right to reprice, or otherwise disposes of or issues (or announces any sale, grant
or any option to purchase or other disposition), any Common Stock or Common Stock Equivalents entitling any Person to acquire shares of
Common Stock at an effective price per share that is lower than the then Conversion Price (such lower price, the &ldquo;<U>Base Conversion
Price</U>&rdquo; and such issuances, collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (if the holder of the Common Stock or Common
Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion,
exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance,
be entitled to receive shares of Common Stock at an effective price per share that is lower than the Conversion Price, such issuance shall
be deemed to have occurred for less than the Conversion Price on such date of the Dilutive Issuance), then simultaneously with the consummation
(or, if earlier, the announcement) of each Dilutive Issuance the Conversion Price shall be reduced to equal the Base Conversion Price.
Notwithstanding the foregoing, no adjustment will be made under this Section 7(b) in respect of an Exempt Issuance. If the Corporation
enters into a Variable Rate Transaction, despite the prohibition set forth in the Purchase Agreement, the Corporation shall be deemed
to have issued Common Stock or Common Stock Equivalents at the lowest possible conversion price at which such securities may be converted
or exercised. The Corporation shall notify the Holders in writing, no later than the Trading Day following the issuance of any Common
Stock or Common Stock Equivalents subject to this Section 7(b), indicating therein the applicable issuance price, or applicable reset
price, exchange price, conversion price and other pricing terms (such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;). For
purposes of clarification, whether or not the Corporation provides a Dilutive Issuance Notice pursuant to this Section 7(b), upon the
occurrence of any Dilutive Issuance, the Holders are entitled to receive a number of Conversion Shares based upon the Base Conversion
Price on or after the date of such Dilutive Issuance, regardless of whether a Holder accurately refers to the Base Conversion Price in
the Notice of Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)  <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 7(a) above, if at any time the Corporation grants, issues or
sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders
of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the
terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete conversion of such Holder&rsquo;s Preferred Stock (without regard to any limitations
on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is
taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders
of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent
that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation or the Corporation&rsquo;s issuance of shares in excess of
the Issuable Maximum).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)  <U>Pro
Rata Distributions</U>. During such time as this Preferred Stock is outstanding, if the Corporation declares or makes any dividend or
other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Preferred Stock, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete conversion of this Preferred Stock (without regard to any limitations on conversion hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution
(<U>provided</U>, <U>however</U>, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in
the Holder exceeding the Beneficial Ownership Limitation or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum,
then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares
of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)  <U>Fundamental
Transaction</U>. If, at any time while this Preferred Stock is outstanding, (i) the Corporation, directly or indirectly, in one or more
related transactions effects any merger or consolidation of the Corporation with or into another Person, (ii) the Corporation (and all
of its Subsidiaries, taken as a whole), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or
other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Corporation or another Person) is completed pursuant to which holders of
Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the
holders of 50% or more of the outstanding Common Stock, (iv) the Corporation, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Corporation, directly or
indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person
acquires more than 50% of the outstanding shares of Common Stock (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any
subsequent conversion of this Preferred Stock, the Holder shall have the right to receive, for each Conversion Share that would have been
issuable upon such conversion immediately prior to the occurrence of such Fundamental Transaction (without regard to any limitation in
Section 6(d) and Section 6(e) on the conversion of this Preferred Stock), the number of shares of Common Stock of the successor or acquiring
corporation or of the Corporation, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Preferred Stock
is convertible immediately prior to such Fundamental Transaction (without regard to any limitation in Section 6(d) and Section 6(e) on
the conversion of this Preferred Stock). For purposes of any such conversion, the determination of the Conversion Price shall be appropriately
adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Corporation shall apportion the Conversion Price among the Alternate Consideration in a
reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock
are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given
the same choice as to the Alternate Consideration it receives upon any conversion of this Preferred Stock following such Fundamental Transaction.
To the extent necessary to effectuate the foregoing provisions, any successor to the Corporation or surviving entity in such Fundamental
Transaction shall file a new Certificate of Designation with the same terms and conditions and issue to the Holders new preferred stock
consistent with the foregoing provisions and evidencing the Holders&rsquo; right to convert such preferred stock into Alternate Consideration.
The Corporation shall cause any successor entity in a Fundamental Transaction in which the Corporation is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Corporation under this Certificate of Designation and the other
Transaction Documents (as defined in the Purchase Agreement) in accordance with the provisions of this Section 7(e) pursuant to written
agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to
such Fundamental Transaction and shall, at the option of the holder of this Preferred Stock, deliver to the Holder in exchange for this
Preferred Stock a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Preferred Stock which is convertible for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity)
equivalent to the shares of Common Stock acquirable and receivable upon conversion of this Preferred Stock (without regard to any limitations
on the conversion of this Preferred Stock) prior to such Fundamental Transaction, and with a conversion price which applies the conversion
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to
such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such conversion
price being for the purpose of protecting the economic value of this Preferred Stock immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions
of this Certificate of Designation and the other Transaction Documents referring to the &ldquo;Corporation&rdquo; shall refer instead
to the Successor Entity), and may exercise every right and power of the Corporation and shall assume all of the obligations of the Corporation
under this Certificate of Designation and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Corporation herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)  <U>Calculations</U>.
All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 7, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding any treasury shares of the Corporation) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)  <U>Notice
to the Holders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">i.  <U>Adjustment
to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section 7, the Corporation shall
promptly deliver to each Holder by email a notice setting forth the Conversion Price after such adjustment and setting forth a brief statement
of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">ii.  <U>Notice
to Allow Conversion by Holder</U>. If (A) the Corporation shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Corporation shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Corporation
shall authorize the granting to all holders of the Common Stock of rights or warrants to subscribe for or purchase any shares of capital
stock of any class or of any rights, (D) the approval of any stockholders of the Corporation shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which the Corporation is a party, any sale or transfer of all or
substantially all of the assets of the Corporation (and all of its Subsidiaries, taken as a whole), or any compulsory share exchange whereby
the Common Stock is converted into other securities, cash or property or (E) the Corporation shall authorize the voluntary or involuntary
dissolution, liquidation or winding up of the affairs of the Corporation, then, in each case, the Corporation shall cause to be filed
at each office or agency maintained for the purpose of conversion of this Preferred Stock, and shall cause to be delivered by email to
each Holder at its last email address as it shall appear upon the stock books of the Corporation, at least twenty (20) calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders
of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)
the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close,
and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common
Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange,
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided hereunder constitutes, or contains, material,
non-public information regarding the Corporation or any of the Subsidiaries, the Corporation shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to convert the Conversion Amount of this Preferred
Stock (or any part hereof) during the 20-day period commencing on the date of such notice through the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><U>Section 8</U>. <U>[RESERVED].</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; margin: 0pt; text-align: justify">   <U>Section 9</U>. <U>Negative Covenants</U>.
As long as any shares of Preferred Stock are outstanding, unless the Required Holders shall have otherwise given prior written consent,
the Corporation shall not, and shall not permit any of the Subsidiaries to, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)  other
than Permitted Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)  other
than Permitted Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property
or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)  amend
its charter documents, including, without limitation, its certificate of incorporation and bylaws, in any manner that materially and adversely
affects any rights of the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)  repay,
repurchase or offer to repay, repurchase or otherwise acquire more than a <U>de minimis</U> number of shares of its Common Stock, Common
Stock Equivalents or Junior Securities, other than as to (i) the Conversion Shares or Warrant Shares as permitted or required under the
Transaction Documents and (ii) repurchases of Common Stock or Common Stock Equivalents of departing officers and directors of the Corporation,
provided that such repurchases shall not exceed an aggregate of $100,000 for all officers and directors for so long as the Preferred Stock
is outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)  pay
cash dividends or distributions on Junior Securities of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)  enter
into any transaction with any Affiliate of the Corporation which would be required to be disclosed in any public filing with the Commission,
unless such transaction is made on an arm&rsquo;s-length basis and expressly approved by a majority of the disinterested directors of
the Corporation (even if less than a quorum otherwise required for board approval);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)  enter
into any factoring agreement, merchant cash advance agreement, revenue-based financing or similar arrangement whereby the Corporation
receives funds from any third party against future product or services sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)  enter
into any agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">   <U>Section 10</U>. <U>Redemption Upon Triggering
Events</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)  &ldquo;<U>Triggering
Event</U>&rdquo; means, wherever used herein any of the following events (whatever the reason for such event and whether such event shall
be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order, rule
or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">i.  the
failure of the initial Conversion Shares Registration Statement to be declared effective by the Commission on or prior to the 120<SUP>th</SUP>
day after the Original Issue Date or the Corporation does not meet the current public information requirements under Rule 144 in respect
of the Registrable Securities (as defined under the Registration Rights Agreement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">ii.  if,
during the Effectiveness Period (as defined in the Registration Rights Agreement), the effectiveness of any Conversion Shares Registration
Statement lapses for more than an aggregate of 30 calendar days (which need not be consecutive calendar days) during any 12 month period,
or the Holders shall not otherwise be permitted to resell the applicable Registrable Securities under a Conversion Shares Registration
Statement for more than an aggregate of 30 calendar days (which need not be consecutive calendar days) during any 12 month period;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">iii.  the
Corporation shall fail to deliver Conversion Shares issuable upon a conversion hereunder that comply with the provisions hereof prior
to the fifth Trading Day after such shares are required to be delivered hereunder, or the Corporation shall provide written notice to
any Holder, including by way of public announcement, at any time, of its intention not to comply with requests for conversion of any shares
of Preferred Stock in accordance with the terms hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">iv.  one
of the Events (as defined in the Registration Rights Agreement) described in subsections (i), (ii) or (iii) of Section 2(d) of the Registration
Rights Agreement shall not have been cured to the satisfaction of the Holders prior to the expiration of 30 calendar days from the Event
Date (as defined in the Registration Rights Agreement) relating thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">v.  the
Corporation shall fail for any reason to pay in full the amount of cash due pursuant to a Buy-In within five calendar days after notice
therefor is delivered hereunder or shall fail to pay all amounts owed on account of any Event (as defined in the Registration Rights Agreement)
within five days of the date due and payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">vi.  the
Corporation shall fail to have available a sufficient number of authorized and unreserved shares of Common Stock to issue to such Holder
upon a conversion hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">vii.  unless
specifically addressed elsewhere in this Certificate of Designation as a Triggering Event, the Corporation shall fail to observe or perform
any other covenant, agreement or warranty contained in, or otherwise commit any breach of the Transaction Documents, and such failure
or breach shall not, if subject to the possibility of a cure by the Corporation, have been cured within 30 calendar days after the date
on which written notice of such failure or breach shall have been delivered;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">viii.  the
Corporation shall terminate Michael Breen as the Chief Executive Officer of the Corporation without prior consent of all of the holders
of Preferred Stock then outstanding;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">ix.  the
Corporation shall redeem more than a <U>de minimis</U> number of Junior Securities other than as to repurchases of Common Stock or Common
Stock Equivalents from departing officers and directors, provided that, while any of the Preferred Stock remains outstanding, such repurchases
shall not exceed an aggregate of $100,000 from all officers and directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">x.  the
Corporation shall be party to a Fundamental Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">xi.  there
shall have occurred a Bankruptcy Event;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">xii.  the
Common Stock shall fail to be listed or quoted for trading on a Trading Market for more than five Trading Days, which need not be consecutive
Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">xiii.  the
electronic transfer by the Corporation of shares of Common Stock through the Depository Trust Company or another established clearing
corporation is no longer available or is subject to a &ldquo;chill&rdquo;; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 27pt">xiv.  any
monetary judgment, writ or similar final process shall be entered or filed against the Corporation, any subsidiary or any of their respective
property or other assets for more than $250,000, and such judgment, writ or similar final process shall remain unvacated, unbonded or
unstayed for a period of 45 calendar days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)  Upon
the occurrence of a Triggering Event, each Holder shall (in addition to all other rights it may have hereunder or under applicable law)
have the right, exercisable at the sole option of such Holder, to require the Corporation to, (A) with respect to the Triggering Events
set forth in Sections 10(a)(iii), (v), (vii), (viii), (ix), (x) (as to Changes of Control approved by the Board of Directors of the Corporation)
and (xi) (as to voluntary filings only), redeem all of the Preferred Stock then held by such Holder for a redemption price, in cash, equal
to the Triggering Redemption Amount or (B) at the option of each Holder and with respect to the Triggering Events set forth in Sections
10(a)(i), (ii), (iv), (vi), (x) (as to Fundamental Transactions not approved by the Board of Directors of the Corporation), (xi) (as to
involuntary filings only), (xii), (xiii) and (xiv), either (a) subject to Section 6(e) redeem all of the Preferred Stock then held by
such Holder for a redemption price, in shares of Common Stock, equal to a number of shares of Common Stock equal to the Triggering Redemption
Amount divided by 50% of the average of the 10 VWAPs immediately prior to the date of election hereunder or (b) increase the dividend
rate on all of the outstanding Preferred Stock held by such Holder to 18% per annum thereafter. The Triggering Redemption Amount, in cash
or in shares, shall be due and payable or issuable, as the case may be, within five Trading Days of the date on which the notice for the
payment therefor is provided by a Holder (the &ldquo;<U>Triggering Redemption Payment Date</U>&rdquo;). If the Corporation fails to pay
in full the Triggering Redemption Amount hereunder on the date such amount is due in accordance with this Section (whether in cash or
shares of Common Stock), the Corporation will pay interest thereon at a rate equal to the lesser of 18% per annum or the maximum rate
permitted by applicable law, accruing daily from such date until the Triggering Redemption Amount, plus all such interest thereon, is
paid in full. For purposes of this Section, a share of Preferred Stock is outstanding until such date as the applicable Holder shall have
received Conversion Shares upon a conversion (or attempted conversion) thereof that meets the requirements hereof or has been paid the
Triggering Redemption Amount in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">   <U>Section 11</U>.   <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)  <U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Conversion, shall be in writing and delivered personally, by e-mail attachment, or sent by a nationally recognized overnight courier
service, addressed to the Corporation, at 505 Montgomery Street, 10<SUP>th</SUP> Floor, San Francisco, CA 94111, Attention: Secretary,
e-mail address Alan.Urban@gtbiopharma.com, or such other e-mail address or address as the Corporation may specify for such purposes by
notice to the Holders delivered in accordance with this Section 11. Any and all notices or other communications or deliveries to be provided
by the Corporation hereunder shall be in writing and delivered personally, by e-mail attachment, or sent by a nationally recognized overnight
courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Corporation, or
if no such e-mail address or address appears on the books of the Corporation, at the principal place of business of such Holder, as set
forth in the Purchase Agreement. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the
earliest of (i) the date of transmission, if such notice or communication is delivered via e-mail attachment at the e-mail address set
forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if
such notice or communication is delivered via e-mail attachment at the e-mail address set forth in this Section on a day that is not a
Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)  <U>Absolute
Obligation</U>. Except as expressly provided herein, no provision of this Certificate of Designation shall alter or impair the obligation
of the Corporation, which is absolute and unconditional, to pay liquidated damages, accrued dividends and accrued interest, as applicable,
on the shares of Preferred Stock at the time, place, and rate, and in the coin or currency, herein prescribed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)  <U>Lost
or Mutilated Preferred Stock Certificate</U>. If a Holder&rsquo;s Preferred Stock certificate shall be mutilated, lost, stolen or destroyed,
the Corporation shall execute and deliver, in exchange and substitution for and upon cancellation of a mutilated certificate, or in lieu
of or in substitution for a lost, stolen or destroyed certificate, a new certificate for the shares of Preferred Stock so mutilated, lost,
stolen or destroyed, but only upon receipt of evidence of such loss, theft or destruction of such certificate, and of the ownership hereof
reasonably satisfactory to the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)  <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Certificate of Designation shall
be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles
of conflict of laws thereof. All legal proceedings concerning the interpretation, enforcement and defense of the transactions contemplated
by any of the Transaction Documents (whether brought against a party hereto or its respective Affiliates, directors, officers, shareholders,
employees or agents) shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the &ldquo;<U>New
York Courts</U>&rdquo;). The Corporation and each Holder hereby irrevocably submits to the exclusive jurisdiction of the New York Courts
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein
(including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert
in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such New York Courts, or such New
York Courts are improper or inconvenient venue for such proceeding. The Corporation and each Holder hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Certificate of Designation and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by applicable law. The Corporation
and each Holder hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any
legal proceeding arising out of or relating to this Certificate of Designation or the transactions contemplated hereby. If the Corporation
or any Holder shall commence an action or proceeding to enforce any provisions of this Certificate of Designation, then the prevailing
party in such action or proceeding shall be reimbursed by the other party for its attorneys&rsquo; fees and other costs and expenses incurred
in the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)  <U>Waiver</U>.
Any waiver by the Corporation or a Holder of a breach of any provision of this Certificate of Designation shall not operate as or be construed
to be a waiver of any other breach of such provision or of any breach of any other provision of this Certificate of Designation or a waiver
by any other Holders. The failure of the Corporation or a Holder to insist upon strict adherence to any term of this Certificate of Designation
on one or more occasions shall not be considered a waiver or deprive that party (or any other Holder) of the right thereafter to insist
upon strict adherence to that term or any other term of this Certificate of Designation on any other occasion. Any waiver by the Corporation
or a Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)  <U>Severability</U>.
If any provision of this Certificate of Designation is invalid, illegal or unenforceable, the balance of this Certificate of Designation
shall remain in effect, and if any provision is inapplicable to any Person or circumstance, it shall nevertheless remain applicable to
all other Persons and circumstances. If it shall be found that any interest or other amount deemed interest due hereunder violates the
applicable law governing usury, the applicable rate of interest due hereunder shall automatically be lowered to equal the maximum rate
of interest permitted under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)  <U>Next
Business Day</U>. Whenever any payment or other obligation hereunder shall be due on a day other than a Business Day, such payment shall
be made on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)  <U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Certificate of Designation and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)  <U>Status
of Converted or Redeemed Preferred Stock</U>. Shares of Preferred Stock may only be issued pursuant to the Purchase Agreement. If any
shares of Preferred Stock shall be converted, redeemed or reacquired by the Corporation, such shares shall resume the status of authorized
but unissued shares of preferred stock and shall no longer be designated as its Series L 10% Convertible Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">RESOLVED, FURTHER, that the Chairman, the president
or any vice-president, and the secretary or any assistant secretary, of the Corporation be and they hereby are authorized and directed
to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution
and the provisions of Delaware law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">IN WITNESS WHEREOF, the undersigned
have executed this Certificate this 12 day of May, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 49%">/s/ Michael Breen</TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 49%">/s/ Alan Urban</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name: Michael Breen</P></TD>
  <TD>&nbsp;</TD>
  <TD>Name: Alan Urban</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title: Chief Executive Officer &amp; Executive
      Chairman</P>
</TD>
  <TD>&nbsp;</TD>
  <TD>Title: Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>ANNEX A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">NOTICE OF CONVERSION</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">(To be Executed
by the Registered Holder in order to Convert Shares of Preferred Stock)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The undersigned hereby elects to convert the number
of shares of Series L 10% Convertible Preferred Stock indicated below into shares of common stock, par value $0.001 per share (the &ldquo;<U>Common
Stock</U>&rdquo;), of GT Biopharma, Inc., a Delaware corporation (the &ldquo;<U>Corporation</U>&rdquo;), according to the conditions hereof,
as of the date written below. If shares of Common Stock are to be issued in the name of a Person other than the undersigned, the undersigned
will pay all transfer taxes payable with respect thereto and is delivering herewith such certificates and opinions as may be required
by the Corporation in accordance with the Purchase Agreement. No fee will be charged to the Holders for any conversion, except for any
such transfer taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Conversion calculations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Date to Effect Conversion: _____________________________________________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Number of shares of Preferred Stock
owned prior to Conversion: _______________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Number of shares of Preferred Stock
to be Converted: ________________________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Stated Value of shares of Preferred
Stock to be Converted: ____________________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Number of shares of Common Stock
to be Issued: ___________________________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Applicable Conversion Price:____________________________________________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Number of shares of Preferred Stock
subsequent to Conversion: ________________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Address for Delivery: ______________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><U>or</U></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">DWAC Instructions:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Broker no: _________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Account no: ___________</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">[HOLDER]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">By:___________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 15pt">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 15pt">Title:</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>GT Biopharma,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">Warrant No.: _______ </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Warrant Shares: _______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-size: 10pt">Issue Date: May 12, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">THIS COMMON STOCK PURCHASE WARRANT (this
&ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled,
upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May 12, 2025
(the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on May 12, 2030 (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from GT Biopharma, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated May 12, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise of Warrant</U>.
Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail
attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of
(i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein)
following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable
Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and this Warrant has been exercised in full, in which case, the Holder shall surrender this
Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to
the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder
shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable
number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and
the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Trading Day of receipt of
such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of
this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The exercise price per share of Common Stock under this Warrant shall be <B>$2.043</B>, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not
available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time
by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the
quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">(A) </FONT></TD>
    <TD STYLE="text-align: center; width: 0.25in">=</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s delivery of the Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo; or with two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is delivered pursuant to Section 2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">(B) </FONT></TD>
    <TD STYLE="text-align: center">=</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the Exercise Price of this Warrant, as adjusted hereunder; and </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">(X) </FONT></TD>
    <TD STYLE="text-align: center">=</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Company and reasonably acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and
expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX Best
Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or
OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by the
OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Company and reasonably acceptable to the Purchasers of a majority in interest of the
Securities then outstanding, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this
Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Mechanics of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">i.</FONT> <FONT STYLE="font-size: 10pt"><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of this Warrant), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;); provided, however, that the aggregate Exercise Price has been delivered to the Company by the Warrant Share Delivery Date. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Holder duly exercises this Warrant pursuant to Section 2(a) hereof and the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">ii.</FONT> <FONT STYLE="font-size: 10pt"><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">iii.</FONT> <FONT STYLE="font-size: 10pt"><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"> <FONT STYLE="font-size: 10pt">iv.</FONT> <FONT STYLE="font-size: 10pt"><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of this Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of this Warrant as required pursuant to the terms hereof.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"> <FONT STYLE="font-size: 10pt">v.</FONT> <FONT STYLE="font-size: 10pt"><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">vi.</FONT> <FONT STYLE="font-size: 10pt"><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"> <FONT STYLE="font-size: 10pt">vii.</FONT> <FONT STYLE="font-size: 10pt"><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation. To ensure compliance
with this restriction, Holder will be deemed to represent to the Corporation each time it delivers a Notice of Exercise that such Notice
of Exercise has not violated the restrictions set forth in this paragraph and the Company shall have no obligation to verify or confirm
the accuracy of such determination. In addition, a determination as to any group status as contemplated above shall be determined in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares
of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.
The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Issuance Limitations</U>.
Notwithstanding anything herein to the contrary, if the Company has not obtained Shareholder Approval, then the Company may not issue,
upon exercise of this Warrant, in whole or in part, a number of shares of Common Stock which, when aggregated with any shares of Common
Stock issued on or after the Issue Date and prior to the exercise of this Warrant, in whole or in part, (i) in connection with any conversion
of Series L 10% Convertible Preferred Stock (the &ldquo;<U>Preferred Stock</U>&rdquo;) issued pursuant to the Purchase Agreement, (ii)
in connection with the exercise of any Warrants issued pursuant to the Purchase Agreement and (iii) in connection with the exercise of
any warrants issued to any registered broker-dealer as a fee in connection with the issuance of the Securities pursuant to the Purchase
Agreement, would exceed 507,025 shares of Common Stock (subject to adjustment for forward and reverse stock splits, recapitalizations
and the like) (such number of shares, the &ldquo;<U>Issuable Maximum</U>&rdquo;). Holder shall be entitled to a portion of the Issuable
Maximum equal to the quotient obtained by dividing (x) the original Stated Value of Holder&rsquo;s Preferred Stock by (y) the aggregate
Stated Value of all Preferred Stock issued on the Original Issue Date (as defined in the Certificate of Designation of Preferences, Rights
and Limitations of Preferred Stock of the Company) to all holders of Preferred Stock. In addition, Holder may allocate its pro-rata portion
of the Issuable Maximum among Preferred Stock and Warrants held by it in its sole discretion. Such portion shall be adjusted upward ratably
in the event a Holder no longer holds any Preferred Stock or Warrants and the amount of shares issued to such Holder pursuant to such
Holder&rsquo;s Preferred Stock and Warrants was less than such Holder&rsquo;s pro-rata share of the Issuable Maximum. For avoidance of
doubt, unless and until any required Shareholder Approval is obtained and effective, warrants issued to any registered broker-dealer as
a fee in connection with the Securities issued pursuant to the Purchase Agreement as described in clause (iii) above shall provide that
such warrants shall not be allocated any portion of the Issuable Maximum and shall be unexercisable unless and until such Shareholder
Approval is obtained and effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent Equity
Sales</U>. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell, enter into
an agreement to sell, or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce
any offer, sale, grant or any option to purchase or other disposition), including but not limited, to the exercise of the Greenshoe Rights
pursuant to Section 2.4 of the Purchase Agreement, any Common Stock or Common Stock Equivalents, at an effective price per share less
than the Exercise Price then in effect (such lower price, the &ldquo;<U>Base Share Price</U>&rdquo; and such issuances collectively, a
&ldquo;<U>Dilutive Issuance</U>&rdquo;) (it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents
so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange
prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to
receive shares of Common Stock at an effective price per share that is less than the Exercise Price, such issuance shall be deemed to
have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price), then simultaneously with
the consummation (or, if earlier, the announcement) of each Dilutive Issuance, the Exercise Price shall be reduced and only reduced to
equal the Base Share Price, and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price
payable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior
to such adjustment. Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 3(b) in respect of
an Exempt Issuance. The Company shall notify the Holder, in writing, no later than the Trading Day following the issuance or deemed issuance
of any Common Stock or Common Stock Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable
reset price, exchange price, conversion price and other pricing terms (such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;).
For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 3(b), upon the
occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant Shares based upon the Base Share Price regardless
of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. If the Company enters into a Variable Rate
Transaction, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest possible price, conversion
price or exercise price at which such securities may be issued, converted or exercised. If any shares of Common Stock or Common Stock
Equivalents are issued or sold or deemed to have been issued or sold for cash, the consideration received therefor will be deemed to be
the net amount of cash received by the Company therefor. If any shares of Common Stock or Common Stock Equivalents are issued or sold
for consideration other than cash, the amount of such consideration received by the Company will be the fair value of such consideration,
except where such consideration consists of publicly traded securities or Common Stock (including Common Stock transferred from existing
third-party stockholder), in which case the amount of consideration received by the Company will be the volume weighted average price
of such publicly traded securities on the date of receipt of such publicly traded securities. The fair value of any consideration other
than cash or publicly traded securities will be reasonably and in good faith determined jointly by the Company and the Purchasers of a
majority in interest of the Securities then outstanding. If such parties are unable to reach agreement within ten (10) days after the
occurrence of an event requiring valuation (the &ldquo;<U>Valuation Event</U>&rdquo;), the fair value of such consideration will be determined
within five (5) Business Days after the tenth (10th) day following the Valuation Event by an independent appraiser selected in good faith
by the Company and reasonably acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and
expenses of which shall be paid by the Company. The determination of such appraiser shall be final and binding upon all parties absent
manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common
Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation or the Corporation&rsquo;s
issuance of shares in excess of the Issuable Maximum, then the Holder shall not be entitled to participate in such Purchase Right to such
extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right
to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets
(or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without
regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares
of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent
that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation
or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum, then the Holder shall not be entitled to participate
in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to
such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as
its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation or the Corporation&rsquo;s issuance of
shares in excess of the Issuable Maximum). To the extent that this Warrant has not been partially or completely exercised at the time
of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has exercised
this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental Transaction</U>.
If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects
any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly, effects
any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a
series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of greater than 50% of the outstanding Common Stock or greater than
50% of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly,
in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without
limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby
such other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power
of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately
prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e)
on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if
it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result
of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately
prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any
different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property
to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives
upon any exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any
time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash
equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation
of such Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company&rsquo;s
control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the Company
or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised
portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental
Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock
are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; <U>provided</U>,
<U>further</U>, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction,
such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Successor Entity may be the Company
following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this
Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the
day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding
to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental
Transaction and the Termination Date, (B) an expected volatility equal to the 100 day volatility as obtained from the HVT function on
Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of
the applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental
Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable contemplated
Fundamental Transaction and the Termination Date and (E) a zero cost of borrow. The payment of the Black Scholes Value will be made by
wire transfer of immediately available funds (or such other consideration) within the later of (i) five Business Days of the Holder&rsquo;s
election and (ii) the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations
of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay)
prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable
for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common
Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior
to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction,
each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead
to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities,
jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor
Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with
the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company
herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of
(i) whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental
Transaction occurs prior to the Initial Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. </FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.25in"><FONT STYLE="font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to
be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information
regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a
Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such
notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 4</U>. <U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or the Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be
identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer Restrictions</U>.
If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not
be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities
or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements
pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant,
as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.
Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to
receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to net cash settle
an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft
or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not include the posting
of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period this Warrant is outstanding, it will reserve from its authorized and unissued Common Stock an amount of shares
at least equal to the Required Minimum (as defined in the Purchase Agreement). The Company further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of
the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and
payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from
all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any action
which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver and
Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver
of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant
or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>. Any
notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation of
Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors and
Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit
of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt; text-transform: uppercase"><B>GT Biopharma, Inc. </B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: left">&nbsp;&#8239;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: GT Biopharma,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"> &#9744; in
lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant Shares
in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">(4) Accredited Investor. The undersigned is an &ldquo;accredited
investor&rdquo; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing Warrant,
execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt"><U></U></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">(Please Print)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">(Please Print)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Signature:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Holder&rsquo;s Address:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>4
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 4.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH
THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO
AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>COMMON STOCK VESTING WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>GT Biopharma,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Warrant No.: _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 60%">Warrant Shares: _______</TD>
  <TD STYLE="padding-left: 10pt; text-indent: -10pt; width: 40%">Issue Date: May 12, 2025</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: left; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3.5in; text-align: left"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in">THIS COMMON STOCK VESTING WARRANT
(this &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
May 12, 2025 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on the five-year anniversary
of the date that the applicable Warrant Shares vest hereunder (each, a &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from GT Biopharma, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to
adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock; <U>provided</U>, <U>however</U>, the exercisability of
this Warrant shall vest ratably from time to time in proportion to the Holder&rsquo;s (or its permitted assigns) exercise of such Holder&rsquo;s
Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement compared with all Greenshoe Securities issuable to the Holder pursuant
to the Greenshoe Right pursuant to Section 2.4 of the Purchase Agreement (&ldquo;<U>Vesting Schedule</U>&rdquo;). By way of example, if
the Holder exercises all of its Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement, all Warrant Shares hereunder may be
exercised by the Holder and if the Holder exercises half of its Greenshoe Rights, only half of the Warrant Shares hereunder may be exercised
by the Holder until such time that the Holder exercises additional Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement.
Notwithstanding anything herein to the contrary, the purchase price of one share of Common Stock under this Warrant shall be equal to
the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section
1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain
Securities Purchase Agreement (the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated May 12, 2025, among the Company and the
purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section
2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times
on or after the Initial Exercise Date in accordance with the Vesting Schedule and on or before the applicable Termination Date by
delivery to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form
annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of
Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as
aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by
wire transfer or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section
2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any
medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has
purchased all of the Warrant Shares available hereunder and this Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of
Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of
Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder
in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of
Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares
hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the
face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$2.043</B>, subject to adjustment hereunder
(the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in
whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a
number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 0.25in">(A)</TD>
    <TD STYLE="text-align: center; width: 0.25in">=</TD>
  <TD STYLE="text-align: justify"> as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of
Exercise is (1) delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) delivered pursuant to Section 2(a)
hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated
under the federal securities laws) on such Trading Day, (ii) the highest Bid Price of the Common Stock on the principal Trading Market
as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) within two (2) hours of the time of the Holder&rsquo;s delivery of the
Notice of Exercise pursuant to Section 2(a) hereof if such Notice of Exercise is delivered during &ldquo;regular trading hours,&rdquo;
or with two (2) hours after the close of &ldquo;regular trading hours,&rdquo; on a Trading Day or (iii) the VWAP on the date of the applicable
Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is delivered pursuant to Section
2(a) hereof after two (2) hours following the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(B)</TD>
    <TD STYLE="text-align: center; width: 0.25in">=</TD>
  <TD STYLE="text-align: justify"> the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">(X)</TD>
  <TD STYLE="text-align: center; width: 0.25in">=</TD>
  <TD STYLE="text-align: justify"> the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Company and reasonably acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and
expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&ldquo;<U>OTCQB</U>&rdquo;) or the OTCQX Best
Market (&ldquo;<U>OTCQX</U>&rdquo;) is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or
OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (&ldquo;<U>Pink Market</U>&rdquo;) operated by the
OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Company and reasonably acceptable to the Purchasers of a majority in interest of the
Securities then outstanding, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, on the applicable Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in"> i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of this Warrant), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;); provided, however, that the aggregate Exercise Price has been delivered to the Company by the Warrant Share Delivery Date. Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Holder duly exercises this Warrant pursuant to Section 2(a) hereof and the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder
and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section
2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder,
if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of
Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is
required by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise
purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the
amount, if any, by which (x) the Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of
Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was
required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise
to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of this Warrant and
equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded)
or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its
exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase price of
$11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise
to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of
the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right
to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific
performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon
exercise of this Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other
incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company,
and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered
for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as
a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay
all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or
another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this
Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange
Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the
Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation. To ensure compliance with this restriction, Holder will be deemed to represent to the Corporation
each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this
paragraph and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act
and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the
Company&rsquo;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of
shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm
orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of
Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%/9.99%] of the number of shares
of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of
this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of
this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by
the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall
be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this
paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein
contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Issuance
Limitations</U>. Notwithstanding anything herein to the contrary, if the Company has not obtained Shareholder Approval, then the
Company may not issue, upon exercise of this Warrant, in whole or in part, a number of shares of Common Stock which, when aggregated
with any shares of Common Stock issued on or after the Issue Date and prior to the exercise of this Warrant, in whole or in part,
(i) in connection with any conversion of Series L 10% Convertible Preferred Stock (the &ldquo;<U>Preferred Stock</U>&rdquo;) issued
pursuant to the Purchase Agreement, (ii) in connection with the exercise of any Warrants issued pursuant to the Purchase Agreement
and (iii) in connection with the exercise of any warrants issued to any registered broker-dealer as a fee in connection with the
issuance of the Securities pursuant to the Purchase Agreement, would exceed 507,025 shares of Common Stock (subject to adjustment
for forward and reverse stock splits, recapitalizations and the like) (such number of shares, the &ldquo;<U>Issuable
Maximum</U>&rdquo;). Holder shall be entitled to a portion of the Issuable Maximum equal to the quotient obtained by dividing (x)
the original Stated Value of Holder&rsquo;s Preferred Stock by (y) the aggregate Stated Value of all Preferred Stock issued on the
Original Issue Date (as defined in the Certificate of Designation of Preferences, Rights and Limitations of Preferred Stock of the
Company) to all holders of Preferred Stock. In addition, Holder may allocate its pro-rata portion of the Issuable Maximum among
Preferred Stock and Warrants held by it in its sole discretion. Such portion shall be adjusted upward ratably in the event a Holder
no longer holds any Preferred Stock or Warrants and the amount of shares issued to such Holder pursuant to such Holder&rsquo;s
Preferred Stock and Warrants was less than such Holder&rsquo;s pro-rata share of the Issuable Maximum. For avoidance of doubt,
unless and until any required Shareholder Approval is obtained and effective, warrants issued to any registered broker-dealer as a
fee in connection with the Securities issued pursuant to the Purchase Agreement as described in clause (iii) above shall provide
that such warrants shall not be allocated any portion of the Issuable Maximum and shall be unexercisable unless and until such
Shareholder Approval is obtained and effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section
3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Equity Sales</U>. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall
sell, enter into an agreement to sell, or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose
of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) including but not limited, to the
exercise of the Greenshoe Rights pursuant to Section 2.4 of the Purchase Agreement, any Common Stock or Common Stock Equivalents, at
an effective price per share less than the Exercise Price then in effect (such lower price, the &ldquo;<U>Base Share
Price</U>&rdquo; and such issuances collectively, a &ldquo;<U>Dilutive Issuance</U>&rdquo;) (it being understood and agreed that if
the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price
adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights
per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per
share that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such
date of the Dilutive Issuance at such effective price), then simultaneously with the consummation (or, if earlier, the announcement)
of each Dilutive Issuance, the Exercise Price shall be reduced and only reduced to equal the Base Share Price and the number of
Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price payable hereunder, after taking into
account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment. Notwithstanding
the foregoing, no adjustments shall be made, paid or issued under this Section 3(b) in respect of an Exempt Issuance. The Company
shall notify the Holder, in writing, no later than the Trading Day following the issuance or deemed issuance of any Common Stock or
Common Stock Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable reset price,
exchange price, conversion price and other pricing terms (such notice, the &ldquo;<U>Dilutive Issuance Notice</U>&rdquo;). For
purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 3(b), upon the
occurrence of any Dilutive Issuance, the Holder is entitled to receive a number of Warrant Shares based upon the Base Share Price
regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise. If the Company enters into a
Variable Rate Transaction, the Company shall be deemed to have issued Common Stock or Common Stock Equivalents at the lowest
possible price, conversion price or exercise price at which such securities may be issued, converted or exercised. If any shares of
Common Stock or Common Stock Equivalents are issued or sold or deemed to have been issued or sold for cash, the consideration
received therefor will be deemed to be the net amount of cash received by the Company therefor. If any shares of Common Stock or
Common Stock Equivalents are issued or sold for consideration other than cash, the amount of such consideration received by the
Company will be the fair value of such consideration, except where such consideration consists of publicly traded securities or
Common Stock (including Common Stock transferred from existing third-party stockholder), in which case the amount of consideration
received by the Company will be the volume weighted average price of such publicly traded securities on the date of receipt of such
publicly traded securities. The fair value of any consideration other than cash or publicly traded securities will be reasonably and
in good faith determined jointly by the Company and the Purchasers of a majority in interest of the Securities then outstanding. If
such parties are unable to reach agreement within ten (10) days after the occurrence of an event requiring valuation (the
&ldquo;<U>Valuation Event</U>&rdquo;), the fair value of such consideration will be determined within five (5) Business Days after
the tenth (10th) day following the Valuation Event by an independent appraiser selected in good faith by the Company and reasonably
acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and expenses of which shall be
paid by the Company. The determination of such appraiser shall be final and binding upon all parties absent manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or
sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record
holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to
acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if
the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any
limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of
which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights
(<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would
result in the Holder exceeding the Beneficial Ownership Limitation or the Corporation&rsquo;s issuance of shares in excess of the
Issuable Maximum, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent
shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the
Beneficial Ownership Limitation or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a
dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be
entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is
taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the
Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation or the Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum, then the Holder shall not be entitled to
participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such
Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such
time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation or the
Corporation&rsquo;s issuance of shares in excess of the Issuable Maximum). To the extent that this Warrant has not been partially or
completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of
the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary,
directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender
offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are
permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of
greater than 50% of the outstanding Common Stock or greater than 50% of the voting power of the common equity of the Company, (iv)
the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such
other Person or group acquires greater than 50% of the outstanding shares of Common Stock or greater than 50% of the voting power of
the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this
Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise
immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation
in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or
of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate
Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section
2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If
holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction,
then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant
following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the
Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with,
or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the
applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the
Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such
Fundamental Transaction; <U>provided</U>, <U>however</U>, that, if the Fundamental Transaction is not within the Company&rsquo;s
control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall only be entitled to receive from the
Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of
the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection
with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether
the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the
Fundamental Transaction; <U>provided</U>, <U>further</U>, that if holders of Common Stock of the Company are not offered or paid any
consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the
Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained
from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction
for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the
time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the applicable
Termination Date, (B) an expected volatility equal to the 100 day volatility as obtained from the HVT function on Bloomberg
(determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the
applicable contemplated Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the
price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such
Fundamental Transaction, (D) a remaining option time equal to the time between the date of the public announcement of the applicable
contemplated Fundamental Transaction and the applicable Termination Date and (E) a zero cost of borrow. The payment of the Black
Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i)
five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental Transaction. The Company
shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents
in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory
to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option
of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of
capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental
Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into
account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of
capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value
of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form
and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the
term &ldquo;Company&rdquo; under this Warrant (so that from and after the occurrence or consummation of such Fundamental
Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &ldquo;Company&rdquo;
shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor
Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior
thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this
Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities,
jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the
benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares of Common
Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the
sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall
promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.25in">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a
party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is
converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the
Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the
applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the
holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be
determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to
become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to
exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or
in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent
that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of
the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.
The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective
date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><U>Section
4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions
of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its
designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such
surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the
assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall
issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be
cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the
Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this
Warrant in full. This Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of
Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for this Warrant or the Warrants to be divided or combined
in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant
and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
&ldquo;<U>Warrant Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat
the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of
this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under
applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current
public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the
Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any
exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for
distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state
securities law, except pursuant to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section
5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as
expressly set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless
exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no
event shall the Company be required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of this Warrant, shall not
include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company
will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or
stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding
Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants
that, during the period this Warrant is outstanding, it will reserve from its authorized and unissued Common Stock an amount of shares
at least equal to the Required Minimum (as defined in the Purchase Agreement). The Company further covenants that its issuance of this
Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the
exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of
the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon the
exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and
payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from
all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of
all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant
and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any action
which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in
accordance with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does
not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate
as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be
sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of
appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its
rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered
in accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder
for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or
by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to
specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation
for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the
defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to
the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of
Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall
be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="text-transform: uppercase"><B>GT Biopharma, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%"></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:
GT Biopharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in lawful money of
the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise
procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">(4) Accredited
Investor. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act of
1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><I>(To assign the foregoing Warrant,
execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><U></U></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Address:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><U></U></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Phone Number:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holder&rsquo;s
    Signature: ______________________________<U></U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Holder&rsquo;s Address:_______________________________<U></U></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This Securities Purchase
Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of May 12, 2025, between GT Biopharma, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the
terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act (as defined below), and Rule 506
promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires
to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">ARTICLE I.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>.
In addition to the terms defined elsewhere in this Agreement: (a) capitalized terms that are not otherwise defined herein have the meanings
given to such terms in the Certificate of Designation (as defined herein), and (b) the following terms have the meanings set forth in
this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of
Directors</U>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized
or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo;
or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority
so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Certificate
of Designation</U>&rdquo; means the Certificate of Designation to be filed prior to the Closing by the Company with the Secretary of State
of Delaware, in the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Warrants</U>&rdquo; means the Common Stock Warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a)
hereof, which Common Stock Warrants shall be exercisable immediately and have a term of exercise equal to five (5) years, in the form
of <U>Exhibit C</U> attached hereto and with an exercise price equal to $2.043, subject to adjustment therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Stock Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Company
Counsel</U>&rdquo; means Stubbs Alderton &amp; Markiles, LLP, with offices located at 15260 Ventura Boulevard, 20<SUP>th</SUP> Floor,
Sherman Oaks, CA 91403.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Price</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Conversion
Shares</U>&rdquo; shall have the meaning ascribed to such term in the Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Schedules</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day,
no later than 9:01 a.m. (New York City time) on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Effective
Date</U>&rdquo; means the earliest of the date that (a) the initial Registration Statement has been declared effective by the Commission,
(b) all of the Underlying Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for the
Company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions,
(c) immediately follows the one year anniversary of the Closing Date provided that a holder of Underlying Shares is not an Affiliate of
the Company, or (d) all of the Underlying Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities
Act without volume or manner-of-sale restrictions and Company Counsel has delivered to such holders a standing written unqualified opinion
that resales may then be made by such holders of the Underlying Shares pursuant to such exemption which opinion shall be in form and substance
reasonably acceptable to such holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>EGS</U>&rdquo;
means Ellenoff Grossman &amp; Schole LLP, with offices located at 1345 Avenue of the Americas, New York, New York 10105-0302.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt Issuance</U>&rdquo;
means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock or
option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members
of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise
or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible
into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion
price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities or (c)
securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company,
provided that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights
that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section 4.13(a)
herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through
its subsidiaries, an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide
to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities. Notwithstanding
anything herein to the contrary, in no event shall the exercise of the Greenshoe Rights pursuant to Section 2.4 be deemed an Exempt Issuance
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(ll).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(ll).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Floor Price</U>&rdquo;
shall have the meaning set forth in Section 6(b) of the Certificate of Designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(bb).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Legend Removal
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 4.1(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up
Agreement</U>&rdquo; means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors, officers, and
10% and greater stockholders of the Company, in the form of <U>Exhibit F</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Permits</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Maximum Rate</U>&rdquo;
shall have the meaning ascribed to such term in Section 5.17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Participation
Maximum</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pharmaceutical
Product</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(ll).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Stock</U>&rdquo; means the up to 28,056 shares of the Company&rsquo;s Series L 10% Convertible Preferred Stock issued hereunder having
the rights, preferences and privileges set forth in the Certificate of Designation, in the form of <U>Exhibit A</U> hereto and with a
conversion price equal to $2.043 per share, subject to adjustment therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Pro
Rata Portion</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(e).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Information Failure</U>&rdquo; shall have the meaning ascribed to such term in Section 4.3(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Public
Information Failure Payments</U>&rdquo; shall have the meaning ascribed to such term in Section 4.3(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Rights Agreement</U>&rdquo; means the Registration Rights Agreement, dated on or about the date hereof, among the Company and the Purchasers,
in the form of <U>Exhibit B</U> attached hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means a registration statement meeting the requirements set forth in the Registration Rights Agreement and covering
the resale of the Underlying Shares by each Purchaser as provided for in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required Approvals</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required
Minimum</U>&rdquo; means, as of any date, the maximum aggregate number of shares of Common Stock then issued or potentially issuable in
the future pursuant to the Transaction Documents, including any Underlying Shares issuable upon exercise in full of all Warrants or conversion
in full of all shares of Preferred Stock, ignoring any conversion or exercise limits set forth therein and assuming a Conversion Price
and Exercise Price, as applicable, equal to the Floor Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Preferred Stock, the Warrants, the Warrant Shares and the Underlying Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shareholder
Approval</U>&rdquo; means such approval as may be required by the applicable rules and regulations of the Nasdaq Stock Market (or any
successor entity) from the shareholders of the Company with respect to the transactions contemplated by the Transaction Documents, including
the issuance of all of the Underlying Shares and the Dividend Conversion Shares (as defined in the Certificate of Designation) in excess
of 19.99% of the issued and outstanding Common Stock on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short Sales</U>&rdquo;
means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Stated Value</U>&rdquo;
means $1,000 per share of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for the Preferred Stock purchased hereunder as of the Closing
Date as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription
Amount,&rdquo; in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsequent
Financing</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsequent
Financing Notice</U>&rdquo; shall have the meaning ascribed to such term in Section 4.12(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U> and shall, where applicable, also include any direct or indirect
subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
Pink Open Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Price</U>&rdquo; means on any particular date (a) the lowest reported trading price per share of Common Stock on such date on the Trading
Market (as reported by Bloomberg L.P. at 4:15 p.m. (New York City time)), (b) if there is no such price on such date, then the lowest
trading price on the Trading Market on the date nearest preceding such date (as reported by Bloomberg L.P. at 4:15 p.m. (New York City
time)), (c) if the Common Stock is not then listed or quoted on a Trading Market and if prices for the Common Stock are then reported
on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the lowest trading price
per share of the Common Stock so reported, or (d) if the shares of Common Stock are not then publicly traded the fair market value as
of such date of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority
in interest of the shares then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Certificate of Designation, the Warrants, the Registration Rights Agreement, the Lock-Up
Agreement, the Voting Agreement, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection
with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Computershare Trust Company, N.A., the current transfer agent of the Company, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underlying
Shares</U>&rdquo; means the Conversion Shares and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Variable
Rate Transaction</U>&rdquo; shall have the meaning ascribed to such term in Section 4.13(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Vesting
Warrants</U>&rdquo; means, collectively, the Common Stock Vesting Warrants delivered to the Purchasers at the Closing in accordance with
Section 2.2(a) hereof, which Vesting Warrants shall vest pursuant to the terms therein and have a term of exercise that expires five (5)
years from the date on which the applicable Purchaser elects to purchase the applicable Greenshoe Securities, in the form of <U>Exhibit
D</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Vesting
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Vesting Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Voting
Agreement</U>&rdquo; means the written agreement, in the form of <U>Exhibit G </U>attached hereto, of all of the officers and directors,
and the stockholders party thereto holding more than 10% of the issued and outstanding shares of Common Stock on the date hereof, to vote
all Common Stock over which such Persons have voting control as of the record date for the meeting of stockholders of the Company referenced
therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB Venture Market (&ldquo;OTCQB&rdquo;) or OTCQX Best Market (&ldquo;OTCQX&rdquo;)
is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB
or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common
Stock are then reported on the Pink Open Market (&ldquo;Pink Market&rdquo;) operated by OTC Markets Group, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Company and reasonably acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and
expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means, collectively, the Common Stock Warrants and the Vesting Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means, collectively, the Common Stock Warrant Shares and the Vesting Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">ARTICLE II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>PURCHASE AND SALE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">2.1 <U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and the Purchasers, severally and not jointly, agree to purchase,
up to an aggregate of $6,055,555.56 of shares of Preferred Stock for an aggregate purchase price equal to $5,450,000. The aggregate number
of shares of Preferred Stock sold hereunder on the Closing Date shall be up to 6,056. Each Purchaser shall deliver to the Company, via
wire transfer, immediately available funds equal to such Purchasers Subscription Amount and the Company shall deliver to each Purchaser
its respective shares of Preferred Stock and Warrants as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall
deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth
in Sections 2.2 and 2.3, the Closing shall occur at the offices of EGS or such other location as the parties shall mutually agree and
take place remotely by electronic transfer of the Closing documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2
<U>Deliveries</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"> (i) this Agreement duly executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) a
legal opinion of Company Counsel, substantially in the form of <U>Exhibit E</U> attached hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) confirmation
of book-entry or a certificate evidencing the applicable number of shares of Preferred Stock registered in the name of such Purchaser
and evidence of the filing and acceptance of the Certificate of Designation from the Secretary of State of Delaware;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) a
Warrant registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of such Purchaser&rsquo;s
Conversion Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(v) a
Vesting Warrant to purchase up to an additional number of shares of Common stock equal to the number of Greenshoe Conversion Shares (as
defined herein) issuable hereunder in full, registered in the name of such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(vi) the
Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead and executed by the Chief
Executive Officer or Chief Financial Officer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(vii) the
Voting Agreement duly executed by the Company, each officer and director of the Company, and the stockholders party thereto holding more
than 10% of the issued and outstanding shares of Common Stock on the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(viii) the
Lock-Up Agreements; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ix) the
Registration Rights Agreement duly executed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) On
or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"> (i) this Agreement duly executed by such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) such
Purchaser&rsquo;s Subscription Amount by wire transfer to the account specified in writing by the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the
Registration Rights Agreement duly executed by such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 2.3 <U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the
Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case
they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all
respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) all
obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the
delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The
respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date
therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by
materiality or Material Adverse Effect, in all respects) as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iv) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(v) Michael
Breen shall be formally appointed by the Board of Directors as Chief Executive Officer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(vi) from
the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or the Company&rsquo;s
principal Trading Market and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall
not have been suspended or limited, or minimum prices shall not have been established on securities whose trades are reported by such
service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities
nor shall there have occurred any material outbreak or escalation of hostilities or other national or international calamity of such magnitude
in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser,
makes it impracticable or inadvisable to purchase the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 2.4 <U>Greenshoe Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) From
the date hereof until the date that no Greenshoe Securities (as defined herein) remain available for purchase, each Purchaser may, in
its sole determination, elect to purchase, severally and not jointly with the other Purchasers and, subject to the proviso below, in one
or more closings, shares of Preferred Stock with an aggregate Stated Value thereof of up to $22,000,000 (such securities, the &ldquo;<U>Greenshoe
Securities</U>&rdquo; and such shares of Common Stock issuable upon conversion of such Greenshoe Securities (the &ldquo;<U>Greenshoe Conversion
Shares</U>&rdquo;) and such right to receive the Greenshoe Securities pursuant to this Section 2.4, the &ldquo;<U>Greenshoe Rights</U>&rdquo;),
for an aggregate purchase price equal to $19,800,000, provided the conversion price of the Preferred Stock and Exercise Price of the Vesting
Warrants shall be equal to the Conversion Price (as set forth in Section 6(b) of the Certificate of Designation) and the Warrants shall
be adjusted pursuant to the adjustment provisions thereunder. Each Purchaser is hereby entitled to exercise its respective Greenshoe Rights
for an amount of Greenshoe Securities equal to the ratio of such Purchaser&rsquo;s original Subscription Amount to the original aggregate
Subscription Amount of all Purchasers, provided that, in connection with the exercise of Greenshoe Rights, such Purchaser shall purchase
Greenshoe Securities having a Stated Value at least equal to the lesser of (i) $100,000 and (ii) the balance of the Greenshoe Rights attributable
to such Purchaser hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) Any
Greenshoe Right exercised by a Purchaser shall close within 3 Trading Days of a duly delivered exercise notice by the exercising party;
provided, however, within one (1) Trading Day of receipt of an exercise notice hereunder, the Company shall notify all Purchasers hereunder
of such exercise, the time of such exercise and of the new Adjusted Price (if applicable and as defined Section 6(b) of the Certificate
of Designation), which Adjusted Price shall be deemed the new Conversion Price of the Preferred Stock effective as of the delivery of
such notice. Any additional investment in the Greenshoe Securities shall be on terms identical to those set forth in the Transaction Documents,
<I>mutatis mutandis</I>. In order to effectuate a purchase and sale of the Greenshoe Securities, the Company and the Purchasers shall
enter into a Securities Purchase Agreement identical to this Agreement, <I>mutatis mutandis</I> and shall include updated disclosure schedules
but shall exclude the issuance of additional Vesting Warrants or the delivery of Voting Agreements, Lock-Ups and a Registration Rights
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">ARTICLE III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>REPRESENTATIONS AND WARRANTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">3.1 <U>Representations
and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules provided with this Agreement (the &ldquo;<U>Disclosure
Schedules</U>&rdquo;), which shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent
of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations
and warranties to each Purchaser as of the date hereof and as of the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth on <U>Schedule 3.1(a)</U>. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding
shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and similar rights
to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries or any of them in
the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business or condition (financial or otherwise) of the Company and the Subsidiaries, taken
as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis its
obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors or the Company&rsquo;s stockholders in connection herewith or therewith other
than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or
upon delivery will have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute
the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>No
Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it
is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do
not and will not (i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with
notice or lapse of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets
of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration
or cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing
a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property
or asset of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in
a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority
to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property
or asset of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not
have or reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Filings,
Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to,
or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection
with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant
to Section 4.6 of this Agreement, (ii) the filing with the Commission pursuant to the Registration Rights Agreement, (iii) the notice
and/or application(s) to each applicable Trading Market for the issuance and sale of the Securities and the listing of the Underlying
Shares for trading thereon in the time and manner required thereby, (iv) the filing of Form D with the Commission and such filings as
are required to be made under applicable state securities laws and (v) Shareholder Approval (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Issuance
of the Securities</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other than
restrictions on transfer provided for in the Transaction Documents. The Underlying Shares, when issued in accordance with the terms of
the Transaction Documents, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company other
than restrictions on transfer provided for in the Transaction Documents. The Company has reserved from its duly authorized capital stock
a number of shares of Common Stock for issuance of the Underlying Shares at least equal to the Required Minimum on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Capitalization</U>.
The capitalization of the Company as of the date hereof is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U> shall
also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company as of the date hereof.
Except as set forth on <U>Schedule 3.1(g)</U>, the Company has not issued any capital stock since its most recently filed periodic report
under the Exchange Act, other than pursuant to the exercise of employee stock incentives under the Company&rsquo;s stock incentive plans,
the issuance of shares of Common Stock to employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the
conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed periodic report under the
Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate
in the transactions contemplated by the Transaction Documents. Except as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares
of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any
Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or
other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary
with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities
by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any
redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. Except as set forth on <U>Schedule 3.1(g)</U>,
the Company does not have any stock appreciation rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement.
All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have
been issued in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase securities. Except for the Required Approvals, no further approval or
authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. Other than
the Voting Agreement, there are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s
capital stock to which the Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>SEC
Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be
filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two
years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein as the
&ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC
Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects
with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any
untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never been an issuer
subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles
applied on a consistent basis during the periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial
statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly
present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof
and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial,
year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Material
Changes; Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within
the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or
that could reasonably be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent
or otherwise) other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice
and (B) liabilities not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings
made with the Commission, (iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any
shares of its capital stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant
to existing Company stock incentive plans. The Company does not have pending before the Commission any request for confidential treatment
of information. Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no
event, liability, fact, circumstance, occurrence or development has occurred or exists or is reasonably expected to occur or exist with
respect to the Company or its Subsidiaries or their respective businesses, properties, operations, assets or financial condition, that
would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made
that has not been publicly disclosed at least 1 Trading Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Litigation</U>.
Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending
or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties
before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign)
(collectively, an &ldquo;<U>Action</U>&rdquo;). None of the Actions set forth on <U>Schedule 3.1(j)</U>, (i) adversely affects or challenges
the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii) could, if there were an unfavorable
decision, have or reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor any director
or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities
laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated,
any investigation by the Commission involving the Company or any current or former director or officer of the Company. The Commission
has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary
under the Exchange Act or the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Labor
Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company,
which could reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees
is a member of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company
nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received
all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and
(iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(n) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(o) <U>Title
to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good
and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each
case free and clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal,
state or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither
delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by
them under valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have could have a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;). None of, and neither
the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate or be abandoned, within two (2) years from the date of this Agreement.
Neither the Company nor any Subsidiary has received, since the date of the latest audited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the
rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect. To the knowledge of the
Company, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. The Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and
value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged. Neither the Company nor
any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires
or to obtain similar coverage from similar insurers as may be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(r) <U>Transactions
with Affiliates and Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company or
any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract,
agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to
or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director
or such employee or, to the knowledge of the Company, any entity in which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i) payment
of salary or consulting fees for services rendered, (ii) reimbursement for expenses incurred on behalf of the Company and (iii) other
employee benefits, including stock option agreements under any stock incentive plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the
Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a
system of internal accounting controls sufficient to provide reasonable assurance that: (i) transactions are executed in accordance with
management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(t) <U>Certain
Fees</U>. Except for fees payable by the Company as set forth on <U>Schedule 3.1(t)</U>, no brokerage or finder&rsquo;s fees or commissions
are or will be payable by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment
banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no
obligation with respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated
in this Section that may be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(u) <U>Private
Placement</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.
The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(v) <U>Investment
Company.</U> The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be
or be an Affiliate of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company
shall conduct its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the
Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(w) <U>Registration
Rights</U>. Other than the rights of the Purchasers set forth in the Registration Rights Agreement, no Person has any right to cause the
Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(x) <U>Listing
and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company
has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common
Stock under the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration.
Except as set forth on <U>Schedule 3.1(x),</U> the Company has not, in the 12 months preceding the date hereof, received notice from any
Trading Market on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the
listing or maintenance requirements of such Trading Market. Except as set forth on <U>Schedule 3.1(x)</U>, Company is, and has no reason
to believe that it will not in the foreseeable future continue to be, in compliance with all such listing and maintenance requirements.
The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation
and the Company is current in payment of the fees to the Depository Trust Company (or such other established clearing corporation) in
connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(y) <U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of
the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(z) <U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information. The Company understands and confirms that the Purchasers
will rely on the foregoing representation in effecting transactions in securities of the Company. All of the disclosure furnished by or
on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions
contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement
of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date
of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and
when made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(aa) <U>No Integrated
Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company,
nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
prior offerings by the Company for purposes of (i) the Securities Act which would require the registration of any such securities under
the Securities Act, or (ii) any applicable shareholder approval provisions of any Trading Market on which any of the securities of the
Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(bb) <U>Solvency</U>.
Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect to the receipt by the Company
of the proceeds from the sale of the Securities hereunder (i) the fair saleable value of the Company&rsquo;s assets exceeds the amount
that will be required to be paid on or in respect of the Company&rsquo;s existing debts and other liabilities (including known contingent
liabilities) as they mature, (ii) the Company&rsquo;s assets do not constitute unreasonably small capital to carry on its business as
now conducted and as proposed to be conducted including its capital needs taking into account the particular capital requirements of the
business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii) the current
cash flow of the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into
account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when such amounts
are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account
the timing and amounts of cash to be payable on or in respect of its debt). The Company has no knowledge of any facts or circumstances
which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction
within one year from the Closing Date. <U>Schedule 3.1(bb)</U> sets forth as of the date hereof all outstanding secured and unsecured
Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement,
&ldquo;<U>Indebtedness</U>&rdquo; means (x) any liabilities for borrowed money in excess of $50,000 (other than trade accounts payable
incurred in the ordinary course of business), (y) all guaranties, endorsements and other contingent obligations in respect of indebtedness
of others, whether or not the same are or should be reflected in the Company&rsquo;s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of
business; and (z) the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance
with GAAP. Neither the Company nor any Subsidiary is in default with respect to any Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(cc) <U>Tax Status</U>.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and
franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations
and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(dd) <U>No General
Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Securities by any
form of general solicitation or general advertising. The Company has offered the Securities for sale only to the Purchasers and certain
other &ldquo;accredited investors&rdquo; within the meaning of Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ee) <U>Foreign
Corrupt Practices.</U> Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts,
entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign
or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)
failed to disclose fully any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the
Company is aware) which is in violation of law or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ff) <U>Accountants</U>.
The Company&rsquo;s accounting firm is set forth on <U>Schedule 3.1(ff)</U> of the Disclosure Schedules. To the knowledge and belief of
the Company, such accounting firm (i) is a registered public accounting firm as required by the Exchange Act and (ii) shall express its
opinion with respect to the financial statements to be included in the Company&rsquo;s Annual Report for the fiscal year end.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(gg) <U>Seniority</U>.
As of the Closing Date, no Indebtedness or other claim against the Company is senior to the Preferred Stock in right of payment, whether
with respect to interest or upon liquidation or dissolution, or otherwise, other than indebtedness secured by purchase money security
interests (which is senior only as to underlying assets covered thereby) and capital lease obligations (which is senior only as to the
property covered thereby).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(hh) <U>No Disagreements
with Accountants and Lawyers.</U> There are no disagreements of any kind presently existing, or reasonably anticipated by the Company
to arise, between the Company and the accountants and lawyers formerly or presently employed by the Company and the Company is current
with respect to any fees owed to its accountants and lawyers which could affect the Company&rsquo;s ability to perform any of its obligations
under any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(jj) <U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Sections 3.2(g) and 4.15 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked
by the Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company,
or &ldquo;derivative&rdquo; securities based on securities issued by the Company or to hold the Securities for any specified term, (ii)
past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo;
transactions, before or after the closing of this or future private placement transactions, may negatively impact the market price of
the Company&rsquo;s publicly-traded securities, (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which
any such Purchaser is a party, directly or indirectly, may presently have a &ldquo;short&rdquo; position in the Common Stock and (iv)
each Purchaser shall not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo;
transaction. The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various
times during the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Underlying
Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of
the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted.
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(kk) <U>Regulation
M Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of clauses (ii) and (iii), compensation paid to any agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ll) <U>FDA</U>.
As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Pharmaceutical Product</U>&rdquo;),
such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance
with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket
clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product
listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have
a Material Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its
Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the
FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of,
the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical
Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising
or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by
the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters
or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges
any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate,
would have a Material Adverse Effect. <FONT STYLE="letter-spacing: -0.15pt">The properties, business and operations of the Company have
been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company
has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed
to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any
product being developed or proposed to be developed by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(mm) <U>Stock
Incentive Plans</U>. Each stock incentive granted by the Company under any of the Company&rsquo;s stock incentive plans was granted (i)
in accordance with the terms of the applicable stock incentive plan and (ii) with an exercise price at least equal to the fair market
value of the Common Stock on the date such stock incentive would be considered granted under GAAP and applicable law. No stock option
granted under any of the Company&rsquo;s stock incentive plans has been backdated. The Company has not knowingly granted, and there is
no and has been no Company policy or practice to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant
of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their
financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(nn) <U>Cybersecurity</U>.
(i)(x) There has been no security breach or other compromise of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information
technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers,
vendors and any third party data maintained by or on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;)
and (y) the Company and the Subsidiaries have not been notified of, and have no knowledge of any event or condition that would reasonably
be expected to result in, any security breach or other compromise to their IT Systems and Data; (ii) the Company and the Subsidiaries
are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
maintained commercially reasonable safeguards to maintain and protect their material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(oo) <U>Compliance
with Data Privacy Laws</U>. (i) The Company and the Subsidiaries are, and at all times during the last three (3) years were, in compliance
with all applicable state, federal and foreign data privacy and security laws and regulations, including, without limitation, the European
Union General Data Protection Regulation (&ldquo;<U>GDPR</U>&rdquo;) (EU 2016/679) (collectively, &ldquo;<U>Privacy Laws</U>&rdquo;);
(ii) the Company and the Subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance
with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis
of Personal Data (as defined below) (the &ldquo;<U>Policies</U>&rdquo;); (iii) the Company provides accurate notice of its applicable
Policies to its customers, employees, third party vendors and representatives as required by the Privacy Laws; and (iv) applicable Policies
provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating to its subject matter, and do not
contain any material omissions of the Company&rsquo;s then-current privacy practices, as required by Privacy Laws. &ldquo;<U>Personal
Data</U>&rdquo; means (i) a natural person&rsquo;s name, street address, telephone number, email address, photograph, social security
number, bank information, or customer or account number; (ii) any information which would qualify as &ldquo;personally identifying information&rdquo;
under the Federal Trade Commission Act, as amended; (iii) &ldquo;personal data&rdquo; as defined by GDPR; and (iv) any other piece of
information that allows the identification of such natural person, or his or her family, or permits the collection or analysis of any
identifiable data related to an identified person&rsquo;s health or sexual orientation. (i) None of such disclosures made or contained
in any of the Policies have been inaccurate, misleading, or deceptive in violation of any Privacy Laws and (ii) the execution, delivery
and performance of the Transaction Documents will not result in a breach of any Privacy Laws or Policies. Neither the Company nor the
Subsidiaries (A) to the knowledge of the Company, has received written notice of any actual or potential liability of the Company or the
Subsidiaries under, or actual or potential violation by the Company or the Subsidiaries of, any of the Privacy Laws; (B) is currently
conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant to any regulatory request
or demand pursuant to any Privacy Law; or (C) is a party to any order, decree, or agreement by or with any court or arbitrator or governmental
or regulatory authority that imposed any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(pp) <U>Office
of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent,
employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign
Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(qq) <U>U.S. Real
Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of
Section 897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(rr) <U>Bank Holding
Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as
amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ss) <U>Money
Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance with applicable
financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(tt) <U>No Disqualification
Events</U>. With respect to the Securities to be offered and sold hereunder in reliance on Rule 506 under the Securities Act, none of
the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating
in the offering hereunder, any beneficial owner of 20% or more of the Company&rsquo;s outstanding voting equity securities, calculated
on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company
in any capacity at the time of sale (each, an &ldquo;<U>Issuer Covered Person</U>&rdquo; and, together, &ldquo;<U>Issuer Covered Persons</U>&rdquo;)
is subject to any of the &ldquo;Bad Actor&rdquo; disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a
&ldquo;<U>Disqualification Event</U>&rdquo;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has
exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied,
to the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures
provided thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(uu) <U>Other
Covered Persons</U>. The Company is not aware of any person (other than any Issuer Covered Person) that has been or will be paid (directly
or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(vv) <U>Notice
of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification
Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of time, become a Disqualification Event relating
to any Issuer Covered Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">3.2 <U>Representations
and Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the
date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Organization;
Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company
or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise
to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such
Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership,
limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a
party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute
the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except (i) as limited
by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application
affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable
law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Own
Account</U>. Such Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered under
the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not with
a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state
securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state
securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution
of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting
such Purchaser&rsquo;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable
federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Purchaser
Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which
it exercises any Warrants or converts any shares of Preferred Stock, it will be an &ldquo;accredited investor&rdquo; as defined in Rule
501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act. The information set forth on the signature
page hereto regarding such Purchaser is true and complete in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>Experience
of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>General
Solicitation</U>. Such Purchaser is not, to such Purchaser&rsquo;s knowledge, purchasing the Securities as a result of any advertisement,
article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over
television or radio or presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Access
to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets
and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners,
legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made
to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for
the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">ARTICLE IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>OTHER AGREEMENTS OF THE PARTIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.1 <U>Transfer
Restrictions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities
other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection
with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of
counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities
Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and the Registration
Rights Agreement and shall have the rights and obligations of a Purchaser under this Agreement and the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) The
Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following
form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">[NEITHER] THIS SECURITY [NOR THE SECURITIES
INTO WHICH THIS SECURITY IS [EXERCISABLE] [CONVERTIBLE]] HAS [NOT] BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES
ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY [AND THE SECURITIES ISSUABLE UPON [EXERCISE] [CONVERSION] OF THIS
SECURITY] MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL
INSTITUTION THAT IS AN &ldquo;ACCREDITED INVESTOR&rdquo; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH
SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">The Company acknowledges
and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with a registered broker-dealer or grant
a security interest in some or all of the Securities to a financial institution that is an &ldquo;accredited investor&rdquo; as defined
in Rule 501(a) under the Securities Act and, if required under the terms of such arrangement, such Purchaser may transfer pledged or secured
Securities to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal
opinion of legal counsel of the pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall
be required of such pledge. At the appropriate Purchaser&rsquo;s expense, the Company will execute and deliver such reasonable documentation
as a pledgee or secured party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including,
if the Securities are subject to registration pursuant to the Registration Rights Agreement, the preparation and filing of any required
prospectus supplement under Rule 424(b)(3) under the Securities Act or other applicable provision of the Securities Act to appropriately
amend the list of Selling Stockholders (as defined in the Registration Rights Agreement) thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Certificates
evidencing the Underlying Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration
statement (including the Registration Statement) covering the resale of such security is effective under the Securities Act, (ii) following
any sale of such Underlying Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants), (iii) if such Underlying Shares
are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants), without the requirement for the Company to be in compliance
with the current public information required under Rule 144 as to such Underlying Shares and without volume or manner-of-sale restrictions
or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements
issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser
promptly after the Effective Date if required by the Transfer Agent to effect the removal of the legend hereunder, or if requested by
a Purchaser, respectively. If all or any shares of Preferred Stock are converted or any portion of a Warrant is exercised at a time when
there is an effective registration statement to cover the resale of the Underlying Shares, or if such Underlying Shares may be sold under
Rule 144 and the Company is then in compliance with the current public information required under Rule 144, or if the Underlying Shares
may be sold under Rule 144 (assuming cashless exercise of the Warrants) without the requirement for the Company to be in compliance with
the current public information required under Rule 144 as to such Underlying Shares and without volume or manner-of-sale restrictions
or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and
pronouncements issued by the staff of the Commission) then such Underlying Shares shall be issued free of all legends. The Company agrees
that following the Effective Date or at such time as such legend is no longer required under this Section 4.1(c), it will, no later than
the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below)
following the delivery by a Purchaser to the Company or the Transfer Agent of a certificate representing Underlying Shares, as applicable,
issued with a restrictive legend (such date, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be delivered to such Purchaser
a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its
records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section 4. Certificates
for Underlying Shares subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the
account of the Purchaser&rsquo;s prime broker with the Depository Trust Company System as directed by such Purchaser. As used herein,
&ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s
primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a certificate representing Underlying
Shares, as applicable, issued with a restrictive legend.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) In
addition to such Purchaser&rsquo;s other available remedies, the Company shall pay to a Purchaser, in cash, (i) as partial liquidated
damages and not as a penalty, for each $1,000 of Underlying Shares (based on the VWAP of the Common Stock on the date such Securities
are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section 4.1(c), $10 per Trading Day
(increasing to $20 per Trading Day five (5) Trading Days after the Legend Removal Date) for each Trading Day after the Legend Removal
Date until such certificate is delivered without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered)
to a Purchaser by the Legend Removal Date a certificate representing the Securities so delivered to the Company by such Purchaser that
is free from all restrictive and other legends and (b) if after the Legend Removal Date such Purchaser purchases (in an open market transaction
or otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares
of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of shares of Common Stock that
such Purchaser anticipated receiving from the Company without any restrictive legend, then, an amount equal to the excess of such Purchaser&rsquo;s
total purchase price (including brokerage commissions and other out-of-pocket expenses, if any) for the shares of Common Stock so purchased
(including brokerage commissions and other out-of-pocket expenses, if any) (the &ldquo;<FONT STYLE="font-weight: normal"><U>Buy-In Price</U></FONT>&rdquo;)
over the product of (x) such number of Underlying Shares that the Company was required to deliver to such Purchaser by the Legend Removal
Date multiplied by (y) the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of
the delivery by such Purchaser to the Company of the applicable Underlying Shares (as the case may be) and ending on the date of such
delivery and payment under this clause (ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) Each
Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell any Securities pursuant
to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption
therefrom, and that if Securities are sold pursuant to a Registration Statement, they will be sold in compliance with the plan of distribution
set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth
in this Section 4.1 is predicated upon the Company&rsquo;s reliance upon this understanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.2 <U>Acknowledgment
of Dilution</U>. The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common
Stock, which dilution may be substantial under certain market conditions. The Company further acknowledges that its obligations under
the Transaction Documents, including, without limitation, its obligation to issue the Underlying Shares pursuant to the Transaction Documents,
are unconditional and absolute and not subject to any right of set off, counterclaim, delay or reduction, regardless of the effect of
any such dilution or any claim the Company may have against any Purchaser and regardless of the dilutive effect that such issuance may
have on the ownership of the other stockholders of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.3 <U>Furnishing
of Information; Public Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)  Until
the earlier of the time that (i) no Purchaser owns Securities or (ii) the Warrants have expired, the Company covenants to maintain the
registration of the Common Stock under Section 12(b) or 12(g) of the Exchange Act and to timely file (or obtain extensions in respect
thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to
the Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)  At
any time during the period commencing from the six (6) month anniversary of the date hereof and ending at such time that all of the Securities
may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise without restriction or limitation
pursuant to Rule 144, if the Company (i) shall fail for any reason to satisfy the current public information requirement under Rule 144(c)
or (ii) has ever been an issuer described in Rule 144(i)(1)(i) or becomes an issuer in the future, and the Company shall fail to satisfy
any condition set forth in Rule 144(i)(2) (a &ldquo;<U>Public Information Failure</U>&rdquo;) then, in addition to such Purchaser&rsquo;s
other available remedies, the Company shall pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason
of any such delay in or reduction of its ability to sell the Securities, an amount in cash equal to one percent (1.0%) of the aggregate
Subscription Amount of such Purchaser&rsquo;s Securities on the day of a Public Information Failure and on every thirtieth (30<SUP>th</SUP>)
day (pro rated for periods totaling less than thirty days) thereafter until the earlier of (a) the date such Public Information Failure
is cured and (b) such time that such public information is no longer required for the Purchasers to transfer the Underlying Shares pursuant
to Rule 144. The payments to which a Purchaser shall be entitled pursuant to this Section 4.3(b) are referred to herein as &ldquo;<U>Public
Information Failure Payments</U>.&rdquo; Public Information Failure Payments shall be paid on the earlier of (i) the last day of the calendar
month during which such Public Information Failure Payments are incurred and (ii) the third (3<SUP>rd</SUP>) Business Day after the event
or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information
Failure Payments in a timely manner, such Public Information Failure Payments shall bear interest at the rate of 1.5% per month (prorated
for partial months) until paid in full. Nothing herein shall limit such Purchaser&rsquo;s right to pursue actual damages for the Public
Information Failure, and such Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.4 <U>Integration</U>.
The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section
2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration
under the Securities Act of the sale of the Securities or that would be integrated with the offer or sale of the Securities for purposes
of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other
transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.5 <U>Conversion
and Exercise Procedures</U>. Each of the form of Notice of Exercise included in the Warrants and the form of Notice of Conversion included
in the Certificate of Designation set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants
or convert the Preferred Stock. Without limiting the preceding sentences, no ink-original Notice of Exercise or Notice of Conversion shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise or Notice of Conversion
form be required in order to exercise the Warrants or convert the Preferred Stock. No additional legal opinion, other information or instructions
shall be required of the Purchasers to exercise their Warrants or convert their Preferred Stock. The Company shall honor exercises of
the Warrants and conversions of the Preferred Stock and shall deliver Underlying Shares in accordance with the terms, conditions and time
periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.6 <U>Securities
Laws Disclosure; Publicity</U>. The Company shall by each of (a) the Disclosure Time and (b) the exercise of any Greenshoe Right pursuant
to Section 2.4, file a Current Report on Form 8-K (or, in the case of Greenshoe Rights, a press release), including the Transaction Documents
as exhibits thereto, with the Commission disclosing the material terms of the transactions contemplated hereby. From and after the filing
of each such Current Report on Form 8-K (or, as applicable, press release), the Company represents to the Purchasers that it shall have
publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its Subsidiaries,
or any of their respective officers, directors, employees, Affiliates or agents, in connection with the transactions contemplated by the
Transaction Documents. In addition, effective upon the filing of each such Current Report on Form 8-K (or, as applicable, a press release),
the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether written or oral,
between the Company, any of its Subsidiaries or any of their respective officers, directors, agents, employees, Affiliates or agents,
on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate and be of no further force or
effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions
in securities of the Company. The Company and each Purchaser shall consult with each other in issuing any press releases with respect
to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make
any such public statement without the prior consent of the Company, with respect to any press release of any Purchaser, or without the
prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or
delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with
prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name
of any Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of such Purchaser, except (a) as required by federal securities law in connection with (i) any registration
statement contemplated by the Registration Rights Agreement and (ii) the filing of final Transaction Documents with the Commission and
(b) to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers
with prior notice of such disclosure permitted under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.7 <U>Shareholder
Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser
is an &ldquo;<U>Acquiring Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution
under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser
could be deemed to trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents
or under any other agreement between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.8  <U>Non-Public
Information</U>. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
which shall be disclosed pursuant to Section 4.6, the Company covenants and agrees that neither it, nor any other Person acting on its
behalf will provide any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes,
material non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information
and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser
shall be relying on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any
of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public
information to a Purchaser without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not
have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agents, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or
agents, not to trade on the basis of, such material, non-public information, provided that the Purchaser shall remain subject to applicable
law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Company understands and confirms that each Purchaser shall be relying on the
foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.9 <U>Use
of Proceeds</U>. Except as set forth on <U>Schedule 4.9</U> attached hereto, the Company shall use the net proceeds from the sale of the
Securities hereunder for working capital purposes and shall not use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s
debt (other than payment of trade payables in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption
of any Common Stock or Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC
regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.10 <U>Indemnification
of Purchasers</U>. Subject to the provisions of this Section 4.10, the Company will indemnify and hold each Purchaser and its directors,
officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person
holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning
of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners
or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such
title or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and reasonable expenses, including all judgments, amounts paid in settlements,
court costs and reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result
of or relating to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement
or in the other Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity, or any of them or their
respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions
contemplated by the Transaction Documents (unless such action is solely based upon a material breach of such Purchaser Party&rsquo;s representations,
warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which
is finally judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any
Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the
Company in writing, and, the Company shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable
to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the
defense thereof, but the fees and expenses of such counsel shall be at the expense of such Purchaser Party except to the extent that (i)
the employment thereof has been specifically authorized by the Company in writing, (ii) the Company has failed after a reasonable period
of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of counsel a material
conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company
shall be responsible for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to
any Purchaser Party under this Agreement (y) for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written
consent, which shall not be unreasonably withheld or delayed; or (z) to the extent, but only to the extent that a loss, claim, damage
or liability is attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties, covenants or agreements
made by such Purchaser Party in the Transaction Documents. The indemnification required by this Section 4.10 shall be made by periodic
payments of the amount thereof during the course of the investigation or defense, as and when bills are received or are incurred. The
indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the
Company or others and any liabilities the Company may be subject to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">4.11 <U>Reservation
and Listing of Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) The
Company shall maintain a reserve of the Required Minimum from its duly authorized shares of Common Stock for issuance pursuant to the
Transaction Documents in such amount as may then be required to fulfill its obligations in full under the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) If,
on any date, the number of authorized but unissued (and otherwise unreserved) shares of Common Stock is less than (i) the Required Minimum
on such date, minus (ii) the number of shares of Common Stock previously issued pursuant to the Transaction Documents, then the Board
of Directors shall use commercially reasonable efforts to amend the Company&rsquo;s certificate of incorporation to increase the number
of authorized but unissued shares of Common Stock to at least the Required Minimum at such time (minus the number of shares of Common
Stock previously issued pursuant to the Transaction Documents), as soon as possible and in any event not later than the 75<SUP>th</SUP>
day after such date, provided that the Company will not be required at any time to authorize a number of shares of Common Stock greater
than the maximum remaining number of shares of Common Stock that could possibly be issued after such time pursuant to the Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) The
Company shall, if applicable: (i) in the time and manner required by the principal Trading Market, prepare and file with such Trading
Market an additional shares listing application covering a number of shares of Common Stock at least equal to the Required Minimum on
the date of such application, (ii) take all steps necessary to cause such shares of Common Stock to be approved for listing or quotation
on such Trading Market as soon as possible thereafter, (iii) provide to the Purchasers evidence of such listing or quotation and (iv)
maintain the listing or quotation of such Common Stock on any date at least equal to the Required Minimum on such date on such Trading
Market or another Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the
Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to the
Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) In
addition, the Company shall hold a special meeting of shareholders (which may also be at the annual meeting of shareholders) at the earliest
practical date after the date hereof for the purpose of obtaining Shareholder Approval, with the recommendation of the Company&rsquo;s
Board of Directors that such proposal be approved, and the Company shall solicit proxies from its shareholders in connection therewith
in the same manner as all other management proposals in such proxy statement and all management-appointed proxyholders shall vote their
proxies in favor of such proposal. The Company shall use commercially reasonable efforts to obtain such Shareholder Approval. If the Company
does not obtain Shareholder Approval at the first meeting, the Company shall call a meeting every four months thereafter to seek Shareholder
Approval until the earlier of the date Shareholder Approval is obtained or the Preferred Stock is no longer outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.12 <U>Participation
in Future Financing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) From
the date hereof until the date that is the 18-month anniversary of the Effective Date, upon any issuance by the Company or any of its
Subsidiaries of Common Stock or Common Stock Equivalents for cash consideration, Indebtedness or a combination of units thereof (a &ldquo;<U>Subsequent
Financing</U>&rdquo;), each Purchaser shall have the right to participate in up to an amount of the Subsequent Financing equal to 100%
of the Subsequent Financing (the &ldquo;<U>Participation Maximum</U>&rdquo;) on the same terms, conditions and price provided for in the
Subsequent Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) At
least five (5) Trading Days prior to the closing of the Subsequent Financing, the Company shall deliver to each Purchaser a written notice
of its intention to effect a Subsequent Financing (&ldquo;<U>Pre-Notice</U>&rdquo;), which Pre-Notice shall ask such Purchaser if it wants
to review the details of such financing (such additional notice, a &ldquo;<U>Subsequent Financing Notice</U>&rdquo;). Upon the request
of a Purchaser, and only upon a request by such Purchaser, for a Subsequent Financing Notice, the Company shall promptly, but no later
than one (1) Trading Day after such request, deliver a Subsequent Financing Notice to such Purchaser. The Subsequent Financing Notice
shall describe in reasonable detail the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder
and the Person or Persons through or with whom such Subsequent Financing is proposed to be effected and shall include a term sheet or
similar document relating thereto as an attachment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Any
Purchaser desiring to participate in such Subsequent Financing must provide written notice to the Company by not later than 5:30 p.m.
(New York City time) on the fifth (5<SUP>th</SUP>) Trading Day after all of the Purchasers have received the Pre-Notice that such Purchaser
is willing to participate in the Subsequent Financing, the amount of such Purchaser&rsquo;s participation, and representing and warranting
that such Purchaser has such funds ready, willing, and available for investment on the terms set forth in the Subsequent Financing Notice.
If the Company receives no such notice from a Purchaser as of such fifth (5<SUP>th</SUP>) Trading Day, such Purchaser shall be deemed
to have notified the Company that it does not elect to participate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) If
by 5:30 p.m. (New York City time) on the fifth (5<SUP>th</SUP>) Trading Day after all of the Purchasers have received the Pre-Notice,
notifications by the Purchasers of their willingness to participate in the Subsequent Financing (or to cause their designees to participate)
is, in the aggregate, less than the total amount of the Subsequent Financing, then the Company may effect the remaining portion of such
Subsequent Financing on the terms and with the Persons set forth in the Subsequent Financing Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) If
by 5:30 p.m. (New York City time) on the fifth (5<SUP>th</SUP>) Trading Day after all of the Purchasers have received the Pre-Notice,
the Company receives responses to a Subsequent Financing Notice from Purchasers seeking to purchase more than the aggregate amount of
the Participation Maximum, each such Purchaser shall have the right to purchase its Pro Rata Portion (as defined below) of the Participation
Maximum. &ldquo;<U>Pro Rata Portion</U>&rdquo; means the ratio of (x) the Subscription Amount of Securities purchased on the Closing Date
by a Purchaser participating under this Section 4.12 and (y) the sum of the aggregate Subscription Amounts of Securities purchased on
the Closing Date by all Purchasers participating under this Section 4.12 plus the aggregate subscription amounts of investors party to
securities purchase agreement(s) contemplated by clause (d) in the definition of Exempt Issuance that are participating in such Subsequent
Financing pursuant to participation rights granted to such investors under such agreements that are substantially similar to this Section
4.12.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(f) The
Company must provide the Purchasers with a second Subsequent Financing Notice, and the Purchasers will again have the right of participation
set forth above in this Section 4.12, if the Subsequent Financing subject to the initial Subsequent Financing Notice is not consummated
for any reason on the terms set forth in such Subsequent Financing Notice within thirty (30) Trading Days after the date of the initial
Subsequent Financing Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) The
Company and each Purchaser agree that if any Purchaser elects to participate in the Subsequent Financing, the transaction documents related
to the Subsequent Financing shall not include any term or provision that, directly or indirectly, will, or is intended to, exclude one
or more of the Purchasers from participating in a Subsequent Financing, including, but not limited to, provisions whereby such Purchaser
shall be required to agree to any restrictions on trading as to any securities of the Company or be required to consent to any amendment
to or termination of, or grant any waiver, release or the like under or in connection with, this Agreement, without the prior written
consent of such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(h) Notwithstanding
anything to the contrary in this Section 4.12 and unless otherwise agreed to by such Purchaser, the Company shall either confirm in writing
to such Purchaser that the transaction with respect to the Subsequent Financing has been abandoned or shall publicly disclose its intention
to issue the securities in the Subsequent Financing, in either case in such a manner such that such Purchaser will not be in possession
of any material, non-public information, by the tenth (10th) Business Day following delivery of the Subsequent Financing Notice. If by
such tenth (10th) Business Day, no public disclosure regarding a transaction with respect to the Subsequent Financing has been made, and
no notice regarding the abandonment of such transaction has been received by such Purchaser, such transaction shall be deemed to have
been abandoned and such Purchaser shall not be deemed to be in possession of any material, non-public information with respect to the
Company or any of its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) Notwithstanding
the foregoing, this Section 4.12 shall not apply in respect of (i) an Exempt Issuance and (ii) shares of Common Stock or non-debt Common
Stock Equivalents issued and/or issuable to Cytovance Biologics, Inc. in connection with that certain Settlement and Investment Agreement
dated August 24, 2022 (as amended), between the Company and Cytovance Biologics, Inc. provided that the effective Common Stock per share
price is not less than the greater of (a) the Nasdaq Official Closing Price on the day immediately prior to such issuance and (b) the
Conversion Price then in effect as adjusted from time to time, and provided further that no amendment or modification to such agreement
shall be made without first obtaining the prior written consent of the two largest Purchasers hereunder (based on initial Subscription
Amounts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.13 <U>Subsequent
Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) From
the date hereof until 30 days after the later of (i) the Effective Date and (ii) the date that Shareholder Approval is obtained and deemed
effective, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed
issuance of any shares of Common Stock or Common Stock Equivalents or (ii) file any registration statement or any amendment or supplement
thereto, in each case other than as contemplated pursuant to the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) From
the date hereof until such time as no Purchaser holds any of the Preferred Stock or Warrants, the Company shall be prohibited from effecting
or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents
(or a combination of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction
in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or
include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other
price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset
at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events
directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price regardless of whether shares pursuant to such agreement have actually been issued
and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, from the date hereof and until
the two-year anniversary of the Closing Date, the Company shall be permitted to undertake and equity line of credit facility with Bristol
Investment Funds, Ltd. without the consent of the other Purchasers in the amount not to exceed $20,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Notwithstanding
the foregoing, this Section 4.13 shall not apply in respect of (i) an Exempt Issuance, except that no Variable Rate Transaction shall
be an Exempt Issuance and (ii) shares of Common Stock or non-debt Common Stock Equivalents issued and/or issuable to Cytovance Biologics,
Inc. in connection with that certain Settlement and Investment Agreement dated August 24, 2022 (as amended), between the Company and Cytovance
Biologics, Inc. provided that the effective Common Stock per share price is not less than the greater of (a) the Nasdaq Official Closing
Price on the day immediately prior to such issuance and (b) the Conversion Price then in effect as adjusted from time to time, and provided
further that no amendment or modification to such agreement shall be made without first obtaining the prior written consent of the two
largest Purchasers hereunder (based on initial Subscription Amounts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.14 <U>Equal
Treatment of Purchasers</U>. No consideration (including any modification of any Transaction Document) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration is
also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers
as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition
or voting of Securities or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.15 <U>Certain
Transactions and Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it,
nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales,
of any of the Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that
the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section
4.6. Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated
by this Agreement are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.6, such Purchaser
will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules
(other than as disclosed to its legal and other representatives). Notwithstanding the foregoing, and notwithstanding anything contained
in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i) no Purchaser makes any representation, warranty
or covenant hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.6, (ii) no
Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable
securities laws from and after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to
the initial press release as described in Section 4.6 and (iii) no Purchaser shall have any duty of confidentiality or duty not to trade
in the securities of the Company to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates
or agent, including, after the issuance of the initial press release as described in Section 4.6. Notwithstanding the foregoing, in the
case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.16 <U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and
to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably
determine is necessary in order to obtain an exemption for, or to qualify the Securities for, sale to the Purchasers at the Closing under
applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, and shall provide evidence of such actions promptly
upon request of any Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.17 <U>Capital
Changes</U>. Until the one year anniversary of the later of (a) the Effective Date and (b) the date that Shareholder Approval is obtained
and deemed effective, the Company shall not undertake a reverse or forward stock split or reclassification of the Common Stock without
the prior written consent of the Purchasers holding a majority in interest of the shares of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.18 <U>Lock-Up
Agreements</U>. The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend
the term of the lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to
a Lock-Up Agreement breaches any provision of a Lock-Up Agreement, the Company shall promptly use commercially reasonable efforts to seek
specific performance of the terms of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4.19 <U>No
Broker-Dealer</U>. The Company acknowledges and agrees that the Purchasers are not acting as a broker, dealer, underwriter or agent of
the Company or any of its Subsidiaries. The Company and its Subsidiaries shall not, and the Company shall direct its agents, affiliates
and representatives not to, take the position that the Purchasers are acting in any manner as a broker, dealer or agent of the Company
or any of its Subsidiaries in any respect (whether pursuant to the transactions contemplated hereby or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">ARTICLE V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>MISCELLANEOUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.1 <U>Termination</U>.
This Agreement may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever
on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated
on or before the fifth (5<SUP>th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination
will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.2 <U>Fees
and Expenses</U>. At the Closing, the Company has agreed to reimburse the two largest Purchasers hereunder (based on Subscription Amounts)
for their reasonable legal fees and expenses. Except as expressly set forth in the Transaction Documents to the contrary, each party shall
pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party
incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent
fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered by the Company and
any conversion or exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery
of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.3 <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.4 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email
attachment at the e-mail address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on
a Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment
at the e-mail address as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the signature pages attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Preferred Stock based on the
initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the
party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately
and adversely impacts a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers)
shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed
to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.
Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser
relative to the comparable rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected
Purchaser. Any amendment effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.6 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.7 <U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other
than by merger). Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or
transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by
the provisions of the Transaction Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.8 <U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
Section 4.10 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.10, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.10 <U>Survival</U>.
The representations and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo;
format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature
is executed) with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.13 <U>Rescission
and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of
the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw,
in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part
without prejudice to its future actions and rights; <U>provided</U>, <U>however</U>, that, in the case of a rescission of a conversion
of the Preferred Stock or exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject
to any such rescinded conversion or exercise notice concurrently with the return to such Purchaser of the aggregate exercise price paid
to the Company for such shares and the restoration of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s
Warrant (including, issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.14 <U>Replacement
of Securities</U>. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of
and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable
third-party costs (including customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.15 <U>Remedies</U>.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers
and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.16 <U>Payment
Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser
enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part
thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required
to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without
limitation, any bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration
the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
payment had not been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.17 <U>Usury</U>.
To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim, and will
resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any time hereafter
in force, in connection with any Action or Proceeding that may be brought by any Purchaser in order to enforce any right or remedy under
any Transaction Document. Notwithstanding any provision to the contrary contained in any Transaction Document, it is expressly agreed
and provided that the total liability of the Company under the Transaction Documents for payments in the nature of interest shall not
exceed the maximum lawful rate authorized under applicable law (the &ldquo;<U>Maximum Rate</U>&rdquo;), and, without limiting the foregoing,
in no event shall any rate of interest or default interest, or both of them, when aggregated with any other sums in the nature of interest
that the Company may be obligated to pay under the Transaction Documents exceed such Maximum Rate. It is agreed that if the maximum contract
rate of interest allowed by law and applicable to the Transaction Documents is increased or decreased by statute or any official governmental
action subsequent to the date hereof, the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to
the Transaction Documents from the effective date thereof forward, unless such application is precluded by applicable law. If under any
circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to any Purchaser with respect to indebtedness
evidenced by the Transaction Documents, such excess shall be applied by such Purchaser to the unpaid principal balance of any such indebtedness
or be refunded to the Company, the manner of handling such excess to be at such Purchaser&rsquo;s election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.18 <U>Independent
Nature of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and
not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
EGS. EGS does not represent any of the Purchasers and only represents Bristol Investment Funds, Ltd. The Company has elected to provide
all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested
to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this Agreement and in each other
Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not
between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.19 <U>Liquidated
Damages</U>. The Company&rsquo;s obligations to pay any partial liquidated damages or other amounts owing under the Transaction Documents
is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been
paid notwithstanding the fact that the instrument or security pursuant to which such partial liquidated damages or other amounts are due
and payable shall have been canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.20 <U>Saturdays,
Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.21 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.22 <B><U>WAIVER
OF JURY TRIAL</U>. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH
KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY
WAIVES FOREVER TRIAL BY JURY. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="text-transform: uppercase"><B>gt biophARMA, INC.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><P STYLE="margin-top: 0; margin-bottom: 0"><U>Address for Notice</U>:</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">505 Montgomery
                                            Street, 10th Floor</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">San Francisco, CA 94111</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">E-Mail: mb@gtbiopharma.com</P></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">By:__________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 15pt; text-indent: 0pt">Michael Breen</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 15pt">Title: Executive Chairman &amp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 15pt">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 13.5pt">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">With a copy to (which shall not constitute notice):</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Stubbs Alderton &amp; Markiles, LLP<BR>
    15260 Ventura Boulevard, 20<SUP>th</SUP> Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Sherman Oaks, CA 91403<BR>
    Attention: Louis Wharton</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Email: lwharton@stubbsalderton.com</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">[PURCHASER SIGNATURE PAGES TO <FONT STYLE="text-transform: uppercase">GTBP</FONT>
SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date
first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Name of Purchaser: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><I>Signature of Authorized Signatory of Purchaser</I>: __________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Name of Authorized Signatory: ____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Title of Authorized Signatory: _____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Email Address of Authorized Signatory: ___________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Address for Delivery of Securities to Purchaser (if not same as address
for notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Subscription Amount: $____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Shares of Preferred Stock: ____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Warrant Shares: ________________ Beneficial Ownership Blocker
<B>&#9744;</B> 4.99%/<B>&#9744;</B> 9.99%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EIN
Number: _______________________</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">[SIGNATURE PAGES CONTINUE]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>CERTIFICATE OF DESIGNATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>COMMON STOCK WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT D</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>VESTING WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT E</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>LEGAL OPINION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B></B>&nbsp;</P>


<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT F</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>LOCK-UP AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B><U>EXHIBIT G</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>VOTING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 53; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>ex10-2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Exhibit 10.2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">REGISTRATION
RIGHTS AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Registration Rights Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is made and entered into as of May 12, 2025, between GT Biopharma,
Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), and each of the several purchasers signatory hereto (each such purchaser,
a &ldquo;<U>Purchaser</U>&rdquo; and, collectively, the &ldquo;<U>Purchasers</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser
(the &ldquo;<U>Purchase Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt
and adequacy of which are hereby acknowledged, the Company and each Purchaser hereby agrees as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capitalized
terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the
Purchase Agreement.</B> As used in this Agreement, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Advice</U>&rdquo;
shall have the meaning set forth in Section 6(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Date</U>&rdquo; means the 60<SUP>th</SUP> calendar day following the Closing Date and each Trigger Date, as applicable (or, in the event
of a &ldquo;full review&rdquo; by the Commission, the 90<SUP>th</SUP> calendar day following the Closing Date and each Trigger Date,
as applicable) and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c),
the 60<SUP>th</SUP> calendar day following the date on which an additional Registration Statement is required to be filed hereunder (or,
in the event of a &ldquo;full review&rdquo; by the Commission, the 90<SUP>th</SUP> calendar day following the date such additional Registration
Statement is required to be filed hereunder); <U>provided</U>, <U>however</U>, that in the event the Company is notified by the Commission
that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the
Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the Company is so notified
if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a
Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Effectiveness
Period</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event</U>&rdquo;
shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Event
Date</U>&rdquo; shall have the meaning set forth in Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Filing
Date</U>&rdquo; means the 30<SUP>th</SUP> calendar day following the Closing Date and each Trigger Date, as applicable, and, with respect
to any additional Registration Statements which may be required pursuant to Section 2(c) or Section 3(c), the earliest practical date
on which the Company is permitted by SEC Guidance to file such additional Registration Statement related to the Registrable Securities,
provided, further, if such Filing Date falls on a day that is not a Trading Day, then the Filing Date shall be the next succeeding Trading
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Holder</U>&rdquo;
or &ldquo;<U>Holders</U>&rdquo; means the holder or holders, as the case may be, from time to time of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnified
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Indemnifying
Party</U>&rdquo; shall have the meaning set forth in Section 5(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Losses</U>&rdquo;
shall have the meaning set forth in Section 5(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Plan
of Distribution</U>&rdquo; shall have the meaning set forth in Section 2(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prime
Rate</U>&rdquo; means the rate last quoted by The Wall Street Journal as the &ldquo;Prime Rate&rdquo; in the United States or, if The
Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Federal Reserve Board in Federal
Reserve Statistical Release H.15 (519) (Selected Interest Rates) as the &ldquo;bank prime loan&rdquo; rate or, if such rate is no longer
quoted therein, any similar rate quoted therein or any similar release by the Federal Reserve Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Prospectus</U>&rdquo;
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information
previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the
Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the
offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to
the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference
in such Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registrable
Securities</U>&rdquo; means, as of any date of determination and provided that the Holder has completed and delivered to the Company
a Selling Stockholder Questionnaire, (a) all Conversion Shares issued and issuable pursuant to then outstanding Preferred Stock (assuming
on such date the Preferred Stock is converted in full without regard to any conversion limitations therein and the Conversion Price equals
the Floor Price), (b) all Warrant Shares issued and issuable upon exercise of the Warrants (assuming on such date the Warrants are exercised
in full without regard to any exercise limitations therein and assuming the Exercise Price equals the Floor Price) and (c) any securities
issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;
<U>provided, however</U>, that any such Registrable Securities shall cease to be Registrable Securities (and the Company shall not be
required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for so long as
(a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the
Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement,
(b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible for resale
without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a written opinion
letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that such securities
and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities were issued
or are issuable, were at no time held by any Affiliate of the Company, as reasonably determined by the Company, upon the advice of counsel
to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Registration
Statement</U>&rdquo; means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
415</U>&rdquo; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
424</U>&rdquo; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>SEC
Guidance</U>&rdquo; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements
or requests of the Commission staff and (ii) the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Selling
Stockholder Questionnaire</U>&rdquo; shall have the meaning set forth in Section 3(a).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trigger
Date</U>&rdquo; means, in the event that, and to the extent that, the Company is unable to register the Registrable Securities underlying
the Greenshoe Rights, each day that Registrable Securities in respect of a Greenshoe Right are not registered pursuant to Section 2.4
of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Shelf Registration</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale of
all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on a
continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not
then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate
form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 85%
in interest of the Holders) substantially the &ldquo;<U>Plan of Distribution</U>&rdquo; attached hereto as <U>Annex A</U> and substantially
the &ldquo;<U>Selling Stockholder</U>&rdquo; section attached hereto as <U>Annex B</U>; <U>provided</U>, <U>however</U>, that no Holder
or affiliate of a Holder shall be required to be named as, and in no event shall the Company be permitted to name any Holder or affiliate
of a Holder as, an &ldquo;underwriter&rdquo; without such Holder&rsquo;s express prior written consent. Subject to the terms of this
Agreement, the Company shall use commercially reasonable efforts to cause a Registration Statement filed under this Agreement (including,
without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof,
but in any event no later than the applicable Effectiveness Date, and shall use commercially reasonable efforts to keep such Registration
Statement continuously effective under the Securities Act until the date that all Registrable Securities covered by such Registration
Statement (i) have been sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant
to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule
144, as determined by counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer
Agent and the affected Holders (the &ldquo;<U>Effectiveness Period</U>&rdquo;). The Company shall telephonically request effectiveness
of a Registration Statement as of 5:00 p.m. (New York City time) on a Trading Day. Notwithstanding anything herein to the contrary, as
to the initial Registration Statement, the Company shall submit a Registration Statement including all of the Registrable Securities
represented by Underlying Shares issuable pursuant to the Securities issued at the Closing and at least 25% of the Registrable Securities
represented by the Underlying Shares issuable pursuant to the Securities issuable pursuant to the Greenshoe Rights. The Company shall
immediately notify the Holders via e-mail of the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically
confirms effectiveness with the Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company
shall, by 9:30 a.m. (New York City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus
with the Commission as required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness
or failure to file a final Prospectus as foresaid shall be deemed an Event under Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable
Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration
statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts to file amendments
to the each Registration Statement as required by the Commission, covering the maximum number of Registrable Securities permitted to
be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities as a secondary
offering, subject to the provisions of Section 2(e) with respect to filing on Form S-3 or other appropriate form, and subject to the
provisions of Section 2(d) with respect to the payment of liquidated damages; <U>provided</U>, <U>however</U>, that prior to filing such
amendment, the Company shall be obligated to use commercially reasonable efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation
612.09.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d), if the Commission or
any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration
Statement as a secondary offering (and notwithstanding that the Company used commercially reasonable efforts to advocate with the Commission
for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a Holder as to its
Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
                                            the Company shall reduce or eliminate any securities to be included other than the Registrable
                                            Securities;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
                                            the Company shall reduce the Registrable Securities represented by the Conversion Shares
                                            underlying the Preferred Stock issuable pursuant to the Greenshoe Rights and Vesting Warrant
                                            Shares (applied, in the case that some of such Registrable Securities may be registered but
                                            not all, to the Holders on a pro rata basis based on each Holder&rsquo;s Subscription Amount
                                            at the Closing, and within such pro rata amounts one (1) Conversion Share to one (1) Vesting
                                            Warrant Share);</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third,
                                            the Company shall reduce Registrable Securities represented by Common Stock Warrant Shares
                                            (applied, in the case that some of such Common Stock Warrant Shares may be registered but
                                            not all, to the Holders on a pro rata basis based on each Holder&rsquo;s Subscription Amount
                                            at the Closing); and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fourth,
                                            the Company shall reduce Registrable Securities represented by the Conversion Shares underlying
                                            the Preferred Stock issued at the Closing (applied, in the case that some of such Conversions
                                            Shares may be registered but not all, to the Holders on a pro rata basis based on each Holder&rsquo;s
                                            Subscription Amount at the Closing).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a cutback hereunder, the Company shall give the Holder at least three (3) Trading Days prior written notice along with the
calculations as to such Holder&rsquo;s allotment. In the event the Company amends a Registration Statement in accordance with the foregoing,
the Company will use commercially reasonable efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance
provided to the Company or to registrants of securities in general, one or more registration statements on Form S-3 or such other form
available to register for resale those Registrable Securities that were not registered for resale on each Registration Statement, as
amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If:
(i) a Registration Statement is not filed on or prior to its respective Filing Date (if the Company files a Registration Statement without
affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein or the Company subsequently
withdraws the filing of a Registration Statement, the Company shall be deemed to have not satisfied this clause (i) as of the respective
Filing Date), or (ii) the Company fails to file with the Commission a request for acceleration of effectiveness of a Registration Statement
in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five Trading Days of the date that the
Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement will not be &ldquo;reviewed&rdquo;
or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement, the Company fails to file
a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of such Registration Statement
within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment is required in order
for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale all of the Registrable
Securities required by the terms of this Agreement to be registered for resale is not declared effective by the Commission by the respective
Effectiveness Date of each Registration Statement (provided that, if a Registration Statement does not allow for the resale of Registrable
Securities at prevailing market prices (i.e., only allows for fixed price sales), the Company shall have been deemed to have not satisfied
this clause) or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain
continuously effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted
to utilize the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than
an aggregate of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure
or breach being referred to as an &ldquo;<U>Event</U>&rdquo;, and for purposes of clauses (i) and (iv), the date on which such Event
occurs, and for purpose of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii)
the date which such ten (10) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen
(15) calendar day period, as applicable, is exceeded being referred to as &ldquo;<U>Event Date</U>&rdquo;), then, in addition to any
other rights the Holders may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each
such Event Date (if the applicable Event shall not have been cured by such date) until the applicable Event is cured, the Company shall
pay to each Holder an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.5% multiplied by
the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement (provided, as to the Subscription Amount payable
pursuant to the Greenshoe Rights, liquidated damages payable hereunder shall only accrue after the exercise thereof and after the applicable
Event Date with respect to such Greenshoe Rights has elapsed). If the Company fails to pay any partial liquidated damages pursuant to
this Section in full within seven days after the date payable, the Company will pay interest thereon at the Prime Rate plus 12% (or such
lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing daily from the date such partial liquidated
damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated damages pursuant to the
terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the cure of an Event.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register the
resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form S-3
as soon as such form is available, provided that the Company shall maintain the effectiveness of a Registration Statement then in effect
until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate of a Holder as
any &ldquo;underwriter&rdquo; without the prior written consent of such Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Procedures</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Company&rsquo;s registration obligations hereunder, the Company shall:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior to the
filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed
to be incorporated therein by reference other than Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form
8-K and any similar or successor reports), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders,
and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall
be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning
of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto
to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is
notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration
Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements
thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as <U>Annex C
</U>(a &ldquo;<U>Selling Stockholder Questionnaire</U>&rdquo;) on a date that is not less than two (2) Trading Days prior to the Filing
Date or by the end of the fourth (4<SUP>th</SUP>) Trading Day following the date on which such Holder receives draft materials in accordance
with this Section 3(a). Each Holder further agrees that it shall not be entitled to be named as a selling securityholder in any Registration
Statement or use the Prospectus for offers and resales of Registrable Securities at any time, unless such Holder has timely furnished
to the Company a completed and signed Selling Stockholder Questionnaire as described in the previous sentence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)
Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and the Prospectus
used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable Registrable
Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in order to
register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended or supplemented
by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant
to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to a Registration
Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies of all correspondence
from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information contained therein
which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply in all material
respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable
Securities covered by a Registration Statement during the applicable period (subject to the terms of this Agreement) in accordance with
the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in such Prospectus
as so supplemented; <U>provided</U>, <U>however</U>, that each Purchaser shall be responsible for the delivery of the Prospectus to the
Persons to whom such Purchaser sells any of the Shares or the Warrant Shares (including in accordance with Rule 172 under the Securities
Act), and each Purchaser agrees to dispose of Registrable Securities in compliance with the plan of distribution described in each Registration
Statement and otherwise in compliance with applicable federal and state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common Stock
then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior to
the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of such
Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notify
the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (v) hereof, be accompanied by
an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably possible (and,
in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person) confirm such
notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement or post-effective
amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether there will be a &ldquo;review&rdquo;
of such Registration Statement and whenever the Commission comments in writing on such Registration Statement, and (C) with respect to
a Registration Statement or any post-effective amendment, when the same has become effective, (ii) of any request by the Commission or
any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional
information, (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending
the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings
for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption
from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding
for such purpose, and (v) of the occurrence of any event or passage of time that makes the financial statements included in a Registration
Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus or any document incorporated
or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions to a Registration Statement,
Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the case may be, it will not contain
any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending
the effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of
the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furnish
to each Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including
financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested
by such Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference)
promptly after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or
successor thereto) need not be furnished in physical form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by
each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus and any
amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the registration or qualification) of
such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United
States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during
the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions
of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally
to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
requested by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable
Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted
by the Purchase Agreement and applicable law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations
and registered in such names as any such Holder may request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account
the Company&rsquo;s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure
of such event, prepare a supplement or amendment, including a post-effective amendment, to the affected Registration Statements or a
supplement to any related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other
required document so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement
of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading. <FONT STYLE="text-decoration: double">If the
Company notifies the Holders in accordance with clauses (iii) through (v) of Section 3(d) above to suspend the use of any Prospectus
until the requisite changes to such Prospectus have been made, then the Holders shall suspend use of such Prospectus. The Company will
use commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company
shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration Statement and Prospectus,
subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period not to exceed 60 calendar
days (which need not be consecutive days) in any 12-month period</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Otherwise
use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities Act and
the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement
or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at
any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company shall use commercially reasonable efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the
registration of the resale of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common Stock beneficially
owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive control over the
shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable
Securities solely because any Holder fails to furnish such information within three Trading Days of the Company&rsquo;s request, any
liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise occur solely
because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.25in; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Expenses</U>. All fees and expenses incident to the performance of or compliance
with, this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration
Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing
fees (including, without limitation, fees and expenses) (A) with respect to filings made with the Commission, (B) with respect to filings
required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C) in compliance with applicable
state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation, fees and disbursements
of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities), (ii) printing expenses
(including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger, telephone and delivery
expenses, (iv) fees and disbursements of counsel and independent registered public accountants for the Company, (v) Securities Act liability
insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection
with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its
internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without
limitation, all salaries and expenses of its officers and employees performing legal or accounting duties), the expense of any annual
audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required
hereunder. In no event shall the Company be responsible for any broker or similar commissions of any Holder or, except to the extent
provided for in the Transaction Documents, any legal fees or other costs of the Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by the Company</U>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the
officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as
a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees (and any other
Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title)
of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the
Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with a functionally
equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling Person,
to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including,
without limitation, reasonable attorneys&rsquo; fees) and expenses (collectively, &ldquo;<U>Losses</U>&rdquo;), as incurred, arising
out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any Prospectus
or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to
any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the
case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation
or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder,
in connection with the performance of its obligations under this Agreement, except to the extent, but only to the extent, that (i) such
untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder
expressly for use therein, or to the extent that such information relates to such Holder or such Holder&rsquo;s proposed method of distribution
of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly for use in a Registration Statement,
such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has approved Annex A hereto for this purpose)
or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(v), the use by such Holder of an outdated,
defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated,
defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of the Advice contemplated in Section
6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding arising from or in connection
with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity shall remain in full force and effect
regardless of any investigation made by or on behalf of such indemnified person and shall survive the transfer of any Registrable Securities
by any of the Holders in accordance with Section 6(f).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
by Holders</U>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents
and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange
Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law,
from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged untrue statement of
a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto or in any preliminary
prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary
to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were
made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information
so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such Prospectus, (ii)
to the extent, but only to the extent, that such information relates to such Holder&rsquo;s information provided in the Selling Stockholder
Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by
such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex A hereto for this purpose),
such Prospectus or in any amendment or supplement thereto or (iii) in the case of an occurrence of an event of the type specified in
Section 3(d)(iii)-(v), to the extent, but only to the extent, related to the use by such Holder of an outdated, defective or otherwise
unavailable Prospectus after the Company has notified such Holder in writing that the Prospectus is outdated, defective or otherwise
unavailable and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). In no event shall the liability of a
selling Holder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable
Securities giving rise to such indemnification obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conduct
of Indemnification Proceedings</U>. If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder
(an &ldquo;<U>Indemnified Party</U>&rdquo;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the
&ldquo;<U>Indemnifying Party</U>&rdquo;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including
the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees and expenses incurred
in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying
Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined
by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially
and adversely prejudiced the Indemnifying Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party
has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such
Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to
any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to
the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent
such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing
that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to
assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying
Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which
consent shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified
Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to
the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section)
shall be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided
that the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such
actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject
to appeal or further review) not to be entitled to indemnification hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Contribution</U>.
If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party
harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party, in such
proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions,
statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of such
Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including
any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made
by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&rsquo; relative intent, knowledge,
access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party
as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&rsquo;
or other fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified
for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata
allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately
preceding paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the
dollar amount of the net proceeds received by such Holder from the sale of Registrable Securities subject to the Proceeding exceeds the
amount of any damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
indemnity and contribution agreements contained in this Section 5 are in addition to any liability that the Indemnifying Parties may
have to the Indemnified Parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Remedies</U>.
In the event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the
Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including
recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder
agrees that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the
provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach,
it shall not assert or shall waive the defense that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Piggyback on Registrations; Prohibition on Filing Other Registration Statements</U>. Except as set forth on <U>Schedule 6(b)</U> attached
hereto, and the shares of Common Stock issuable upon exercise of the warrants issued to the Placement Agent in the transactions contemplated
by the Purchase Agreement, neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto)
may include securities of the Company in any Registration Statements other than the Registrable Securities. The Company shall not file
any other registration statements other than a Registration Statement during the prohibition period set forth in Section 4.11(a) of the
Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Discontinued
Disposition</U>. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue disposition
of such Registrable Securities under a Registration Statement until it is advised in writing (the &ldquo;<U>Advice</U>&rdquo;) by the
Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use
commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. The Company agrees
and acknowledges that any periods during which the Holder is required to discontinue the disposition of the Registrable Securities hereunder
shall be subject to the provisions of Section 2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Amendments
and Waivers</U>. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented,
and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by
the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of clarification, this includes
any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any amendment, modification or waiver
disproportionately and adversely impacts a Holder (or group of Holders), the consent of such disproportionately impacted Holder (or group
of Holders) shall be required. If a Registration Statement does not register all of the Registrable Securities pursuant to a waiver or
amendment done in compliance with the previous sentence, then the number of Registrable Securities to be registered for each Holder shall
be reduced pro rata among all Holders and each Holder shall have the right to designate which of its Registrable Securities shall be
omitted from such Registration Statement. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with
respect to a matter that relates exclusively to the rights of a Holder or some Holders and that does not directly or indirectly affect
the rights of other Holders may be given only by such Holder or Holders of all of the Registrable Securities to which such waiver or
consent relates; <U>provided</U>, <U>however</U>, that the provisions of this sentence may not be amended, modified, or supplemented
except in accordance with the provisions of the first sentence of this Section 6(d). No consideration shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration also is offered
to all of the parties to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth
in the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Successors
and Assigns</U>. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the
parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations hereunder
without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may assign their
respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>No
Inconsistent Agreements</U>. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company
or any of its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would
have the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof. Except
as set forth on <U>Schedule 6(g)</U>, neither the Company nor any of its Subsidiaries has previously entered into any agreement granting
any registration rights with respect to any of its securities to any Person that have not been satisfied in full.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Execution
and Counterparts</U>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party,
it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file or any electronic signature complying with the U.S. federal ESIGN Act of 2000 (e.g., www.docusign.com),
such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with
the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in
accordance with the provisions of the Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Cumulative
Remedies</U>. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or
unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Headings</U>.
The headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or
affect any of the provisions hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Nature of Holders&rsquo; Obligations and Rights</U>. The obligations of each Holder hereunder are several and not joint with the obligations
of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of any other Holder
hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder
pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint venture or any other
kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a group or entity with respect
to such obligations or the transactions contemplated by this Agreement or any other matters, and the Company acknowledges that the Holders
are not acting in concert or as a group, and the Company shall not assert any such claim, with respect to such obligations or transactions.
Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement,
and it shall not be necessary for any other Holder to be joined as an additional party in any proceeding for such purpose. The use of
a single agreement with respect to the obligations of the Company contained was solely in the control of the Company, not the action
or decision of any Holder, and was done solely for the convenience of the Company and not because it was required or requested to do
so by any Holder. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and a
Holder, solely, and not between the Company and the Holders collectively and not between and among Holders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal"><I>(Signature
Pages Follow)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: normal 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties have executed this Registration Rights Agreement as of the date first written above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>gt biopharma,
    inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGE OF HOLDERS FOLLOWS]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
PAGE OF HOLDERS TO gtbp RRA]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: __________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[SIGNATURE
PAGES CONTINUE]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Plan
of Distribution</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Selling Stockholder (the &ldquo;<U>Selling Stockholders</U>&rdquo;) of the securities and any of their pledgees, assignees and successors-in-interest
may, from time to time, sell any or all of their securities covered hereby on the Nasdaq Capital Market or any other stock exchange,
market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices.
A Selling Stockholder may use any one or more of the following methods when selling securities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary
                                            brokerage transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block
                                            trades in which the broker-dealer will attempt to sell the securities as agent but may position
                                            and resell a portion of the block as principal to facilitate the transaction;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases
                                            by a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
                                            exchange distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately
                                            negotiated transactions;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement
                                            of short sales effected after the effective date of the registration statement of which this
                                            prospectus is a part;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
                                            transactions through broker-dealers that agree with the Selling Stockholders to sell a specified
                                            number of such securities at a stipulated price per security;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through
                                            the writing or settlement of options or other hedging transactions, whether through an options
                                            exchange or otherwise;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
                                            combination of any such methods of sale; or</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any
                                            other method permitted pursuant to applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933,
as amended (the &ldquo;<U>Securities Act</U>&rdquo;), if available, rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or
markdown in compliance with FINRA Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Stockholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is required to pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company
has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under
the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
agreed to keep this prospectus effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders
without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for
the Company to be in compliance with the current public information under Rule 144 under the Securities Act or any other rule of similar
effect or (ii) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule
of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable
state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered
or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is
complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M,
prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
common stock by the Selling Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELLING
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
common stock being offered by the selling shareholders are those previously issued to the selling shareholders, and those issuable to
the selling shareholders, upon conversion of shares of preferred stock and exercise of the warrants. For additional information regarding
the issuances of those shares of preferred stock and warrants, see &ldquo;Private Placement of Shares of Preferred Stock and Warrants&rdquo;
above. We are registering the shares of common stock in order to permit the selling shareholders to offer the shares for resale from
time to time. Except for the ownership of the shares of capital stock and warrants, the selling shareholders have not had any material
relationship with us within the past three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below lists the selling shareholders and other information regarding the beneficial ownership of the shares of common stock by
each of the selling shareholders. The second column lists the number of shares of common stock beneficially owned by each selling shareholder,
based on its ownership of the shares of capital stock and warrants, as of May 12, 2025, assuming conversion of the shares of preferred
stock and exercise of the warrants held by the selling shareholders on that date, without regard to any limitations on conversion or
exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
third column lists the shares of common stock being offered by this prospectus by the selling shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale
of the sum of (i) the number of shares of common stock underlying the shares of preferred stock issued to the selling shareholders in
the &ldquo;Private Placement of Shares of Preferred Stock and Warrants&rdquo; described above, determined as if the outstanding shares
of preferred stock were converted in full, and (ii) the maximum number of shares of common stock issuable upon exercise of the related
warrants, determined as if the outstanding warrants were exercised in full, each determined as of the trading day immediately preceding
the applicable date of determination and all subject to adjustment as provided in the registration right agreement, without regard to
any limitations on the conversion of the shares of preferred stock or exercise of the warrants. The fourth column assumes the sale of
all of the shares offered by the selling shareholders pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the terms of the shares of preferred stock and the warrants, a selling shareholder may not convert or exercise any such security, as
applicable, to the extent such conversion or exercise would cause such selling shareholder, together with its affiliates and attribution
parties, to beneficially own a number of shares of common stock which would exceed [4.99% or] 9.99%[, as applicable,] of our then outstanding
common stock following such conversion or exercise, excluding for purposes of such determination shares of common stock issuable upon
conversion of such shares of preferred stock which have not been converted, and exercise of such warrants which have not been exercised.
The number of shares in the second and fourth columns do not reflect this limitation. The selling shareholders may sell all, some or
none of their shares in this offering. See &ldquo;Plan of Distribution.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><BR STYLE="clear: both">
    <U>Name of Selling Shareholder</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Number
    of shares of Common Stock Owned Prior to Offering</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 23%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Maximum
    Number of shares of Common Stock to be Sold Pursuant to this Prospectus</U></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Number
    of shares of Common Stock Owned After Offering</U></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
C</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">gt
biopharma, inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
Stockholder Notice and Questionnaire</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned beneficial owner of common stock (the &ldquo;<U>Registrable Securities</U>&rdquo;) of GT Biopharma, Inc., a Delaware corporation
(the &ldquo;<U>Company</U>&rdquo;), understands that the Company has filed or intends to file with the Securities and Exchange Commission
(the &ldquo;<U>Commission</U>&rdquo;) a registration statement (the &ldquo;<U>Registration Statement</U>&rdquo;) for the registration
and resale under Rule 415 of the Securities Act of 1933, as amended (the &ldquo;<U>Securities Act</U>&rdquo;), of the Registrable Securities,
in accordance with the terms of the Registration Rights Agreement (the &ldquo;<U>Registration Rights Agreement</U>&rdquo;) to which this
document is annexed. A copy of the Registration Rights Agreement is available from the Company upon request at the address set forth
below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
order to sell or otherwise dispose of any Registrable Securities pursuant to the Registration Statement, a holder of Registrable Securities
generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented,
the &ldquo;<U>Prospectus</U>&rdquo;), deliver the Prospectus to purchasers of Registrable Securities (including pursuant to Rule 172
under the Securities Act) and be bound by the provisions of the Registration Rights Agreement (including certain indemnification provisions,
as described therein). Holders must complete and deliver this Notice and Questionnaire in order to be named as selling stockholders in
the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly,
holders and beneficial owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences
of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTICE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned beneficial owner (the &ldquo;<U>Selling Stockholder</U>&rdquo;) of Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QUESTIONNAIRE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
                                            Legal Name of Selling Stockholder</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                              <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                              </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
                                            Legal Name of Registered Holder (if not the same as (a) above) through which Registrable
                                            Securities are held:</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                 <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Full
                                            Legal Name of Natural Control Person (which means a natural person who directly or indirectly
                                            alone or with others has power to vote or dispose of the securities covered by this Questionnaire):</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Address for Notices to Selling Stockholder:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:<U>&#9;</U>_______________________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:<U>&#9;</U>__________________________________________________________________________________________</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact
    Person:<U>&#9;</U>___________________________________________________________________________________</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Broker-Dealer Status:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
                                            you a broker-dealer?</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;Yes
&#9744; &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            &ldquo;yes&rdquo; to Section 3(a), did you receive your Registrable Securities as compensation
                                            for investment banking services to the Company?</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;Yes
&#9744; &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9;Note:
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9;If &ldquo;no&rdquo;
to Section 3(b), the Commission&rsquo;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Are
                                            you an affiliate of a broker-dealer?</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;Yes
&#9744; &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable
                                            Securities in the ordinary course of business, and at the time of the purchase of the Registrable
                                            Securities to be resold, you had no agreements or understandings, directly or indirectly,
                                            with any person to distribute the Registrable Securities?</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9;Yes
&#9744; &#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">Note:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">If &ldquo;no&rdquo; to Section 3(d), the Commission&rsquo;s staff has indicated that you should be identified as an underwriter in the
Registration Statement.</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Beneficial Ownership of Securities of the Company Owned by the Selling Stockholder.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than
the securities issuable pursuant to the Purchase Agreement.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Type
                                            and Amount of other securities beneficially owned by the Selling Stockholder:</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Relationships with the Company:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Except
as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5%
of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with
the Company (or its predecessors or affiliates) during the past three years.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
any exceptions here:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                                                          </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B>Plan of Distribution</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
undersigned has reviewed the form of Plan of Distribution attached as Annex A to the Registration Rights Agreement, and hereby confirms
that, except as set forth below, the information contained therein regarding the undersigned and its plan of distribution is correct
and complete.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">State
any exceptions here:<BR>
___________________________________________________________<BR>
___________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may
occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall
not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 6 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment
of the Registration Statement and the related prospectus and any amendments or supplements thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions
of the Exchange Act and the rules and regulations thereunder, particularly Regulation M in connection with any offering of Registrable
Securities pursuant to the Registration Statement. The undersigned also acknowledges that it understands that the answers to this Questionnaire
are furnished for use in connection with Registration Statements filed pursuant to the Registration Rights Agreement and any amendments
or supplements thereto filed with the Commission pursuant to the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned hereby acknowledges and is advised of the following Interpretation A.65 of the July 1997 SEC Manual of Publicly Available
Telephone Interpretations regarding short selling:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&ldquo;An
Issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet effective. One of the selling
stockholders wanted to do a short sale of common stock &ldquo;against the box&rdquo; and cover the short sale with registered shares
after the effective date. The issuer was advised that the short sale could not be made before the registration statement become effective,
because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation
of Section 5 if the shares were effectively sold prior to the effective date.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing interpretation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this Questionnaire)
are correct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either
in person or by its duly authorized agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 19%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    Owner: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLEASE
EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">GT
Biopharma, Inc.<BR>
505 Montgomery Street, 10<SUP>th</SUP> Floor<BR>
San Francisco, CA 94111<BR>
Attention: Chief Executive Officer<BR>
E-Mail: mb@gtbiopharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to (which shall not constitute notice):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stubbs
Alderton &amp; Markiles, LLP<BR>
15260 Ventura Boulevard, 20<SUP>th</SUP> Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sherman
Oaks, CA 91403<BR>
Attention: Louis Wharton</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:
lwharton@stubbsalderton.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>7
<FILENAME>ex10-3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-right: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 10.3</B></P>

<P STYLE="margin-right: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">TO:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Purchasers of GT Biopharma, Inc., Series L 10% Convertible Preferred Stock and Warrants</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">To Whom It May Concern:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This letter will confirm my agreement
to vote all shares of GT Biopharma, Inc. (&ldquo;<U>GTBP</U>&rdquo;) voting stock over which[ my affiliates and] I have voting control
in favor of any resolution presented to the shareholders of GTBP to approve the issuance, in the aggregate, of more than 19.99% of the
number of shares of common stock of GTBP outstanding on the date of closing pursuant to that certain Securities Purchase Agreement, dated
May 12, 2025, among GTBP and the purchasers signatory thereto (the &ldquo;<U>Purchase Agreement</U>&rdquo;) and the other agreements entered
into in connection therewith or as otherwise may be required by the applicable rules and regulations of the Nasdaq Stock Market LLC (or
any successor entity). This agreement is given in consideration of, and as a condition to enter into such Purchase Agreement and is not
revocable by me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This letter is intended for the
benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision
hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 17.1pt; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name of Shareholder:</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Number of voting shares over which I have
    voting control: _________________</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>8
<FILENAME>ex10-4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><B>Exhibit 10.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><B>LOCK-UP AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: right">May 12, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">GT Biopharma, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Securities Purchase Agreement, dated as of May 12, 2025 (the &ldquo;Purchase Agreement&rdquo;), between GT Biopharma, Inc. (the &ldquo;Company&rdquo;) and the purchasers signatory thereto (each, a &ldquo;Purchaser&rdquo; and, collectively, the &ldquo;Purchasers&rdquo;)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Defined terms not otherwise
defined in this letter agreement (the &ldquo;<U>Letter Agreement</U>&rdquo;) shall have the meanings set forth in the Purchase Agreement.
Pursuant to Section 2.2(a) of the Purchase Agreement and in satisfaction of a condition of the Company&rsquo;s obligations under the Purchase
Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until thirty (30) days after the later of (i)
the Effective Date and (ii) the date that Shareholder Approval is obtained and deemed effective (such period, the &ldquo;<U>Restriction
Period</U>&rdquo;), the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into
any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or
effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate of the undersigned or any person
in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent
position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934,
as amended (the &ldquo;<U>Exchange Act</U>&rdquo;), with respect to, any shares of Common Stock of the Company or securities convertible,
exchangeable or exercisable into, shares of Common Stock of the Company beneficially owned, held or hereafter acquired by the undersigned
(the &ldquo;<U>Securities</U>&rdquo;)<FONT STYLE="letter-spacing: -0.1pt">. </FONT>Beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act. In order to enforce this covenant, the Company shall impose irrevocable stop-transfer instructions
preventing the transfer agent of the Company from effecting any actions in violation of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, and subject to the conditions below, the undersigned may transfer the Securities provided that (1) the Company receives a signed
lock-up letter agreement (in the form of this Letter Agreement) for the balance of the Restriction Period from each donee, trustee, distributee,
or transferee, as the case may be, prior to such transfer (2) any such transfer shall not involve a disposition for value, (3) such transfer
is not required to be reported with the Securities and Exchange Commission in accordance with the Exchange Act and no report of such transfer
shall be made voluntarily, and (4) neither the undersigned nor any donee, trustee, distributee or transferee, as the case may be, otherwise
voluntarily effects any public filing or report regarding such transfers, with respect to transfer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">as a <I>bona fide</I> gift or gifts;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">to any immediate family member or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this Letter Agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">to any corporation, partnership, limited liability company, or other business entity all of the equity holders of which consist of the undersigned and/or the immediate family of the undersigned;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">if the undersigned is a corporation, partnership, limited liability company, trust or other business entity (a) to another corporation, partnership, limited liability company, trust or other business entity that is an Affiliate of the undersigned or (b) in the form of a distribution to limited partners, limited liability company members or stockholders of the undersigned;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">if the undersigned is a trust, to the beneficiary of such trust;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">vi)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">vii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;of securities purchased in open market transactions after the Closing Date.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, notwithstanding
the foregoing, this Letter Agreement shall not restrict the delivery of shares of Common Stock to the undersigned upon (i) exercise any
options granted under any employee benefit plan of the Company; provided that any shares of Common Stock or Securities acquired in connection
with any such exercise will be subject to the restrictions set forth in this Letter Agreement, or (ii) the exercise of warrants; provided
that such shares of Common Stock delivered to the undersigned in connection with such exercise are subject to the restrictions set forth
in this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Furthermore, the undersigned
may enter into any new plan established in compliance with Rule 10b5-1 of the Exchange Act; provided that (i) such plan may only be established
if no public announcement or filing with the Securities and Exchange Commission, or other applicable regulatory authority, is made in
connection with the establishment of such plan during the Restriction Period and (ii) no sale of shares of Common Stock are made pursuant
to such plan during the Restriction Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The undersigned acknowledges
that the execution, delivery and performance of this Letter Agreement is a material inducement to the Company to complete the transactions
contemplated by the Purchase Agreement and the Company shall be entitled to specific performance of the undersigned&rsquo;s obligations
hereunder. The undersigned hereby represents that the undersigned has the power and authority to execute, deliver and perform this Letter
Agreement, that the undersigned has received adequate consideration therefor and that the undersigned will indirectly benefit from the
closing of the transactions contemplated by the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 4.5pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This Letter Agreement may
not be amended or otherwise modified in any respect without the written consent of each of the Company and the undersigned. This Letter
Agreement shall be construed and enforced in accordance with the laws of the State of New York without regard to the principles of conflict
of laws. The undersigned hereby irrevocably submits to the exclusive jurisdiction of the United States District Court sitting in the Southern
District of New York and the courts of the State of New York located in Manhattan, for the purposes of any suit, action or proceeding
arising out of or relating to this Letter Agreement, and hereby waives, and agrees not to assert in any such suit, action or proceeding,
any claim that (i) it is not personally subject to the jurisdiction of such court, (ii) the suit, action or proceeding is brought in an
inconvenient forum, or (iii) the venue of the suit, action or proceeding is improper. The undersigned hereby irrevocably waives personal
service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to the
Company at the address in effect for notices to it under the Purchase Agreement and agrees that such service shall constitute good and
sufficient service of process and notice thereof. The undersigned hereby waives any right to a trial by jury. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. The undersigned agrees and understands
that this Letter Agreement does not intend to create any relationship between the undersigned and any Purchaser and that no Purchaser
is entitled to cast any votes on the matters herein contemplated and that no issuance or sale of the Securities is created or intended
by virtue of this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This Letter Agreement shall
be binding on successors and assigns of the undersigned with respect to the Securities and any such successor or assign shall enter into
a similar agreement for the benefit of the Company. This Letter Agreement is intended for the benefit of the parties hereto and their
respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in">*** SIGNATURE PAGE FOLLOWS***</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This Letter Agreement may be executed
in two or more counterparts, all of which when taken together may be considered one and the same agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Print Name</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Position in Company, if any</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0in">&nbsp;</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Address for Notice:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Number of shares of Common Stock</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 100%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Number of shares of Common Stock underlying subject to warrants, options, debentures or other convertible securities</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, the Company
agrees to enforce the restrictions on transfer set forth in this Letter Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>GT BIOPHAMRA, INC. </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>gtbp-20250512.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaqIebP9z5Z8WekhvWBxbVlKLyMhWX68vSaRsBR20egG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:GTBP="http://gtbiopharma.com/20250512" elementFormDefault="qualified" targetNamespace="http://gtbiopharma.com/20250512">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://gtbiopharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="gtbp-20250512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>gtbp-20250512_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>gtbp-20250512_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://gtbiopharma.com/role/Cover" xlink:href="gtbp-20250512.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://gtbiopharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-40023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GT
Biopharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000109657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-1620407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">505 Montgomery Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">10th Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">919-4040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GTBP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "9(K5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( "9(K5H$[KM-[@   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DL]*Q# 0AU]%<F^G:5D/H9N+XDE!<$'Q%I+9
MW6#SAV2DW;<WK;M=1!_ 8V9^^>8;F%Y'H4/"YQ0B)K*8;R8W^"QTW+(C410
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MM5II ,,X?<D3$L/<@HL(2W@4R]9<X%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ )DBM6JK$(A8S 0  (@(   \
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M4$L! A0#%     @ )DBM6@3NNTWN    *P(  !$              ( !PP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ )DBM6IE<G",0!@  G"<
M !,              ( !X $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  F2*U:CL&],WL$  "R$0  &               @($A"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ )DBM6I^@&_"Q @  X@P
M  T              ( !T@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  F
M2*U:EXJ[',     3 @  "P              @ &N#P  7W)E;',O+G)E;'-0
M2P$"% ,4    "  F2*U:JL0B%C,!   B @  #P              @ &7$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ )DBM6B0>FZ*M    ^ $  !H
M             ( !]Q$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ )DBM6F60>9(9 0  SP,  !,              ( !W!(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  )A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://gtbiopharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>gtbp-20250512.xsd</File>
    <File>gtbp-20250512_lab.xml</File>
    <File>gtbp-20250512_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "GTBP",
   "nsuri": "http://gtbiopharma.com/20250512",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "gtbp-20250512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "gtbp-20250512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gtbp-20250512_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2024": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://gtbiopharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-05-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-05-12",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://gtbiopharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001641172-25-009854-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001641172-25-009854-xbrl.zip
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MA<_[O@;3H*FYS=4L8]<VHN>I6W"F4Q%_&M;MZ3]H^0$>1A8B.&@(L:@SETE
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M:%@;\M/XZY2N^23OD247+4W&$O6T8L=R.Y$5B1X93,\T@]4G#0BX-=JPT,_
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M!CL.$T*RTW@M"([FEOK R-8FR'0^I'[W'@#;7&FC$YU+I]-G\<:%X3.*.''
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M4)KR<FWLNXNPUI'<)AC'J)MHYV7G-"+F264](U!<T_U<;9E$.@2[2)5+:E?
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M02V9L7FPQBQUI[+M<:L@(QQLE<*98D9M,V+,0S9;#8!^Q079?[L)&TKP'F:
MMMZH/#RN<\*,L$H5&)R S'!P*0((IH*PP*";_,R]HM)YO<[6@=TW@,^14%A7
M=G)Y4YF^CK9K, 14"\-?<]$,]@I<[0&PP8&8.F[SH-49$@3=.+60;WD_'A,(
MA&_\<B+, HD?06S<M56*4M-!\<[I%3Y]/ ,9DRN0M+P-&2)G7!FUDWONX@F8
M+*4?<I])TBB(*PZL,68!\+S;)9O$,#L-QP*==>8GERXP)"'&L%C:9.&W#F/+
M$E)?&^"<]!&7/85DIU+#GKP)>&WK&$!=KQ;*W&$8.4"!V^"<F#%JMK@6T&G-
MNS-A71"QNPI]FT^.M;]4>PZ]2QET\7U<D09A*1TRWLX+<$,-H*S>'ET<#>0K
M2X0'-3^7)(HFI \H6@HM,TT4]/)_J@\)0S24:"=\5VP2UA[S[GY\"QHK/W:-
M?JHN<>IT$C*GAH-SF?HQD7;?@(I!L46?*><*D<4[Q"-C],;T_=\>.WH\QHX^
M:>SH\1@[&F-'GT7GS3DES<E:<=SL9ZLRNP13>"MG$QL>+)D#G>- .$N9S2GP
M@'9]=D3RL6!OGI"YWT'Z% OKD]6!M4]WF4O<Z4,VO:];Z#W"\H:/.PR;]T:I
M+4Q#86+2ODD)O[;SP^XD7IY-17<V@[V%@RG4IKR^%.A()KU@@"6U-%0\6=-2
M8@S+E2/<.8 [6DQ7487@ES(NZHH?A'-&\.HIE75WK/1.SVYD&(V$PJ7?+W87
MX0IU1\@Y0^](W_M1-=J0PK!AIO %N;?3%C13GNY_H\5A*LL6,7MJL06"^Y#&
M%;>4,M*&6"_KLI<F[_&<I\5-5I7Z4EB<)A6G*)Z<M5*M7:=)3KDKB =?IM@K
M>):H]HEF&R?&?]E6YJ@;9-F*^AD;6B52C@FD8_F2?J-#;#H9%2XK@E<D@D_M
M8D\G+V%/]%?FZ!@#Y%D=-@CVM 7L_EO#%;YQI')^X^%AN-[ /.B>$W>2V:B6
M*BQ9S3+:8EF%?OQJF6"_<#?$T56%TD7^R)D!AQ\@%\!,_R(76(+UJ'V[G?ZF
MXH:KV32]AE6AA,04@SP:^G*.??_Q,II?PV_GA*CF07/6),'UD)A/60N;\GTV
MIZO@.OE74BW*#9&C*6P5GKA-ZH;#_=:?[IWI/[G?Z7D( =.4&MF:S-A)/ (N
MFB&SJQQ68H.!1[HO* A2UQ3^MC'L& N;Q#Z*BANAK$ #HL?6)27$4NHJ9=>2
MV"P62EO4TVW"*M^FL+6(IRC/0RHNFKX%SC_+=?H']'3!,\G_!HU.A(VGMJL]
MXUV-L=4Y01XTY%/+!83WK?LQW1>X=DBC2'5871:5,6MCE\E$"CK^ R9KM<FO
MM&0-)^XHP)EO:P,O#<YFI$=3E^X)7W,D%%4SX'F1;KFQ^ M,,X4,!K24<D>=
MR&CW[;::RHZ8[A,V\*4 QK"$&#+B'7*>Q^'6Q,\8](=->'=7$.>>J6/A>?=X
MRQHSORX5)SWWT>/>T#=.[3ZF_VC;WW'5%(=<FE"#AM/)&]ZB_5<-A0KL50/2
MHJ;*/4AN[[EBZQ8;7ZWT=;3[)20B2CAMG'6%6!-W-0GLNAN@[(MO$D[))1_L
M=Q*XQ#7G^_4!]E7G04=[3RD?';8Y#%8=^DT.>2MG/(3/+(O'M \XPOLJ2H69
M-IX)$0D.7+"\2YF/Q5SFCE!Q52Y,V2,1"&X8W,7Q9/')*NED768-AHYA-D\(
M-;/GL:*K@RI#,:L@TAJ2Z&^P/7)P(SU'!L*2]B,GV[%-T*I<15<(MH+-L=[?
MUY[<3C49$ .ML*U:FT !;Q)?NFF?HDQR,V#B)^SY'>QISNY8DA5W*)QJ>')+
MSOV1?CCX +WM!OV0+G7,#843X-J_H^*-F/MF,K8V6J.49!;\GA!"AG&QT_9
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MMA>UW6K+\G>B@BP:/&UCUZ78SP.YZW0B#BVL@I$@ D6&";%P%XFE>0Y)J:)
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M3P2"N^U,!.#M2[2L-_#6YRE>>72E&3_!ZQ<GSZPA.MXQO.O^^4_:=32%YZG
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MI?TC98_'2-DGC90]'B-E8Z3L5_7B WKP\.@!,W=Y()^KJ/FWI-+"WQT67I-
M9QA1EYQ2E.9+!;D2EQ?I%>8QX8,V;->43L^OJWV%^^DD*'&/GIC>ZAZM@!P^
MM2P9A76P*7+*BA=OHY+:<GY;PYS' CVAR@"88P4?:X!CYM&(,"FU1T'!!X??
M_9XK]V7<% <)JY_555((==J3Z>1$'4^\32XZ[+;B>>9Z)I*UP(X@]0$O-LPZ
MK)7I*.^=N0%BY![-%J:,!3LJ"V;>42/=(@0Y+85W3INN*B-J QM DS?Y:!I5
MO>-:+[$OEA>3WP%TVOHZ6\>,PX9^>C#.7,WOTA>])^.?][)']X0T&>S Q_R
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M]+H%<D@/!Z,3G')TZF^:CZ L)WQV#=Y8:DSM4"%G1SBT<1@$Y!-@<8QF\LR
M4XU&]I'!:A=/(C"D1_57%%EUNR#C)NT%"'4&5#@?Y,:>8S-=]T<R8ZYH.XFV
M.5$=3%S;$KS%A9 K(MT(YKTT&JW7G$I9&8#+Q,[WM+J#4(B<T-%GO]?6JB:S
M?*O6%J+$Q>T,_,XLKI] BZ"2V)I;HGY=7W+39K_M4P^.\N8:TCMJ2+VN%YK<
M]77*6[OIM9J%PER-(C,+&-L=%X..]1<.0E^Q4 0/N@YM"MCAQM=A)LPYVA_C
M!@GMQZQ_;+.[ND)+P+>FCB-FS]!A#A:#ZCO3"!"(!S^=F+*0I*6%S=2[4C\T
M2%YG+, RNSJ#!>0KR'S&AH#M.$9<=$CG +LMF),3CJ*W-NMV5YO;F$1Z6X4B
M3LKH"GY9X>"DK(D36=X@\$L.0P.X6A&+V&8Y=06=NB7D!IX\<Y6I=E6'Y9>M
MQY>33Z7MRDK? "L[_3OX<W_+F_C#PMR#7-+ACJJ[(2:JX<J7)FK$=8JIOPPK
M54%:VPH-N#Y-H7;P*+U&\\FW2]DC5F<BZ=9Q"E,4/ZPDN-U7]#%26J#I**Q7
M'G]%9="Y^L:F+^V4*DQ(ZTS#SQ7I.+-I4?_-<11G/]9ZO](]AZU\S&>P.79$
M&:%L&6Q6'\VOCS,JI-ZM13&X:L6$G07Y#8*+EOJO+"YB'SL#L6Z4AAF508H<
MB?-U[ORLECL%AQ@QQMO$QJ8/]2?0PY3ZKP97^8UKM3V_&NF-K>0@!Z_6K3L\
M6'8HNFS5<"9P7&"!:Z1FYWP]E+?OE]1K5;H0^*DAUZ8]N,TCCW%N!>\^7<*[
M"X5WGR[AW26\NU@DXU=$,EQRS#:F.!ZE7$U@%B,1Q*4Z!9M[ II5H&O>HGF6
ME8KPN_R]L'UMS\542F'&TXC&T@<XA\!<T[>T>(B+K>! K<H1)?VH,77-4:3T
MV@:?YSPO.&$_*7,@Z4W@ =?\,B&_S(;O83MS..59%?!!C<.3QGC&6 -,]3J5
M5IK6.B)5XAA.Z:"<-*WY[-E,;3 Y?4G<<M-U)!_E%Q>N\/@JMV"B\]';XT$.
MVU5>-5,\<%UY>;2E2@?04U;J#3 ASSHLD4#68OW. 7CD9^Z+C=\2V(Z'9?$D
M0G'A# LYI#&UF@ RXVA8P-X;$30M-A0I8F$6ED30#KK2-#3'0/NEBP$?HB@2
MF>;<);S5U]JU"4>I)^X5CL9(_$@_;H#@ C=G9M%ZDEJT#:5:G>U=-\JZ)^I=
M#MY3@=XHSZZHQ:?]/)"5>>+CN%U/2 C,72 4= Y)B6TFY4I4QR&B?IC-.7&Q
M2JY)8G9NO6^VRR_+Y&.635H7\%"LSX=9O 3+9^,LR0TPBQ>RA*()>+Y@X-G"
M/;\<)X,K*%R+4=F:,FP1#!<0([7>?!D8 3 Z&'&\%/S-Q&W.N_=4=&F9B(IK
MK_!<FU(:- 0NPT9=7?#QG:<Q"C,2"'WABFQI7+<<Q/V, 2$;&0/6E2")=V!K
MU,[3&IA"0^97W@33]\0L#=RR#-]%E4$54-#J@4'IU14384<7.$O?05QL;^$W
MOIO%NPR'YHVEGLT/-ST,%BAQA!Q)+/A+HAWH&Y=H.C)6(RNGM2X5UWIII(A"
MCX7)*OT+^<;JBL(M_(KJ;L3__I%B3&??DPE[.,V$[^3#O 07YGU-L!_R0[)!
M[?DNNF0<YA4BD/YE-L 6%!LOX;-)VC0I_"Z1E&%[;4T%8S37FO!]5(62XRMZ
MC5J<XB)0%Z_+ZB,IWTYR5C9"*J/*LR/:6V>"A=-]7B$B:-6*0C6JMNA32X5P
MD)TWR9KN8,E"-.60K8_Y!9@#VR&NA%T()5;&G:E:4+4],6R$0\+5.;;/AK'U
M,Y0B/W?CKK*!%33@8?MZ/Y7_\YX)I*Z HP^6$K3F[00XD4:^CJX3-^>*%%1#
M]=)@'9[H*B]'MNAQ?_=X&_YVM+^]BQ9'H,1''A'<"H5[MD3A%HK"/5NB<$L4
M;K%GYM--JGDPYK@@(J/89 >.T!%ZZI<[^QA/*+VR&6FEE?--"'\!T"]T?>#W
MX&D[OQE&(MZT(M*#^YB!D)WY!^0=B\SSL3DJP2!\S3(&5&1?B\KM$*M@@,QG
M?,3,'C))58KN(GW!A"_FQC99@V5P6 KNI2O3!&V7>);XJ<0#%O!7YBRD!R>4
MX?JR%-RP#N.G-54,#Q+%PB:R1?E;\6H0G %+QMJ,5:&ONW);%:=T3;=$*:UI
MQSC*S?S]3'=R]]E>7>F<;OM">)8Q:3GAD:W!JP VCJY,E.D_AIRV5QQL)F6,
MB IIF"H>SJBL:\1D3&R'-;84JSH*3H_ ;")"@L<.I>WP&2XR@]_7C52OV.YR
M2C+2P</F?O^9D@H/O!PLLZUM$9QSBF \X+0U\6L;7[>LBFQ6LP^7#&7WT,<A
M\L6>B%:61H+!8)WB1*%V2SV5NAVLA*2*95+UP96+-<G@8Q&PA.EMD(RMA).H
MV#V6WB83>$V<U9PF2S"(4N&]->4(@KR B$/9/#9U8="TH'CN&KS&<QHA_TV:
M20)SCA5J_##[F)HN"H? ^/<IL#$#V&+,6%]>@==IL0.'#2 RCC/M!&D"QQLM
M!RM2A#WC8^\GSD*)H+.P9FX)SR9K4N:$+2;[4K1L?#<H#R5E::3-I0XE=B\[
M-DRER^6__M45]_X)2Y 5<$.*0*9>K1+)&8@U:5E>MZ(1N+( +MD:[Z70Q6U8
M44<$1H^E]R-R+^ K<1*''2K YZ#=VG4IQ,1)43DG<RJ]/H (DQ&QC3(S#H(Q
M1BN=#GK)165L%50A&MN$'F5)(GC#Z2@9YS7?F[KGN)5O@8GSJIP"\U<I-"G!
M/AZ@7]E($#Y[ #RO*+(QU11B6TZNVDQ&GSX@(P%B,YQ9L$:V/*/0>,[%POAV
M62[VHV$"5#8$LTN8.3P!+ #5WA3UNJZ+I']9$DU*@?5I'] &0M1:+1/P"3:2
M;2]QH!^K/2PZ7LU2P6:;F1T&FQB]]4A8MA+%YD3$?H+'@70D&2YK\>6<4:<E
MW<6^=T84^8-=VU>(2TT;15S+UUG^"!]HS+7H.+^@*H*"(E*V3(J/T^:RK$RX
MT$KUZO=K"4D6IC87@\+V3,C8J3[UJ.2 :D:YBS&_>);/H*EB-2.>?/OJ*^FI
M5G@3WW#K)\MG5S=4;7+E,LX:HK$=CG)J[:"1?*9#Z@PF-LEH@SO6D]-_CQ\!
MG00I+W=2&XM=VY9PP>-$ETQ1)F,J8X4D;Y%)DSQ_R?JX*(8%W'L8O"8L?2=2
M9[BH%.'*D='66+>;ZJ8M$!1TR.%5B3AIYFOZA B61\[#%U,S3]IE('F\'@U3
M<3 3IF#^ U?*_PL8;K3ORF(TB^V/%)U(]A/%+T1717Q*5* R7AOR D0K(#)?
M#I.[+[\*<HV#F,Z]-?>=QR^]]-R/,8.^<$'XZ(R.W)4V+:2TK%B)B,^0R(P8
M$B4CY<.5OB>+;VI(79]3[N,%JEYFFD<U"Y@ &8';P2EE#WP<R*S)8:;<"DYO
MV$XTJB.6KR=$KN&4R<56^TF('%:!,;87E-_ISCLA1]>6(J_B$,]6.%%,B>?U
M^0L9H!\0^KRU&@7#(D\!%CDQFZ2Z4AGNMWG=,./5Q=N+D3B\TX"_]:0YD<,S
MO29I\5O508P#S83:'7DB)N"=.1_'TS$%U8@ 3?W#OZ,K QA_J_ 9:*)VU/:X
M<YO,1DJZLPWN?567V4 9R&B(P%6@]<HR,S=%'3^JI,H"%/R?/U]F$A::27B^
MS"0\N$S"@]SM@)8=#*ER#\D^MB.DZSRC@[HI%#1QY[DU7QX3/&P\+@:=K9F,
MU^C4^T3;+3Q5<"RJ/>4X+Z9UK'=GQTV,KWR5$XN$!WH[]6TZ4^#O.V5:#5@M
MG9%VQ21 E=.*H1L-_ Z'J&\+WN(X\Y4Q'4O+%Z P/FI93<K*B8A3-[1,/2IE
MW#O>07</+) CRU*&.ULGMR>OND93/']V6;/]<Z=W'=WVNBQ15M#$O12N8@J)
MEAYIW4&XYOJ[XO5^W?)D(DDEDG "M4S:5*I8V&K]!<;%+: @\WN;UETF?H 1
M8AM<SO6DGW!:B:T%+N>M>G<E1,SFV9BI3KSJ\7"(<^9X=>5;N##?C0'KQYQ8
MZM=EB7*OT-APS-N(8@(KIX4-SR<F'@4T;M0J##1+?Y*RGJF5OJ:7Q!]=7>$B
MM[30PB.\!$8<CO# F$AK#C]*C]VX9.R6]GJQM?8V=QWQ>EGI>PH ASUR@7K7
M9!. EZ&E&["& (-.+9&IV\*<9RR0Q@JG\GCFG\;8B22R&/.@"C!F#!I;X-!C
MT,Z6_[74$C+X?:'J_F)WY_+'JW5 0YR6>ORS<J%8(S.<REM/OS-+2?#T=GT@
M"F8S66IB8OVV0RWX)#,;(V> R2&+?IR5C<S)595%WM="LY@*H'"KLX6O&EM6
M VJ5U\"OZYN'KXC.:(^L&]MDG,]$>52QUH;\3#<.PTGUW3B26#DM?CTR#XLQ
MD]^-10P:WD93*<#F2 F[!VW6+!.<1-,(DC4"4B'@3D=UJ9(*QG1.N[^X;G,/
M*.5;-U!BCLQ"U&B%O105^!?PFLF5<%F27;2:19S#VV9A1E4^!HV]07Y^D$8
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MK6+<>PO:K5T:1A0;ZBGI\ELUK*-;0I!R7)7)2=H8H\^K6O<J.\]&Y;7M#!J
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MYI6X4#FV79'FKJKCJ^W=VE/=)W$'8<]7+QN@<B8J5_)9LWBCU1'E.<IH>TI
M-M^3)N/IJ,F?D$[I0"M?7&67YLUGKKI!'&JHQ!^6H[QD==.JYG_X'\FYLW%<
MV ,\X#KCAJKH!K2ORJH5/->)-7%^/RH");,^%V/H[J5=(T7W"$VY#!1=EPX)
M$AIHCPTQV\2P'(O6+FHK$: <];Z=A@$_O<Q[.&"0Q\81TYO"A^IX9*^X'-G<
M;@N@EGELBR^=^5_ F3?1Y7AUY?4_DIW1U$S<QUFRGX.$!L?K9_JHLL+?+)]-
MS!,(4,?)ZSBM7J7@:E>I0QCJ278QI7:GYMM(KH?WR%6&D+>=S(0,T'.-.C%K
M*JI=87>SF"XP)JN\_I9^+S/ZE.O$!XTN.4.(R+K5H,]!H6I 6FPL!0QI3$QM
MP'4YC0]_!B2$VXGJ.<!/0  1$8^7!A&<CQ.%+'O@!0ENSI#*6Q-V _5_)>.
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MG[%'OB)OA?2_7"+]"T7Z7RZ1_B72O]ASYP5!3N 1U!S\;7,LQ8@-U3DS)H%
MX+2P;2I*ZX?DVIN!0$(75)ZK;HG.V;7T*J=1Z$!3K*ICI/_"W("8?ZY8C(-"
M:71LCJU7-M> E"@XQ^#0'.<UU47G0Z\?2QD\#.09G$]TE:<)-*4805&T=$2R
MW96?P%^@5AU9/*E6Q)7ND6;R4RS%A2U7<ULE?GQ@YC;$)..RLQL;,0#(Z[6#
MD>1)85YKI!7#?4^#Z@N%9>+W- W8GFR0"NN0XFWO26& L>9(.%&K*Y&6%5Q.
MH::JORZD,9!O7GN&47HQN&64;F80GI/(5F;R$%V?)>\W3C<2"L,!%5]=@4;8
M%X4Q;6;]F]DK,!(WT4X%;8N-DWO%TPV= *@Q&Y95D_;!I+'D( G:73NPPLHT
M:QU8LS]P8Y"#R&^!(D3U+7)K@FUK=]YGO+-'[AAM;6!]P+84;-;_6%WY@%4V
MKOHGJ*N)86F8CY+\5 [_<G(U9$"YS%;R3BAA+"@6A8-4#0H=? 9  R2XWM(
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M@ED$M7'$BRQ7G]X#S%)Y7;A>G53:R#K<"7,8 +3*R)E1DMES2T\VH!4BA#H
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MWTX,P,'@+-M#>I:'=V$]^Z]5_P)U<NNWD:SE0^J>@+T>:NGS@ZT-/*SOH4S
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M=5MV-1MY49[$JBC!W(BF=$K(,!F/NJR;I<H7<5FR!7AR]#KXN8IG$8A*LLW
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MAF9,.-&UQB;?FP:(:91EU>.JJUWZ=;7(\U4NHB_QHEH$:;68H$W815_E>4S
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M@[\/4<1KC"+^?8@B#E'$^VC8;4( CG R1V]HLURN2.KL^" D'Z.@[:1O0-M
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MENV4A1)F0TM48F*C&!-H*XS:)(DECWC(H(<6!9^A1+FR%8ET%4VZ^!OEOKG
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M"6K#,CYT*X<L%'HEL>!UE)<I_0V,2!(]+.L\3E3]H\OSC-.).)=(^72YGCU
M10G 7%DB5PV&?G1@BJ+NRT3-SI2&UJ#GCF $F;YY) @7R8[ Z'=2=YSNAE(\
MA!VNLXNXR!HWV8[VK0G01NL6K/P&\RJ=,F,/<H[#;7&!8790EK)$F#PDA1$G
MF8P0]NV5E(796+J W#O:+T>/^9P^]*-=TG"=3*Y%*,RQ_"V<97'(-H&Z.\T2
M*2[@9/])!R4R=,/ #1[*,^.1&Z_=-;=U_XYQ05[-_=,[_T'/](.*>UOS[V?K
MRE23MU\R74VZ'Y9XQTSO.N*[6:,^# R3=W06(:>;E\F29 4I[],DBA<XL>Q
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M41(<G1S__)YK_LV#@X</'X+1LW>V%P:7EY=[LVQ:85-[T(KA;[=M2VHZ);A
M5R]@VS,QO;;E_'P9[6Y:R58B= 77H[H\SRBKA*I2U;X2%V;K[8J;U4QXO0X6
M(1.DA9:9LXVBO.:$)>02 PT&62FPAZ1U#3;,5LBU>#.Y]C-BJ5/24=]%ERS*
M#F&#Z@Q[PBU.^1$3#"KS2O+":?O&1'^6TKXRXH?H $%-+IVMW.+@\"D!L-+
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M6UXVHGYO/#IMN[1%V(H!AA_P1%P1S#)J36.$2399*:O-MQ:)9@#B$5XP14:
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M9I>,3[G(F#C? 4:5?OT#3>*OR98\K,ON<--NC4"_YO_NZ3K>_8O[FO^[WWK
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M/>\%5O4"'0<>U![D+"?W\C*/TVF\!#L'2P&5JT!7\]BQ]3N>_(4*:RRRW#C
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MVZL/;_Y)/NI?3G]]]_+_ U!+ P04    "  F2*U:.HW<3]X$  !8%@  "@
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M]S 0E5R^WKC[CPGOUX^$7 _<GZFQ8KJHM,>73:R([O>@;+<;<ABFV@^9X=J
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M/<'V;SG5E4A_^AV,-0;5.?11X]CVO][O=D%!P)B V0$LO>&^JB_4%9D8!_J
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MW4UA 6'[;> 7:M/@3INCEN5=@SMD/#J^<W3WX'*"#WV5GW5+ONOK._\],:$
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MO*]PP#LM\9&K/)=X-<P&3)"]>2(G]T4!>A4C5+3K20)00L&8*T0=6 V CZ9
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M\LL2'8>JGF,U@Z #\1>,!V1-OU^\*Q</85[@(8M50=I[%8>BP9FIKFS,E7R
M\W?HLU%A1VY"HA2)X[PANK5J92-#$3=,O+\T=-7*;(5QNL94K8+'N:2]B_+
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M?95#^$K>VA<^+EPF;PD<5/:)M--)&3>3QV '6GN>F$5R;G"8_25<I$NJ<AD
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MVXD['^7$UH_@39L+-!7%SAI$%"Y,E6089)PS$YLE4T8.(J..L/48O'N^8&?
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M40'&O]M]?.,1W]\T!'9#19AL?Z,RR)D2!53C(OR-(<Z^CU#U1:6W"EIL@\6
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M"7)64>+XNB.%H6Q-B;BG<HQ:%6<1X-UW(E2(]5ML.62& L*HHM.1Q]#9BB3
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M#1Y*9("=B2O=S,[S%;L?[F,U%$,\Y7SW27+@Q^#<&WGVU'BD+4OG5_BHP[Z
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M\XI>PD)0MAI$'#0492OT0H,S&@^)3>7I0F2*P>;>& 8GLC7/;NQILDMTV,'
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M9VR0S/-9S4%)VMX6M59U=6MQ5?05&"\=TIN2<WLF<')S?39'_QQ<E<R@(\[
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M.MJV#<E!64]AL<]A66;+/.MW@""F \(>8[+&1B8XWJ3L1]L79 9'Q5(R_C_
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M0KY _?6[D&S!J F'._;*I:C5"AQFWD2N"YVB'%?:T38KS&3$@B*V;8*S96J
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M__KAB\?_HD/YGV]^>?;3_P]02P,$%     @ )DBM6L&??>@530  Q*0!  D
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M6LYV\ V.YCC.JKCXMN+ >B:>-.*]DX/_1-Z"TPD$_[1W!DQS\4<5A_K]WYX
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M\A'YW@\4=7+X812./U\6.8A9],_SXB7&3"KPS(\F)CFH,A %\P#[&;1M#1O
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MM&02!:*'&;0Q)47WQ>Q7M[,1LS6SCS65!4)PFS=IZ5LW!-N"GJ2_4C91M 6
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MW)25]_7Q:=KTO#9\ _1PV^P>5<7$)6CD5DM=#@'SA+?:1*UG_K9TMK%VTX/
M&TQ^6'FO;UK[:_*X^2IQ]K0C4ZDT!%DI!NO?LG8XQX4MJ$5&^SO*NB\4>4T?
MY]+]=.RKP!7OOOQ =#OPR61>X+K-B< #L2;Q\76H6:#L(:HUW,(ZBGB5D2 ^
M5]MSZ_AY<AZTSA0/R6E;45<,;$C6/I<J ^<@K:?F^JO>:]NN[JR?&[O <QK#
M5>P#FB-E>5^!8\?1S;;4S4[8K3F5NIX/>12GIKN1%A.REI-?U#/5M$F\ZWZ:
MYVB,7SK=Q)55A.FPA>) 7[FMUD0\)$:6IRN%&!JL[37L>@\F75)^WIH4<6S
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M^ND2ZL@@KK$WG<B_HZHJQ12WFMY"T9\1SX!A4')AH8!7C!2PNIL4ZN^%=*K
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MM($D!VT]()Z==-13"",%&; F,Q5J3: ;;*112^6*-YQ<N<XM:9.GO:@/!L#
M\G.:$H/6%<_ C/ED9SLD:*N!#(BU,.^H6H?X B0S/0$Q1T_!5[5H5?O4.#^]
M!WX$O:<95TU)?@G:-T_=DM<D(>A^=MV70#/E8+)<\JEL*=GD]0+,.!B3GEL2
M(U#PM:WB<G/*K&#1^[R$VX)ZG8"U>HCFVGPL'9.*X -V@M :Q,ZQ.A[5.(=-
M,HI6^80T6-)S ?.)+C=>5GNM6U5W.RDML.(%1F:!9&TZZ_.#(!H*&(PQ8$HH
M$E7!:NK\W)/ WA>W>2#&L1Y/)+%6,"# '1!UFDF-F*JU7O%JW%I&]S)3CW(]
M!Y-+X;PF2RMP WGBJ+B7([!YI4302T_B1Y+7<0LJ+0K5J$-)!J$JQM+<M BL
M1^:-Z!@5"D$O2%4G.9(Q^4SC)'->& >(&*,DO3G,2HDP:1+/UUKRYC3;,Q+#
M:EX@?A#NC<5U"RP'?4>(*?PLKL8:T(Q;2WC&G#Q"K&2,(QGR*=,_=?*6K$1]
MZEBAS9)"\Y76-T8FYP7#AB4#C=7+3G8P=%IM2*="QKCS@U2?)4(AJH8>_! _
MMZ70.AG0A;MF\(0 ^PF/C$V6YZEV=S:)JCM,5.WN;#)5CRQ3]3A6P1'"/5/A
MS$; _92(/0+ZW&X-C28>HX<'#>C)Y7/,*K8?,(Y1J-:%E)$SQ.<(I629W(:Y
M=F=1->=(8^>=#EAG2@%]2#*<V.)T&!6#JQZ.Z[L&K70Y] W;I')G!;D=]Z2L
M0,-M"<.AWJ\2VZ^4)&F!_>-SRE["4HI+E7LE:,F<\<+X*)T4C;'Y !9)>)Z;
M@EKA)$K;W;%P'>()UILGN"]-^U.1?9>F"H"M.QJI3BVETKYF1=(C2MJU"VC+
M6Z9*D4J]:FGPRH(KTJ%D.V;E1:?2\(:'+5S.E:5H%059\>- ]913R)T/8?$Y
M%L_$*<DQ/"8K3#&>%2WU;T*3%-5 &2</S"^Y_L[HL*5*F=GMDQ)L"]70A.AV
MMZ$AYZKQFIY%Y@<Q6[!$F-%%^* YJP,&MB/F4++NR.P+U<\30YL9EB&5I6ZI
M1$T:\=C#R25&^X+""LS\C(.U? S*8$RS#FJY0[>_.*66&30G$94>1V=H0@*#
M$=TKW#3-6*KFN!MO/$5,OD*HFRPX/>'N9ZQ^?YI@*-$H ^154][@)-^$U%15
M^O<P^V$FV [B-V$WR1%86+Z%U1&Y!<$+W$O'&>6HY0*2-PS7NA,0JJLBGU]>
MB7!P!X0XY712+M=26^(4I=6'4MNSV[END!G15+7I]EW8YH6C!/%G$IKT 1(F
M'Z%65+..0)]26LSJW20LSS/6:Z$";-C%"0H23MR(G [ 90Z*>1)2CJ$L0;29
MF$-1$.(&:2PUA9PIXS'N!N]J>8'J-VK.2Y,R8&]2S2#@6=K<58NS[#HJJ2KK
MO$BH*[4NL5(%&VV!8"FX[+D6[,3;7L89-M^Q"FW03+_,B94JN[Z5Z(2Q1XFL
MH(J3T$I8N%T\_=KM42[C2\0646AG$D$H4Y?/(_'[O.F',\"<GZV&;3EJ>(GN
M=<E-PXV*2/6K]M.E2F:3,DCC2P:-$TLO%=\M)D=[5SSIBPDO@C665%93C!FC
M;ID4\01WO22*<*]:ZY5%U812HL>I)9U&9D%3JI9B"Y50%M, 0VVC/%HHX.IO
M<$;+B//02F,,##T'AJ#<S"M3^ZK)AVS,QY*-.*MC58-=M=$8^S(:E86'D?'=
M#IM*_EQ/M/!-DP6%]&G#=JTWY\74ZKF='3R)()WSES*@R6[2WS0+V;PH\+)!
MXSEM9]1NAS@5<1=YA'ID"<\^LB#6PZ(&_L,BD-5HZ)_SN.1=PDD<<9$I'4&>
MF0[=J\),$"T(0I%VR*SW0 >")5V%C8D% W(TQ<!-.,HZ,&2#!%G9/*H!HV60
M'T#CSUE^D\;195P:#>>KZ;$$ %:J*9F\7%DH!E-$K:HY)&7<[7!3=,YN.NE1
M 8?(B $+[R1Y,#(5P8+)2_9J&&-!+E&,7:E3O\ANPQ%.^Z:,'(R"K9;AEQD.
M#67FP,3_.)\7O+51'*8,EY'"[30DL6H*O0TGF(2%J1\4;B$0C;%/13O,XD*J
MZD-V> HS4H9OI  "-]QG-OX-')FQ#3%P)V#C]'KLL%ER1 .MQ+ALL&Z-1]':
MWU3/MFZJG?1:7"*KLJV'#(C'"1Z"9=E I%)#X!<&VMCZU(%H8-;A)?6G94.3
MJ\J#*)R&=%!==&O=$<1B0K?=!FM@LK+)R] RUZU"Q+B,ZG%2"N8K%@9!N+!V
M)M%!PH-.5"7W=.#$MJ06H)0M@H-)3=;T?![8$T'TSF:4I231+FDF_B7F7?VB
M T*+IC*P@JFC7BJ:6\!T*=%D>\4P$2LFS03<W*6=>0PK;P0(K>+*ZO\F F,/
M"RX8-#V@B&%<6N-'(^D8ZV0QG=FZ>G):7EA-8VJMQNH\[C29:3,7[%8.&ZMA
MG54DC&&Q!KY/NIWWB5WMCDK""#%EN(MC0'!Z$V8)0;H0'OE:![S=$]W:3 +]
M0[5)6BS;D!*$,H$_HR8<J78B$R<J0E-OKA-PS4T_%24WF8\N"?J=<.<B[C0O
M+^O^OE;=J2:;R)O6!A/K2;V-:#8S"(M$LWEHPNVFBH:(;4Y'80P,G^"T,@WH
MD>\?&0>O2,CO;A+R=YF0W]TDY.\[(=^XKP]\Y'X3)X\-EIJ#1V)9S1YF=8O6
M3V,K'ZL%B,(9C18,5S=V&Y:'48\F= _8'!WHV4).?S!NVS &*>D&WXW)M3)_
M2K-FQ"\%V1IS2SLQ@CG>I;!/$::L:4K9%*W54 \](XF>EVR]:I.2356&\B+7
M@P2&3S5&LJGQNQV)E2Y_:GTY.S"Z H'3MS&7#E"_JXR#TE2=:DUD4T1R$A2<
M$64C=$'][,(;>5OK31^9L'^H57QFD)Z:)%"R3[M'O1S$0K6JD=O;\#2TQ+',
M".H&;06HS7P?X01I.I*)5XR7RBP!P972WHVXXZ*)HY3.NBW#F)M1U%IMJF6M
M<YV:7W+AL+/IUJU?M>!)?UFD#7)EZ<@K* M'V4%^,>C2XF,5#"2B.Z8?.=G&
M-G*#3AOVIE6D#*?"+"WZ*$MZ#TSSB+ODH,R;\FXJ@]4(,TGM2X)9NTFJ?8!$
MWMO83ECJH8GR.+9FRI*'9I0XK< ^(9$QC#(#M9-0\RM2,.W3=/19T8%RJ^6!
MS%4/53&XJ5?%;:&@>[T*%;5VMX-!&NYKO\[#X2=7R2@1O<^-9-OOSHLSM[7>
MP:Q0C3>2#HLJO*>>)+ ">0ZE#A1(03X+K4'R6 4OLL)]=JD8W8QS;-??&^ZE
M563$O>]B G/9=N.5?*0'?=:4A=(.U,\X2Y2W3Q.<^"^9&N"C4"D#;8I)W?W
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M]O393Z_D+_?PWT?(4+?FEW5OO6KKR<1:NOE_R /\8/2^P,S&-R:X&,3W;Z6
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M8<\_T =H;X7)#G@>]JM(<B#WR;N#_5\.:#9[QT='![1&-9M@]_AH)WASN'\
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M<51=II9Y![P&BE-<1M<Y\EH4? "6A1& 0#4,.8IR5%FSI*I8[X77Z2]ZH6!
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MM" 642":KGT8%":X*L=DK!,I&N*&3%15>,CD*/V.I,4OY7GC,UF]_83IM3A
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M@VGM2*4&MAU#ZQ[I/L36-2+H#YQ3I9ZOS/,<K0_1T,>+GK64J$.*:$/55V%
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M56%<['P8?8(-5/7)+P1&;;E25,/,]MT1IU\NN^=]-S2C1VS>F?V21RW6[-H
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M("7N";4S6HCRW_ZX.)^J3E9?(U]R_8/")V#920D&C/NP E76919X=YD;L))
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M&IS6#@JQD7]DKFITKEG$F&GDH">(X#5.7(M.G$JCF49(I&D3%Z+(1C <UF,
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MR%)':$>C6WNC!IY@Z!-^M[Z-U2:][%Z_T6"XA]FUI6+4KHW.F6GLYMXF[=B
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MG!KVA"XH!M_6 BTG4=/+/U!+ P04    "  F2*U:7KB=Z?T*  !_A@  %0
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MTE(& 5*O/?AW2*H(I$,<4W,K&1;U\[C<Q#PC&_!MA_X05P0--:\YZM,'0=-
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M>#$P+3$N:'1M4$L! A0#%     @ )DBM6E(_L"/P8P  ,  #  H
M     ( !L\$  &5X,3 M,BYH=&U02P$"% ,4    "  F2*U:.HW<3]X$  !8
M%@  "@              @ '+)0$ 97@Q,"TS+FAT;5!+ 0(4 Q0    ( "9(
MK5K316>QE1   #=K   *              "  =$J 0!E>#$P+30N:'1M4$L!
M A0#%     @ )DBM6K9T&OZ;=   AZ4"  D              ( !CCL! &5X
M,RTQ+FAT;5!+ 0(4 Q0    ( "9(K5K!GWWH%4T  ,2D 0 )
M  "  5"P 0!E>#0M,2YH=&U02P$"% ,4    "  F2*U:\Q4&$6!.  "QK@$
M"0              @ &,_0$ 97@T+3(N:'1M4$L! A0#%     @ )DBM6@N3
MY"F]'@  A;D   L              ( !$TP" &9O<FTX+6LN:'1M4$L! A0#
M%     @ )DBM6@B_=BTL P  ZPL  !$              ( !^6H" &=T8G M
M,C R-3 U,3(N>'-D4$L! A0#%     @ )DBM6EZXG>G]"@  ?X8  !4
M         ( !5&X" &=T8G M,C R-3 U,3)?;&%B+GAM;%!+ 0(4 Q0    (
M "9(K5JG%@+A6@<  -I7   5              "  81Y @!G=&)P+3(P,C4P
A-3$R7W!R92YX;6Q02P4&      L "P"# @  $8$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="gtbp-20250512.xsd" xlink:type="simple"/>
    <context id="AsOf2025-05-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000109657</identifier>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-05-12" id="Fact000003">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="AsOf2025-05-12" id="Fact000004">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-05-12" id="Fact000005">0000109657</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-05-12" id="Fact000010">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-05-12" id="Fact000011">2025-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-05-12" id="Fact000012">GT Biopharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-05-12" id="Fact000013">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-05-12" id="Fact000014">1-40023</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-05-12" id="Fact000015">94-1620407</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="AsOf2025-05-12" id="Fact000016">(415)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-05-12" id="Fact000017">919-4040</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-05-12" id="Fact000018">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-05-12" id="Fact000019">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-05-12" id="Fact000020">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-05-12" id="Fact000021">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-05-12" id="Fact000022">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-05-12" id="Fact000023">GTBP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-05-12" id="Fact000024">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-05-12" id="Fact000025">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-05-12" id="Fact000026">505 Montgomery Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-05-12" id="Fact000027">10th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-05-12" id="Fact000028">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-05-12" id="Fact000029">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-05-12" id="Fact000030">94111</dei:EntityAddressPostalZipCode>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
